ID   MAGA_XENLA     STANDARD;      PRT;   303 AA.
AC   P11006;
DT   01-JUL-1989 (Rel. 11, Created)
DT   01-JUL-1989 (Rel. 11, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Magainins precursor.
OS   Xenopus laevis (African clawed frog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidea; Pipidae;
OC   Xenopodinae; Xenopus; Xenopus.
OX   NCBI_TaxID=8355;
RN   [1]
RP   NUCLEOTIDE SEQUENCE, AND PARTIAL PROTEIN SEQUENCE.
RX   MEDLINE=88186892; PubMed=2833514;
RA   Terry A.S., Poulter L., Williams D.H., Nutkins J.C., Giovannini M.G.,
RA   Moore C.H., Gibson B.W.;
RT   "The cDNA sequence coding for prepro-PGS (prepro-magainins) and
RT   aspects of the processing of this prepro-polypeptide.";
RL   J. Biol. Chem. 263:5745-5751(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE OF 6-158 AND 297-303, AND PARTIAL PROTEIN
RP   SEQUENCE.
RC   TISSUE=Skin, and Skin secretion;
RX   MEDLINE=87261003; PubMed=3299384;
RA   Zasloff M.;
RT   "Magainins, a class of antimicrobial peptides from Xenopus skin:
RT   isolation, characterization of two active forms, and partial cDNA
RT   sequence of a precursor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:5449-5453(1987).
RN   [3]
RP   PROTEIN SEQUENCE OF MAGAININS I AND II.
RC   TISSUE=Stomach;
RX   MEDLINE=92011794; PubMed=1717472;
RA   Moore K.S., Bevins C.L., Brasseur M.M., Tomassini N., Turner K.,
RA   Eck H., Zasloff M.;
RT   "Antimicrobial peptides in the stomach of Xenopus laevis.";
RL   J. Biol. Chem. 266:19851-19857(1991).
RN   [4]
RP   STRUCTURE BY NMR OF MAGAININ II.
RX   MEDLINE=94129391; PubMed=8298457;
RA   Bechinger B., Zasloff M., Opella S.J.;
RT   "Structure and orientation of the antibiotic peptide magainin in
RT   membranes by solid-state nuclear magnetic resonance spectroscopy.";
RL   Protein Sci. 2:2077-2084(1993).
CC   -!- FUNCTION: Antimicrobial peptides that inhibit the growth of
CC       numerous species of bacteria and fungi and induce osmotic lysis of
CC       protozoa. Magainins are membrane lytic agents.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Synthesized in the stomach and stored in a
CC       novel granular multinucleated cell in the gastric mucosa. It is
CC       stored as active, processed peptides in large granules within the
CC       granular gland secretions of the skin.
CC   -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.
CC       Magainin subfamily.
CC   -!- DATABASE: NAME=Protein Spotlight; NOTE=Issue 7 of February 2001;
CC       WWW="http://www.expasy.org/spotlight/back_issues/sptlt007.shtml".
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; J03193; AAA49930.1; -; mRNA.
DR   PIR; A28620; A28620.
DR   PDB; 1D9J; NMR; A=-.
DR   PDB; 1D9L; NMR; A=-.
DR   PDB; 1D9M; NMR; A=-.
DR   PDB; 1D9O; NMR; A=-.
DR   PDB; 1D9P; NMR; A=-.
DR   PDB; 1F0D; NMR; A=-.
DR   PDB; 1F0E; NMR; A=-.
DR   PDB; 1F0F; NMR; A=-.
DR   PDB; 1F0G; NMR; A=-.
DR   PDB; 1F0H; NMR; A=-.
DR   PDB; 2MAG; NMR; @=83-105.
DR   InterPro; IPR001651; Gastrin.
DR   Pfam; PF00918; Gastrin; 1.
KW   3D-structure; Antibiotic; Cleavage on pair of basic residues;
KW   Cytolysis; Direct protein sequencing; Fungicide; Hemolysis; Repeat;
KW   Signal.
FT   SIGNAL        1     18       Potential.
FT   PROPEP       19     26
FT   PEPTIDE      27     32       Small acidic peptide copy A.
FT   PROPEP       33     36
FT   PEPTIDE      37     59       Magainin I.
FT   PROPEP       62     72
FT   PEPTIDE      73     78       Small acidic peptide copy B.
FT   PROPEP       79     82
FT   PEPTIDE      83    105       Magainin II copy A.
FT   PROPEP      108    118
FT   PEPTIDE     119    124       Small aciDic peptide copy C.
FT   PROPEP      125    128
FT   PEPTIDE     129    151       Magainin II copy B.
FT   PROPEP      154    164
FT   PEPTIDE     165    170       Small acidic peptide copy D.
FT   PROPEP      171    174
FT   PEPTIDE     175    197       Magainin II copy C.
FT   PROPEP      200    210
FT   PEPTIDE     211    216       Small acidic peptide copy E.
FT   PROPEP      217    220
FT   PEPTIDE     221    243       Magainin II copy D.
FT   PROPEP      246    256
FT   PEPTIDE     257    262       Small acidic peptide copy F.
FT   PROPEP      263    266
FT   PEPTIDE     267    289       Magainin II copy E.
FT   PROPEP      292    303
FT   CONFLICT     74     74       E -> Q (in Ref. 2).
FT   TURN         84     85
FT   HELIX        86    103
SQ   SEQUENCE   303 AA;  33380 MW;  E369B0DBB033EA80 CRC64;
     MFKGLFICSL IAVICANALP QPEASADEDM DEREVRGIGK FLHSAGKFGK AFVGEIMKSK
     RDAEAVGPEA FADEDLDERE VRGIGKFLHS AKKFGKAFVG EIMNSKRDAE AVGPEAFADE
     DLDEREVRGI GKFLHSAKKF GKAFVGEIMN SKRDAEAVGP EAFADEDLDE REVRGIGKFL
     HSAKKFGKAF VGEIMNSKRD AEAVGPEAFA DEDFDEREVR GIGKFLHSAK KFGKAFVGEI
     MNSKRDAEAV GPEAFADEDL DEREVRGIGK FLHSAKKFGK AFVGEIMNSK RDAEAVDDRR
     WVE
//
ID   CECA_HYACE     STANDARD;      PRT;    64 AA.
AC   P01507;
DT   21-JUL-1986 (Rel. 01, Created)
DT   01-APR-1988 (Rel. 07, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Cecropin A precursor (Cecropin C).
OS   Hyalophora cecropia (Cecropia moth).
OC   Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysia; Bombycoidea;
OC   Saturniidae; Saturniinae; Attacini; Hyalophora.
OX   NCBI_TaxID=7123;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=91268009; PubMed=1711035;
RA   Gudmundsson G.H., Lidholm D.-A., Aasling B., Gan R., Boman H.G.;
RT   "The cecropin locus. Cloning and expression of a gene cluster encoding
RT   three antibacterial peptides in Hyalophora cecropia.";
RL   J. Biol. Chem. 266:11510-11517(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RA   Lidholm D.-A., Gudmundsson G.H., Xanthopoulos K.G., Boman H.G.;
RT   "Insect immunity: cDNA clones coding for the precursor forms of
RT   cecropins A and D, antibacterial proteins from Hyalophora cecropia.";
RL   FEBS Lett. 226:8-12(1987).
RN   [3]
RP   PROTEIN SEQUENCE OF 27-63.
RX   MEDLINE=83053366; PubMed=7140755;
RA   Hultmark D., Engstroem A., Bennich H., Kapur R., Boman H.G.;
RT   "Insect immunity: isolation and structure of cecropin D and four minor
RT   antibacterial components from Cecropia pupae.";
RL   Eur. J. Biochem. 127:207-217(1982).
RN   [4]
RP   PRELIMINARY PROTEIN SEQUENCE OF 27-63.
RX   MEDLINE=81245158; PubMed=7019715;
RA   Steiner H., Hultmark D., Engstroem A., Bennich H., Boman H.G.;
RT   "Sequence and specificity of two antibacterial proteins involved in
RT   insect immunity.";
RL   Nature 292:246-248(1981).
RN   [5]
RP   STRUCTURE BY NMR OF 27-63.
RX   MEDLINE=89088132; PubMed=3207693;
RA   Holak T.A., Engstroem A., Kraulis P.J., Lindeberg G., Bennich H.,
RA   Jones T.A., Gronenborn A.M., Clore G.M.;
RT   "The solution conformation of the antibacterial peptide cecropin A: a
RT   nuclear magnetic resonance and dynamical simulated annealing study.";
RL   Biochemistry 27:7620-7629(1988).
CC   -!- FUNCTION: Cecropins have lytic and antibacterial activity against
CC       several Gram-positive and Gram-negative bacteria.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- PTM: A protein with the same sequence as cecropin A, but lacking
CC       the carboxyl blocking group, has been isolated and called cecropin
CC       C (Ref.3).
CC   -!- SIMILARITY: Belongs to the cecropin family.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; X06672; CAA29871.1; -; mRNA.
DR   EMBL; M63845; AAA29185.1; -; Genomic_DNA.
DR   PIR; A40420; CKWKA.
DR   PDB; 1D9J; NMR; A=-.
DR   PDB; 1D9L; NMR; A=-.
DR   PDB; 1D9M; NMR; A=-.
DR   PDB; 1D9O; NMR; A=-.
DR   PDB; 1D9P; NMR; A=-.
DR   PDB; 1F0D; NMR; A=-.
DR   PDB; 1F0E; NMR; A=-.
DR   PDB; 1F0F; NMR; A=-.
DR   PDB; 1F0G; NMR; A=-.
DR   PDB; 1F0H; NMR; A=-.
DR   InterPro; IPR000875; Cecropin.
DR   InterPro; IPR003254; IIP_cecropin.
DR   Pfam; PF00272; Cecropin; 1.
DR   ProDom; PD003996; IIP_cecropin; 1.
DR   PROSITE; PS00268; CECROPIN; 1.
KW   3D-structure; Amidation; Antibiotic; Direct protein sequencing;
KW   Hemolymph; Immune response; Innate immunity; Multigene family; Signal.
FT   SIGNAL        1     22
FT   PROPEP       23     26       Removed by a dipeptidylpeptidase.
FT   CHAIN        27     63       Cecropin A.
FT   MOD_RES      63     63       Lysine amide (G-64 provides amide group).
SQ   SEQUENCE   64 AA;  6952 MW;  0B3AEA15C32DB3A4 CRC64;
     MNFSRIFFFV FACLTALAMV NAAPEPKWKL FKKIEKVGQN IRDGIIKAGP AVAVVGQATQ
     IAKG
//
ID   SRP09_MOUSE    STANDARD;      PRT;    85 AA.
AC   P49962; Q9D085;
DT   01-OCT-1996 (Rel. 34, Created)
DT   01-OCT-1996 (Rel. 34, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Signal recognition particle 9 kDa protein (SRP9).
GN   Name=Srp9;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=94301784; PubMed=7518078;
RA   Bovia F., Bui N., Strub K.;
RT   "The heterodimeric subunit SRP9/14 of the signal recognition particle
RT   functions as permuted single polypeptide chain.";
RL   Nucleic Acids Res. 22:2028-2035(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Embryo, and Urinary bladder;
RX   MEDLINE=22354683; PubMed=12466851; DOI=10.1038/nature01266;
RA   Okazaki Y., Furuno M., Kasukawa T., Adachi J., Bono H., Kondo S.,
RA   Nikaido I., Osato N., Saito R., Suzuki H., Yamanaka I., Kiyosawa H.,
RA   Yagi K., Tomaru Y., Hasegawa Y., Nogami A., Schonbach C., Gojobori T.,
RA   Baldarelli R., Hill D.P., Bult C., Hume D.A., Quackenbush J.,
RA   Schriml L.M., Kanapin A., Matsuda H., Batalov S., Beisel K.W.,
RA   Blake J.A., Bradt D., Brusic V., Chothia C., Corbani L.E., Cousins S.,
RA   Dalla E., Dragani T.A., Fletcher C.F., Forrest A., Frazer K.S.,
RA   Gaasterland T., Gariboldi M., Gissi C., Godzik A., Gough J.,
RA   Grimmond S., Gustincich S., Hirokawa N., Jackson I.J., Jarvis E.D.,
RA   Kanai A., Kawaji H., Kawasawa Y., Kedzierski R.M., King B.L.,
RA   Konagaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,
RA   Maglott D.R., Maltais L., Marchionni L., McKenzie L., Miki H.,
RA   Nagashima T., Numata K., Okido T., Pavan W.J., Pertea G., Pesole G.,
RA   Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramachandran S.,
RA   Ravasi T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,
RA   Sandelin A., Schneider C., Semple C.A., Setou M., Shimada K.,
RA   Sultana R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita M.,
RA   Verardo R., Wagner L., Wahlestedt C., Wang Y., Watanabe Y., Wells C.,
RA   Wilming L.G., Wynshaw-Boris A., Yanagisawa M., Yang I., Yang L.,
RA   Yuan Z., Zavolan M., Zhu Y., Zimmer A., Carninci P., Hayatsu N.,
RA   Hirozane-Kishikawa T., Konno H., Nakamura M., Sakazume N., Sato K.,
RA   Shiraki T., Waki K., Kawai J., Aizawa K., Arakawa T., Fukuda S.,
RA   Hara A., Hashizume W., Imotani K., Ishii Y., Itoh M., Kagawa I.,
RA   Miyazaki A., Sakai K., Sasaki D., Shibata K., Shinagawa A.,
RA   Yasunishi A., Yoshino M., Waterston R., Lander E.S., Rogers J.,
RA   Birney E., Hayashizaki Y.;
RT   "Analysis of the mouse transcriptome based on functional annotation of
RT   60,770 full-length cDNAs.";
RL   Nature 420:563-573(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Mammary gland;
RX   MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA   Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA   Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA   Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA   Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA   Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA   Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA   Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA   Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA   Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA   Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA   Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA   Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA   Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA   Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA   Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA   Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA   Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT   "Generation and initial analysis of more than 15,000 full-length human
RT   and mouse cDNA sequences.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN   [4]
RP   X-RAY CRYSTALLOGRAPHY (2.53 ANGSTROMS) IN COMPLEX WITH SRP14.
RX   MEDLINE=97377014; PubMed=9233785; DOI=10.1093/emboj/16.13.3757;
RA   Birse D.E., Kapp U., Strub K., Cusack S., Aaberg A.;
RT   "The crystal structure of the signal recognition particle Alu RNA
RT   binding heterodimer, SRP9/14.";
RL   EMBO J. 16:3757-3766(1997).
CC   -!- FUNCTION: Signal-recognition-particle assembly has a crucial role
CC       in targeting secretory proteins to the rough endoplasmic reticulum
CC       membrane. SRP9 together with SRP14 and the Alu portion of the SRP
CC       RNA, constitutes the elongation arrest domain of SRP. The complex
CC       of SRP9 and SRP14 is required for SRP RNA binding.
CC   -!- SUBUNIT: Signal recognition particle consists of a 7S RNA molecule
CC       of 300 nucleotides and six protein subunits: SRP72, SRP68, SRP54,
CC       SRP19, SRP14 and SRP9.
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic.
CC   -!- SIMILARITY: Belongs to the SRP9 family.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; X78304; CAA55114.1; -; mRNA.
DR   EMBL; AK011720; BAB27800.1; -; mRNA.
DR   EMBL; AK020583; BAB32138.1; -; mRNA.
DR   EMBL; AK020620; BAB32151.1; -; mRNA.
DR   EMBL; BC039648; AAH39648.1; -; mRNA.
DR   PIR; S57500; S57500.
DR   PDB; 1914; X-ray; @=-.
DR   SMR; P49962; 3-80.
DR   MGI; MGI:1350930; Srp9.
DR   InterPro; IPR008832; SRP9.
DR   InterPro; IPR009018; SRP9/14.
DR   PANTHER; PTHR12834; SRP9; 1.
DR   Pfam; PF05486; SRP9; 1.
KW   3D-structure; RNA-binding; Signal recognition particle.
FT   INIT_MET      0      0       By similarity.
FT   CONFLICT     21     21       P -> S (in Ref. 2; BAB27800).
FT   HELIX         6     19
FT   TURN         21     23
FT   STRAND       25     31
FT   TURN         32     35
FT   STRAND       36     42
FT   STRAND       47     52
FT   STRAND       54     54
FT   HELIX        55     57
FT   HELIX        58     73
SQ   SEQUENCE   85 AA;  10063 MW;  01C529D4714C62AD CRC64;
     PQFQTWEEFS RAAEKLYLAD PMKVRVVLKY RHVDGNLCIK VTDDLVCLVY RTDQAQDVKK
     IEKFHSQLMR LMVAKESRNV TMETE
//
ID   SRP14_MOUSE    STANDARD;      PRT;   110 AA.
AC   P16254;
DT   01-AUG-1990 (Rel. 15, Created)
DT   01-AUG-1990 (Rel. 15, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Signal recognition particle 14 kDa protein (SRP14).
GN   Name=Srp14;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE, AND PROTEIN SEQUENCE OF 1-19 AND 77-95.
RX   MEDLINE=90099341; PubMed=2557625;
RA   Strub K., Walter P.;
RT   "Isolation of a cDNA clone of the 14-kDa subunit of the signal
RT   recognition particle by cross-hybridization of differently primed
RT   polymerase chain reactions.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:9747-9751(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Hippocampus;
RX   MEDLINE=22354683; PubMed=12466851; DOI=10.1038/nature01266;
RA   Okazaki Y., Furuno M., Kasukawa T., Adachi J., Bono H., Kondo S.,
RA   Nikaido I., Osato N., Saito R., Suzuki H., Yamanaka I., Kiyosawa H.,
RA   Yagi K., Tomaru Y., Hasegawa Y., Nogami A., Schonbach C., Gojobori T.,
RA   Baldarelli R., Hill D.P., Bult C., Hume D.A., Quackenbush J.,
RA   Schriml L.M., Kanapin A., Matsuda H., Batalov S., Beisel K.W.,
RA   Blake J.A., Bradt D., Brusic V., Chothia C., Corbani L.E., Cousins S.,
RA   Dalla E., Dragani T.A., Fletcher C.F., Forrest A., Frazer K.S.,
RA   Gaasterland T., Gariboldi M., Gissi C., Godzik A., Gough J.,
RA   Grimmond S., Gustincich S., Hirokawa N., Jackson I.J., Jarvis E.D.,
RA   Kanai A., Kawaji H., Kawasawa Y., Kedzierski R.M., King B.L.,
RA   Konagaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,
RA   Maglott D.R., Maltais L., Marchionni L., McKenzie L., Miki H.,
RA   Nagashima T., Numata K., Okido T., Pavan W.J., Pertea G., Pesole G.,
RA   Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramachandran S.,
RA   Ravasi T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,
RA   Sandelin A., Schneider C., Semple C.A., Setou M., Shimada K.,
RA   Sultana R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita M.,
RA   Verardo R., Wagner L., Wahlestedt C., Wang Y., Watanabe Y., Wells C.,
RA   Wilming L.G., Wynshaw-Boris A., Yanagisawa M., Yang I., Yang L.,
RA   Yuan Z., Zavolan M., Zhu Y., Zimmer A., Carninci P., Hayatsu N.,
RA   Hirozane-Kishikawa T., Konno H., Nakamura M., Sakazume N., Sato K.,
RA   Shiraki T., Waki K., Kawai J., Aizawa K., Arakawa T., Fukuda S.,
RA   Hara A., Hashizume W., Imotani K., Ishii Y., Itoh M., Kagawa I.,
RA   Miyazaki A., Sakai K., Sasaki D., Shibata K., Shinagawa A.,
RA   Yasunishi A., Yoshino M., Waterston R., Lander E.S., Rogers J.,
RA   Birney E., Hayashizaki Y.;
RT   "Analysis of the mouse transcriptome based on functional annotation of
RT   60,770 full-length cDNAs.";
RL   Nature 420:563-573(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Mammary gland;
RX   MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA   Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA   Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA   Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA   Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA   Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA   Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA   Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA   Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA   Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA   Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA   Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA   Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA   Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA   Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA   Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA   Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA   Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT   "Generation and initial analysis of more than 15,000 full-length human
RT   and mouse cDNA sequences.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN   [4]
RP   X-RAY CRYSTALLOGRAPHY (2.53 ANGSTROMS) IN COMPLEX WITH SRP9.
RX   MEDLINE=97377014; PubMed=9233785; DOI=10.1093/emboj/16.13.3757;
RA   Birse D.E., Kapp U., Strub K., Cusack S., Aaberg A.;
RT   "The crystal structure of the signal recognition particle Alu RNA
RT   binding heterodimer, SRP9/14.";
RL   EMBO J. 16:3757-3766(1997).
CC   -!- FUNCTION: Signal-recognition-particle assembly has a crucial role
CC       in targeting secretory proteins to the rough endoplasmic reticulum
CC       membrane. SRP9 together with SRP14 and the Alu portion of the SRP
CC       RNA, constitutes the elongation arrest domain of SRP. The complex
CC       of SRP9 and SRP14 is required for SRP RNA binding.
CC   -!- SUBUNIT: Signal recognition particle consists of a 7S RNA molecule
CC       of 300 nucleotides and six protein subunits: SRP72, SRP68, SRP54,
CC       SRP19, SRP14 and SRP9.
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic.
CC   -!- SIMILARITY: Belongs to the SRP14 family.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; M29264; AAA40136.1; -; mRNA.
DR   EMBL; AK019310; BAB31658.1; -; mRNA.
DR   EMBL; BC021537; AAH21537.1; -; mRNA.
DR   PIR; B34501; B34501.
DR   PDB; 1914; X-ray; @=-.
DR   Ensembl; ENSMUSG00000009549; Mus musculus.
DR   MGI; MGI:107169; Srp14.
DR   InterPro; IPR003210; SRP14.
DR   InterPro; IPR009018; SRP9/14.
DR   PANTHER; PTHR12013; SRP14; 1.
DR   Pfam; PF02290; SRP14; 1.
DR   ProDom; PD009170; SRP14; 1.
KW   3D-structure; Direct protein sequencing; RNA-binding;
KW   Signal recognition particle.
FT   STRAND        3      4
FT   HELIX         6     19
FT   TURN         20     20
FT   STRAND       26     33
FT   STRAND       55     61
FT   STRAND       66     72
FT   TURN         73     74
FT   HELIX        76     90
FT   STRAND       95     95
SQ   SEQUENCE   110 AA;  12510 MW;  95EB062DBC0CCA25 CRC64;
     MVLLESEQFL TELTRLFQKC RSSGSVFITL KKYDGRTKPI PRKSSVEGLE PAENKCLLRA
     TDGKRKISTV VSSKEVNKFQ MAYSNLLRAN MDGLKKRDKK NKSKKSKPAQ
//
ID   RGS9_BOVIN     STANDARD;      PRT;   484 AA.
AC   O46469;
DT   15-DEC-1998 (Rel. 37, Created)
DT   15-DEC-1998 (Rel. 37, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Regulator of G-protein signaling 9 (RGS9).
GN   Name=RGS9;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC   Pecora; Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=98119533; PubMed=9459445; DOI=10.1016/S0896-6273(00)80437-7;
RA   He W., Cowan C.W., Wensel T.G.;
RT   "RGS9, a GTPase accelerator for phototransduction.";
RL   Neuron 20:95-102(1998).
RN   [2]
RP   INTERACTION WITH GBETA5.
RX   MEDLINE=99162538; PubMed=10051575; DOI=10.1073/pnas.96.5.1947;
RA   Makino E.R., Handy J.W., Li T., Arshavsky V.Y.;
RT   "The GTPase activating factor for transducin in rod photoreceptors is
RT   the complex between RGS9 and type 5 G protein beta subunit.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:1947-1952(1999).
RN   [3]
RP   X-RAY CRYSTALLOGRAPHY (1.94 ANGSTROMS) OF 276-422.
RX   MEDLINE=21128750; PubMed=11234020; DOI=10.1038/35059138;
RA   Slep K.C., Kercher M.A., He W., Cowan C.W., Wensel T.G., Sigler P.B.;
RT   "Structural determinants for regulation of phosphodiesterase by a G
RT   protein at 2.0 A.";
RL   Nature 409:1071-1077(2001).
CC   -!- FUNCTION: Inhibits signal transduction by increasing the GTPase
CC       activity of G protein alpha subunits thereby driving them into
CC       their inactive GDP-bound form. Binds to G(t)-alpha. Involved in
CC       phototransduction; key element in the recovery phase of visual
CC       transduction.
CC   -!- SUBUNIT: Heterodimer with Gbeta5.
CC   -!- TISSUE SPECIFICITY: Photoreceptor outer segments.
CC   -!- PTM: Phosphorylation is decreased by light exposition.
CC   -!- SIMILARITY: Contains 1 DEP domain.
CC   -!- SIMILARITY: Contains 1 G protein gamma domain.
CC   -!- SIMILARITY: Contains 1 RGS domain.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; AF011357; AAC99480.1; -; mRNA.
DR   PDB; 1FQI; X-ray; A=276-422.
DR   PDB; 1FQJ; X-ray; B/E=-.
DR   PDB; 1FQK; X-ray; B/D=-.
DR   Reactome; O46469; -.
DR   InterPro; IPR000591; DEP.
DR   InterPro; IPR001770; G-gamma.
DR   InterPro; IPR000342; Regl_Gprotein.
DR   InterPro; IPR009058; Wing_hlx_DNA_bnd.
DR   Pfam; PF00610; DEP; 1.
DR   Pfam; PF00631; G-gamma; 1.
DR   Pfam; PF00615; RGS; 1.
DR   PRINTS; PR01301; RGSPROTEIN.
DR   ProDom; PD001580; Regl_Gprotein; 1.
DR   SMART; SM00049; DEP; 1.
DR   SMART; SM00224; GGL; 1.
DR   SMART; SM00315; RGS; 1.
DR   PROSITE; PS50186; DEP; 1.
DR   PROSITE; PS50058; G_PROTEIN_GAMMA; FALSE_NEG.
DR   PROSITE; PS50132; RGS; 1.
KW   3D-structure; Phosphorylation; Sensory transduction;
KW   Signal transduction inhibitor; Vision.
FT   DOMAIN       30    105       DEP.
FT   DOMAIN      219    280       G protein gamma-like.
FT   DOMAIN      299    414       RGS.
FT   MOD_RES     475    475       Phosphoserine (By similarity).
FT   HELIX       290    295
FT   TURN        296    298
FT   HELIX       300    304
FT   TURN        305    305
FT   HELIX       307    319
FT   TURN        320    321
FT   TURN        323    323
FT   HELIX       324    336
FT   TURN        337    337
FT   HELIX       340    342
FT   HELIX       343    354
FT   TURN        355    355
FT   TURN        357    358
FT   TURN        360    361
FT   HELIX       367    376
FT   TURN        377    378
FT   TURN        382    385
FT   HELIX       386    399
FT   TURN        400    400
FT   HELIX       401    405
FT   TURN        406    406
FT   HELIX       408    416
SQ   SEQUENCE   484 AA;  56680 MW;  3D8C61CEC1E22949 CRC64;
     MTIRHQGQQY RPRMAFLRKI EALVKDMQDP DTGVRVQNQK VKVVSIPHAM TGSDVLQWIS
     QRLWISGLEA QNLGNFIVKY GYIYPLQDPR NLTLKPDSSL YRFQTPYFWP TQQWPAEDVD
     YAIYLAKRNI KKKGILEEYE KENYNFLNKK INYKWDFVIM QAREQYRAGK ERNKVDRCAL
     DCQEKAYWLV HRCPPGANNV LDYGLDRVTN PNEDQKQTVV SVRKEIMYYR QALMRSTVKS
     SVSLGGIVKY SEQFSSNDAI MSGCLPSNPW ITDDTQFWDL NAKLVDIPTK MRVERWAFNF
     SELIRDPKGR QSFQHFLRKE FSGENLGFWE ACEDLKYGDQ SKVKEKAEEI YKLFLAPGAR
     RWINIDGKTM DITVKGLKHP HRYVLDAAQT HIYMLMKKDS YARYLKSPIY KEMLAKAIEP
     QGTTRKSSSL PFMRRHLRSS PSPVILRQLE EEAKAREAAT TVDITQVMSK LDRRSQLRKE
     PPPK
//
ID   GNAT1_BOVIN    STANDARD;      PRT;   349 AA.
AC   P04695;
DT   13-AUG-1987 (Rel. 05, Created)
DT   01-OCT-1994 (Rel. 30, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Guanine nucleotide-binding protein G(t), alpha-1 subunit (Transducin
DE   alpha-1 chain).
GN   Name=GNAT1;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC   Pecora; Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=85242674; PubMed=2409555;
RA   Medynski D.C., Sullivan K., Smith D., van Dop C., Chang F.-H.,
RA   Fung B.K.-K., Seeburg P.H., Bourne H.R.;
RT   "Amino acid sequence of the alpha subunit of transducin deduced from
RT   the cDNA sequence.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:4311-4315(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=85242675; PubMed=2989813;
RA   Yatsunami K., Khorana H.G.;
RT   "GTPase of bovine rod outer segments: the amino acid sequence of the
RT   alpha subunit as derived from the cDNA sequence.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:4316-4320(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=85213821; PubMed=3923359;
RA   Tanaba T., Nukada T., Nishikawa Y., Sugimoto K., Suzuki H.,
RA   Takahashi H., Noda M., Haga T., Ichiyama A., Kangawa K., Minamino N.,
RA   Matsuo H., Numa S.;
RT   "Primary structure of the alpha-subunit of transducin and its
RT   relationship to ras proteins.";
RL   Nature 315:242-245(1985).
RN   [4]
RP   PARTIAL PROTEIN SEQUENCE.
RX   MEDLINE=86130762; PubMed=3867352;
RA   Lipkin V.M., Obukhov A.N., Bogachuk A.P., Telezhinskaya I.N.,
RA   Shemyakin V.V.;
RT   "Isolation and characteristics of cyanogen bromide peptides of
RT   transducin alpha and beta subunits.";
RL   Bioorg. Khim. 11:1481-1492(1985).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).
RX   MEDLINE=94081949; PubMed=8259210; DOI=10.1038/366654a0;
RA   Noel J.P., Hamm H.E., Sigler P.B.;
RT   "The 2.2 A crystal structure of transducin-alpha complexed with GTP
RT   gamma S.";
RL   Nature 366:654-663(1993).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS).
RX   MEDLINE=94268548; PubMed=8208289; DOI=10.1038/369621a0;
RA   Lambright D.G., Noel J.P., Hamm H.E., Sigler P.B.;
RT   "Structural determinants for activation of the alpha-subunit of a
RT   heterotrimeric G protein.";
RL   Nature 369:621-628(1994).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS).
RX   MEDLINE=95059455; PubMed=7969474; DOI=10.1038/372276a0;
RA   Sondek J., Lambright D.G., Noel J.P., Hamm H.E., Sigler P.B.;
RT   "GTPase mechanism of Gproteins from the 1.7-A crystal structure of
RT   transducin alpha-GDP-AIF-4.";
RL   Nature 372:276-279(1994).
RN   [8]
RP   STRUCTURE BY NMR OF 339-349.
RC   TISSUE=Retina;
RX   MEDLINE=98208529; PubMed=9539726; DOI=10.1073/pnas.95.8.4270;
RA   Kisselev O.G., Kao J., Ponder J.W., Fann Y.C., Gautam N.,
RA   Marshall G.R.;
RT   "Light-activated rhodopsin induces structural binding motif in G
RT   protein alpha subunit.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:4270-4275(1998).
RN   [9]
RP   MYRISTOYLATION.
RX   MEDLINE=93063268; PubMed=1436039; DOI=10.1038/359749a0;
RA   Kokame K., Fukada Y., Yoshizawa T., Takao T., Shimonishi Y.;
RT   "Lipid modification at the N terminus of photoreceptor G-protein
RT   alpha-subunit.";
RL   Nature 359:749-752(1992).
CC   -!- FUNCTION: Guanine nucleotide-binding proteins (G proteins) are
CC       involved as modulators or transducers in various transmembrane
CC       signaling systems. Transducin is an amplifier and one of the
CC       transducers of a visual impulse that performs the coupling between
CC       rhodopsin and cGMP-phosphodiesterase.
CC   -!- SUBUNIT: G proteins are composed of 3 units; alpha, beta and
CC       gamma. The alpha chain contains the guanine nucleotide binding
CC       site.
CC   -!- TISSUE SPECIFICITY: Rod.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; K03253; AAA30787.1; -; mRNA.
DR   EMBL; K03254; AAA30791.1; -; mRNA.
DR   EMBL; X02440; CAA26285.1; -; mRNA.
DR   PIR; A22244; RGBOT1.
DR   PDB; 1AQG; NMR; @=339-349.
DR   PDB; 1FQJ; X-ray; A/D=-.
DR   PDB; 1FQK; X-ray; A/C=-.
DR   PDB; 1LVZ; NMR; A=341-349.
DR   PDB; 1TAD; X-ray; A/B/C=26-349.
DR   PDB; 1TAG; X-ray; @=26-349.
DR   PDB; 1TND; X-ray; A/B/C=26-349.
DR   Reactome; P04695; -.
DR   InterPro; IPR001019; Gprotein_alpha.
DR   InterPro; IPR001408; Gprotein_alpha_I.
DR   InterPro; IPR011025; GproteinA_insert.
DR   Pfam; PF00503; G-alpha; 1.
DR   PRINTS; PR00318; GPROTEINA.
DR   PRINTS; PR00441; GPROTEINAI.
DR   ProDom; PD000281; Gprotein_alpha; 1.
KW   3D-structure; ADP-ribosylation; Direct protein sequencing;
KW   GTP-binding; Lipoprotein; Multigene family; Myristate;
KW   Sensory transduction; Transducer; Vision.
FT   INIT_MET      0      0
FT   NP_BIND      35     42       GTP.
FT   NP_BIND     195    199       GTP.
FT   NP_BIND     264    267       GTP.
FT   MOD_RES     173    173       ADP-ribosylarginine (by cholera toxin).
FT   MOD_RES     346    346       ADP-ribosylcysteine (by pertussis toxin).
FT   LIPID         1      1       N-myristoyl glycine.
FT   STRAND       27     34
FT   TURN         37     38
FT   HELIX        41     52
FT   HELIX        58     85
FT   TURN         86     87
FT   TURN         93     94
FT   HELIX        95    108
FT   TURN        111    112
FT   HELIX       116    127
FT   HELIX       129    135
FT   TURN        136    137
FT   HELIX       138    141
FT   TURN        142    142
FT   TURN        145    146
FT   HELIX       147    151
FT   TURN        152    153
FT   HELIX       154    157
FT   TURN        158    158
FT   TURN        160    161
FT   HELIX       166    171
FT   STRAND      181    186
FT   TURN        187    188
FT   STRAND      189    196
FT   HELIX       200    207
FT   TURN        208    212
FT   STRAND      215    221
FT   HELIX       222    226
FT   STRAND      228    228
FT   TURN        233    234
FT   STRAND      236    236
FT   HELIX       237    249
FT   TURN        250    250
FT   HELIX       252    254
FT   TURN        255    256
FT   STRAND      258    264
FT   HELIX       266    272
FT   TURN        273    275
FT   HELIX       278    280
FT   TURN        281    281
FT   TURN        283    284
FT   HELIX       291    303
FT   TURN        304    305
FT   TURN        307    311
FT   STRAND      315    318
FT   TURN        321    322
FT   HELIX       324    338
SQ   SEQUENCE   349 AA;  39834 MW;  594593ED3AEDBC09 CRC64;
     GAGASAEEKH SRELEKKLKE DAEKDARTVK LLLLGAGESG KSTIVKQMKI IHQDGYSLEE
     CLEFIAIIYG NTLQSILAIV RAMTTLNIQY GDSARQDDAR KLMHMADTIE EGTMPKEMSD
     IIQRLWKDSG IQACFDRASE YQLNDSAGYY LSDLERLVTP GYVPTEQDVL RSRVKTTGII
     ETQFSFKDLN FRMFDVGGQR SERKKWIHCF EGVTCIIFIA ALSAYDMVLV EDDEVNRMHE
     SLHLFNSICN HRYFATTSIV LFLNKKDVFS EKIKKAHLSI CFPDYNGPNT YEDAGNYIKV
     QFLELNMRRD VKEIYSHMTC ATDTQNVKFV FDAVTDIIIK ENLKDCGLF
//
ID   GNAI1_BOVIN    STANDARD;      PRT;   353 AA.
AC   P63097; P04898; P11015; P31871;
DT   13-AUG-1987 (Rel. 05, Created)
DT   01-OCT-1994 (Rel. 30, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Guanine nucleotide-binding protein G(i), alpha-1 subunit (Adenylate
DE   cyclase-inhibiting G alpha protein).
GN   Name=GNAI1;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC   Pecora; Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=86136587; PubMed=2419165; DOI=10.1016/0014-5793(86)80347-7;
RA   Nukada T., Tanabe T., Takahashi H., Noda M., Haga K., Haga T.,
RA   Ichiyama A., Kangawa K., Hiranaga M., Matsuo H., Numa S.;
RT   "Primary structure of the alpha-subunit of bovine adenylate cyclase-
RT   inhibiting G-protein deduced from the cDNA sequence.";
RL   FEBS Lett. 197:305-310(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE OF 105-353.
RX   MEDLINE=87017009; PubMed=3094012;
RA   Michel T., Winslow J.W., Smith J.A., Seidman J.G., Neer E.J.;
RT   "Molecular cloning and characterization of cDNA encoding the GTP-
RT   binding protein alpha i and identification of a related protein, alpha
RT   h.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7663-7667(1986).
CC   -!- FUNCTION: Guanine nucleotide-binding proteins (G proteins) are
CC       involved as modulators or transducers in various transmembrane
CC       signaling systems. The G(i) proteins are involved in hormonal
CC       regulation of adenylate cyclase: they inhibit the cyclase in
CC       response to beta-adrenergic stimuli.
CC   -!- SUBUNIT: G proteins are composed of 3 units; alpha, beta and
CC       gamma. The alpha chain contains the guanine nucleotide binding
CC       site.
CC   -!- SIMILARITY: Belongs to the G-alpha family. G(i/o/t/z) subfamily.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; X03642; CAA27288.1; -; mRNA.
DR   EMBL; M14207; AAA30561.1; -; mRNA.
DR   PIR; A23631; RGBOI1.
DR   SMR; P63097; 31-346.
DR   InterPro; IPR001019; Gprotein_alpha.
DR   InterPro; IPR001408; Gprotein_alpha_I.
DR   Pfam; PF00503; G-alpha; 1.
KW   ADP-ribosylation; GTP-binding; Lipoprotein; Multigene family;
KW   Myristate; Palmitate; Transducer.
FT   INIT_MET      0      0       By similarity.
FT   NP_BIND      39     46       GTP (By similarity).
FT   NP_BIND     199    203       GTP (By similarity).
FT   NP_BIND     268    271       GTP (By similarity).
FT   MOD_RES     177    177       ADP-ribosylarginine (by cholera toxin).
FT   MOD_RES     350    350       ADP-ribosylcysteine (by pertussis toxin).
FT   LIPID         1      1       N-myristoyl glycine (By similarity).
FT   LIPID         2      2       S-palmitoyl cysteine (By similarity).
FT   CONFLICT    112    112       A -> S (in Ref. 2).
FT   CONFLICT    329    329       K -> N (in Ref. 2).
FT   CONFLICT    336    336       D -> E (in Ref. 2).
SQ   SEQUENCE   353 AA;  40230 MW;  B456C4E189530A6D CRC64;
     GCTLSAEDKA AVERSKMIDR NLREDGEKAA REVKLLLLGA GESGKSTIVK QMKIIHEAGY
     SEEECKQYKA VVYSNTIQSI IAIIRAMGRL KIDFGDSARA DDARQLFVLA GAAEEGFMTA
     ELAGVIKRLW KDSGVQACFN RSREYQLNDS AAYYLNDLDR IAQPNYIPTQ QDVLRTRVKT
     TGIVETHFTF KDLHFKMFDV GGQRSERKKW IHCFEGVTAI IFCVALSDYD LVLAEDEEMN
     RMHESMKLFD SICNNKWFTD TSIILFLNKK DLFEEKIKKS PLTICYPEYA GSNTYEEAAA
     YIQCQFEDLN KRKDTKEIYT HFTCATDTKN VQFVFDAVTD VIIKNNLKDC GLF
//
ID   MONA_DIOCU     STANDARD;      PRT;    45 AA.
AC   P02881;
DT   21-JUL-1986 (Rel. 01, Created)
DT   21-JUL-1986 (Rel. 01, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Monellin chain A (Monellin chain I).
OS   Dioscoreophyllum cumminsii (Serendipity berry).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; Ranunculales;
OC   Menispermaceae; Dioscoreophyllum.
OX   NCBI_TaxID=3457;
RN   [1]
RP   PROTEIN SEQUENCE.
RX   MEDLINE=91136778; PubMed=1368575;
RA   Kohmura M., Nio N., Ariyoshi Y.;
RT   "Complete amino acid sequence of the sweet protein monellin.";
RL   Agric. Biol. Chem. 54:2219-2224(1990).
RN   [2]
RP   PROTEIN SEQUENCE.
RX   MEDLINE=77004858; PubMed=964918;
RA   Frank G., Zuber H.;
RT   "The complete amino acid sequences of both subunits of the sweet
RT   protein monellin.";
RL   Hoppe-Seyler's Z. Physiol. Chem. 357:585-592(1976).
RN   [3]
RP   PROTEIN SEQUENCE.
RX   MEDLINE=76277941; PubMed=962914;
RA   Hudson G., Biemann K.;
RT   "Mass spectrometric sequencing of proteins. The structure of subunit I
RT   of monellin.";
RL   Biochem. Biophys. Res. Commun. 71:212-220(1976).
RN   [4]
RP   PROTEIN SEQUENCE OF 2-28.
RX   MEDLINE=76161292; PubMed=4107; DOI=10.1016/0005-2795(76)90293-2;
RA   Bohak Z., Li S.-L.;
RT   "The structure of monellin and its relation to the sweetness of the
RT   protein.";
RL   Biochim. Biophys. Acta 427:153-170(1976).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RX   MEDLINE=87287292; PubMed=3614382; DOI=10.1038/328739a0;
RA   Ogata C., Hatada M., Tomlinson G., Shin W.-C., Kim S.-H.;
RT   "Crystal structure of the intensely sweet protein monellin.";
RL   Nature 328:739-742(1987).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
RX   PubMed=15299859; DOI=10.1107/S0907444997006860;
RA   Bujacz G., Miller M., Harrison R., Thanki N., Gilliland G.L.,
RA   Ogata C., Kim S.-H., Wlodawer A.;
RT   "Structure of monellin refined to 2.3-A resolution in the orthorhombic
RT   crystal form.";
RL   Acta Crystallogr. D 53:713-719(1997).
RN   [7]
RP   SIMILARITY TO CYSTATINS.
RX   MEDLINE=93218009; PubMed=8464079;
RA   Murzin A.G.;
RT   "Sweet-tasting protein monellin is related to the cystatin family of
RT   thiol proteinase inhibitors.";
RL   J. Mol. Biol. 230:689-694(1993).
CC   -!- FUNCTION: Taste-modifying protein; intensely sweet-tasting
CC       protein.
CC   -!- SUBUNIT: Heterodimer of an A chain and a B chain.
CC   -!- BIOTECHNOLOGY: Natural monellin has not been mass marketed to the
CC       food industry, primarily due to the challenge of large-scale
CC       purification of the protein which is relatively sensitive to heat
CC       or acid treatment.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   PIR; JH0209; MLDIA.
DR   PDB; 1FA3; NMR; A=-.
DR   PDB; 1FUW; NMR; A=-.
DR   PDB; 1IV7; X-ray; A/B=-.
DR   PDB; 1IV9; X-ray; A/B=-.
DR   PDB; 1KRL; X-ray; A/C=2-45.
DR   PDB; 1M9G; NMR; A=-.
DR   PDB; 1MNL; NMR; @=-.
DR   PDB; 3MON; X-ray; A/C/E/G=2-45.
DR   PDB; 4MON; X-ray; A/C=1-45.
DR   InterPro; IPR000828; Monellin_A.
DR   PRINTS; PR00630; MONELLINA.
KW   3D-structure; Direct protein sequencing; Taste-modifying protein.
FT   VARIANT       1      1       Missing (in 90% of the chains).
FT   CONFLICT     23     23       D -> N (in Ref. 3).
FT   CONFLICT     26     27       ED -> QN (in Ref. 3).
FT   STRAND        4     10
FT   STRAND       13     15
FT   TURN         16     17
FT   STRAND       18     27
FT   TURN         28     30
FT   STRAND       33     33
FT   STRAND       37     39
SQ   SEQUENCE   45 AA;  5398 MW;  E086DF18521EC5B6 CRC64;
     FREIKGYEYQ LYVYASDKLF RADISEDYKT RGRKLLRFNG PVPPP
//
ID   MONB_DIOCU     STANDARD;      PRT;    50 AA.
AC   P02882;
DT   21-JUL-1986 (Rel. 01, Created)
DT   01-AUG-1991 (Rel. 19, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Monellin chain B (Monellin chain II).
OS   Dioscoreophyllum cumminsii (Serendipity berry).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; Ranunculales;
OC   Menispermaceae; Dioscoreophyllum.
OX   NCBI_TaxID=3457;
RN   [1]
RP   PROTEIN SEQUENCE.
RX   MEDLINE=91136778; PubMed=1368575;
RA   Kohmura M., Nio N., Ariyoshi Y.;
RT   "Complete amino acid sequence of the sweet protein monellin.";
RL   Agric. Biol. Chem. 54:2219-2224(1990).
RN   [2]
RP   PROTEIN SEQUENCE.
RX   MEDLINE=77004858; PubMed=964918;
RA   Frank G., Zuber H.;
RT   "The complete amino acid sequences of both subunits of the sweet
RT   protein monellin.";
RL   Hoppe-Seyler's Z. Physiol. Chem. 357:585-592(1976).
RN   [3]
RP   PROTEIN SEQUENCE.
RX   MEDLINE=76161292; PubMed=4107; DOI=10.1016/0005-2795(76)90293-2;
RA   Bohak Z., Li S.-L.;
RT   "The structure of monellin and its relation to the sweetness of the
RT   protein.";
RL   Biochim. Biophys. Acta 427:153-170(1976).
RN   [4]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RX   MEDLINE=87287292; PubMed=3614382; DOI=10.1038/328739a0;
RA   Ogata C., Hatada M., Tomlinson G., Shin W.-C., Kim S.-H.;
RT   "Crystal structure of the intensely sweet protein monellin.";
RL   Nature 328:739-742(1987).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS).
RX   MEDLINE=94047088; PubMed=8230222;
RA   Somoza J.R., Jiang F., Tong L., Kang C.-H., Cho J.M., Kim S.-H.;
RT   "Two crystal structures of a potently sweet protein. Natural monellin
RT   at 2.75-A resolution and single-chain monellin at 1.7-A resolution.";
RL   J. Mol. Biol. 234:390-404(1993).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
RX   PubMed=15299859; DOI=10.1107/S0907444997006860;
RA   Bujacz G., Miller M., Harrison R., Thanki N., Gilliland G.L.,
RA   Ogata C., Kim S.-H., Wlodawer A.;
RT   "Structure of monellin refined to 2.3-A resolution in the orthorhombic
RT   crystal form.";
RL   Acta Crystallogr. D 53:713-719(1997).
RN   [7]
RP   SIMILARITY TO CYSTATINS.
RX   MEDLINE=93218009; PubMed=8464079;
RA   Murzin A.G.;
RT   "Sweet-tasting protein monellin is related to the cystatin family of
RT   thiol proteinase inhibitors.";
RL   J. Mol. Biol. 230:689-694(1993).
CC   -!- FUNCTION: Taste-modifying protein; intensely sweet-tasting
CC       protein.
CC   -!- SUBUNIT: Heterodimer of an A chain and a B chain.
CC   -!- BIOTECHNOLOGY: Natural monellin has not been mass marketed to the
CC       food industry, primarily due to the challenge of large-scale
CC       purification of the protein which is relatively sensitive to heat
CC       or acid treatment.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   PIR; JH0210; MLDIB.
DR   PDB; 1FA3; NMR; A=-.
DR   PDB; 1FUW; NMR; A=-.
DR   PDB; 1IV7; X-ray; A/B=-.
DR   PDB; 1IV9; X-ray; A/B=-.
DR   PDB; 1KRL; X-ray; B/D=1-50.
DR   PDB; 1M9G; NMR; A=-.
DR   PDB; 1MNL; NMR; @=-.
DR   PDB; 1MOL; X-ray; A/B=1-48.
DR   PDB; 3MON; X-ray; B/D/F/H=1-48.
DR   PDB; 4MON; X-ray; B/D=1-48.
DR   InterPro; IPR002095; Monellin_B.
DR   PRINTS; PR00631; MONELLINB.
KW   3D-structure; Direct protein sequencing; Taste-modifying protein.
FT   SITE         41     41       Blocking, abolishes the sweet taste.
FT   CONFLICT     49     50       EN -> NE (in Ref. 2).
FT   STRAND        2      6
FT   HELIX        10     26
FT   TURN         28     29
FT   STRAND       34     48
FT   TURN         49     50
SQ   SEQUENCE   50 AA;  5835 MW;  F08396DFCD480C81 CRC64;
     GEWEIIDIGP FTQNLGKFAV DEENKIGQYG RLTFNKVIRP CMKKTIYEEN
//
ID   UL47_VZVD      STANDARD;      PRT;   819 AA.
AC   P09263;
DT   01-MAR-1989 (Rel. 10, Created)
DT   01-MAR-1989 (Rel. 10, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Alpha trans-inducing factor 91.8 kDa protein.
GN   Name=11;
OS   Varicella-zoster virus (strain Dumas) (VZV).
OC   Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
OC   Alphaherpesvirinae; Varicellovirus.
OX   NCBI_TaxID=10338;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=86306657; PubMed=3018124;
RA   Davison A.J., Scott J.E.;
RT   "The complete DNA sequence of varicella-zoster virus.";
RL   J. Gen. Virol. 67:1759-1816(1986).
CC   -!- FUNCTION: Modulates alpha trans-inducing factor-dependent
CC       activation of alpha genes.
CC   -!- SIMILARITY: Belongs to the herpesviruses UL47 family.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; X04370; CAA27894.1; -; Genomic_DNA.
DR   PIR; B27342; TNBE11.
DR   InterPro; IPR005029; Herpes_UL47.
DR   Pfam; PF03362; Herpes_UL47; 1.
KW   Repeat; Trans-acting factor; Transcription; Transcription regulation.
FT   REPEAT      117    132       1-1.
FT   REPEAT      133    148       1-2.
FT   REPEAT      149    164       1-3.
FT   REPEAT      165    180       1-4.
FT   REPEAT      181    185       2-1.
FT   REPEAT      186    190       2-2.
FT   REPEAT      191    206       1-5.
FT   REPEAT      207    218       1-6 (incomplete).
FT   REGION      117    218       5.5 X 16 AA tandem repeats.
FT   REGION      181    190       2 X 5 AA tandem repeats of G-E-A-E-E.
SQ   SEQUENCE   819 AA;  91830 MW;  1814DA0D5493B8C8 CRC64;
     MQSGHYNRRQ SRRQRISSNT TDSPRHTHGT RYRSTNWYTH PPQILSNSET LVAVQELLNS
     EMDQDSSSDA SDDFPGYALH HSTYNGSEQN TSTSRHENRI FKLTEREANE EININTDAID
     DEGEAEEGEA EEDAIDDEGE AEEGEAEEDA IDDEGEAEEG EAEEDAIDDE GEAEEGEAEE
     GEAEEGEAEE DAIDDEGEAE EDAAEEDAID DEGEAEEDYF SVSQVCSRDA DEVYFTLDPE
     ISYSTDLRIA KVMEPAVSKE LNVSKRCVEP VTLTGSMLAH NGFDESWFAM RECTRREYIT
     VQGLYDPIHL RYQFDTSRMT PPQILRTIPA LPNMTLGELL LIFPIEFMAQ PISIERILVE
     DVFLDRRASS KTHKYGPRWN SVYALPYNAG KMYVQHIPGF YDVSLRAVGQ GTAIWHHMIL
     STAACAISNR ISHGDGLGFL LDAAIRISAN CIFLGRNDNF GVGDPCWLED HLAGLPREAV
     PDVLQVTQLV LPNRGPTVAI MRGFFGALAY WPELRIAISE PSTSLVRYAT GHMELAEWFL
     FSRTHSLKPQ FTPTEREMLA SFFTLYVTLG GGMLNWICRA TAMYLAAPYH SRSAYIAVCE
     SLPYYYIPVN SDLLCDLEVL LLGEVDLPTV CESYATIAHE LTGYEAVRTA ATNFMIEFAD
     CYKESETDLM VSAYLGAVLL LQRVLGHANL LLLLLSGAAL YGGCSIYIPR GILDAYNTLM
     LAASPLYAHQ TLTSFWKDRD DAMQTLGIRP TTDVLPKEQD RIVQASPIEM NFRFVGLETI
     YPREQPIPSV DLAENLMQYR NEILGLDWKS VAMHLLRKY
//
ID   GSTP1_HUMAN    STANDARD;      PRT;   209 AA.
AC   P09211; O00460; Q15690;
DT   01-MAR-1989 (Rel. 10, Created)
DT   01-MAR-1989 (Rel. 10, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Glutathione S-transferase P (EC 2.5.1.18) (GST class-pi) (GSTP1-1).
GN   Name=GSTP1; Synonyms=GST3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=88026724; PubMed=3664469;
RA   Kano T., Sakai M., Muramatsu M.;
RT   "Structure and expression of a human class pi glutathione S-
RT   transferase messenger RNA.";
RL   Cancer Res. 47:5626-5630(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=89061690; PubMed=3196325;
RA   Cowell I.G., Dixon K.H., Pemble S.E., Ketterer B., Taylor J.B.;
RT   "The structure of the human glutathione S-transferase pi gene.";
RL   Biochem. J. 255:79-83(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=89252918; PubMed=2542132; DOI=10.1016/0378-1119(89)90377-6;
RA   Morrow C.S., Cowan K.H., Goldsmith M.E.;
RT   "Structure of the human genomic glutathione S-transferase-pi gene.";
RL   Gene 75:3-11(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=89168166; PubMed=2466554;
RA   Moscow J.A., Fairchild C.R., Madden M.J., Ransom D.T., Wieand H.S.,
RA   O'Brien E.E., Poplack D.G., Cossman J., Myers C.E., Cowan K.H.;
RT   "Expression of anionic glutathione-S-transferase and P-glycoprotein
RT   genes in human tissues and tumors.";
RL   Cancer Res. 49:1422-1428(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE.
RA   Bora P.S., Smith C., Lange L.G., Bora N.S., Jones C., Gerhard D.S.;
RL   Submitted (JUL-1994) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE, AND VARIANTS VAL-104 AND VAL-113.
RX   MEDLINE=97248556; PubMed=9092542; DOI=10.1074/jbc.272.15.10004;
RA   Ali-Osman F., Akande O., Antoun G., Mao J.X., Buolamwini J.;
RT   "Molecular cloning, characterization, and expression in Escherichia
RT   coli of full-length cDNAs of three human glutathione S-transferase Pi
RT   gene variants. Evidence for differential catalytic activity of the
RT   encoded proteins.";
RL   J. Biol. Chem. 272:10004-10012(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-104 AND VAL-113.
RA   Rieder M.J., Livingston R.J., Daniels M.R., Chung M.-W.,
RA   Miyamoto K.E., Nguyen C.P., Nguyen D.A., Poel C.L., Robertson P.D.,
RA   Schackwitz W.S., Sherwood J.K., Witrak L.A., Nickerson D.A.;
RT   "NIEHS-SNPs, environmental genome project, NIEHS ES15478, Department
RT   of Genome Sciences, Seattle, WA (URL: http://egp.gs.washington.edu).";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-104.
RC   TISSUE=Urinary bladder;
RX   MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA   Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA   Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA   Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA   Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA   Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA   Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA   Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA   Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA   Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA   Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA   Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA   Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA   Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA   Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA   Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA   Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA   Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT   "Generation and initial analysis of more than 15,000 full-length human
RT   and mouse cDNA sequences.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN   [9]
RP   PROTEIN SEQUENCE OF 1-23.
RX   MEDLINE=85154554; PubMed=3979555; DOI=10.1016/0014-5793(85)80324-0;
RA   Alin P., Mannervik B., Joernvall H.;
RT   "Structural evidence for three different types of glutathione
RT   transferase in human tissues.";
RL   FEBS Lett. 182:319-322(1985).
RN   [10]
RP   PROTEIN SEQUENCE OF 1-23.
RX   MEDLINE=86042634; PubMed=3864155;
RA   Mannervik B., Alin P., Guthenberg C., Jensson H., Tahir M.K.,
RA   Warholm M., Joernvall H.;
RT   "Identification of three classes of cytosolic glutathione transferase
RT   common to several mammalian species: correlation between structural
RT   data and enzymatic properties.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:7202-7206(1985).
RN   [11]
RP   PROTEIN SEQUENCE OF 1-13.
RX   MEDLINE=88280250; PubMed=3395118;
RA   Singh S.V., Ahmad H., Kurosky A., Awasthi Y.C.;
RT   "Purification and characterization of unique glutathione S-
RT   transferases from human muscle.";
RL   Arch. Biochem. Biophys. 264:13-22(1988).
RN   [12]
RP   PROTEIN SEQUENCE OF 1-11.
RC   TISSUE=Platelet;
RX   MEDLINE=22608298; PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [13]
RP   PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Colon carcinoma;
RX   MEDLINE=97295306; PubMed=9150948;
RA   Ji H., Reid G.E., Moritz R.L., Eddes J.S., Burgess A.W., Simpson R.J.;
RT   "A two-dimensional gel database of human colon carcinoma proteins.";
RL   Electrophoresis 18:605-613(1997).
RN   [14]
RP   PRIMARY AND SECONDARY STRUCTURAL ANALYZES.
RX   MEDLINE=90225809; PubMed=2327795;
RA   Ahmad H., Wilson D.E., Fritz R.R., Singh S.V., Medh R.D., Nagle G.T.,
RA   Awasthi Y.C., Kurosky A.;
RT   "Primary and secondary structural analyses of glutathione S-
RT   transferase pi from human placenta.";
RL   Arch. Biochem. Biophys. 278:398-408(1990).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS).
RX   MEDLINE=92395662; PubMed=1522586;
RA   Reinemer P., Dirr H.W., Ladenstein R., Huber R., Lo Bello M.,
RA   Federici G., Parker M.W.;
RT   "Three-dimensional structure of class pi glutathione S-transferase
RT   from human placenta in complex with S-hexylglutathione at 2.8-A
RT   resolution.";
RL   J. Mol. Biol. 227:214-226(1992).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS).
RX   MEDLINE=97164911; PubMed=9012673; DOI=10.1021/bi962316i;
RA   Oakley A.J., Rossjohn J., Lo Bello M., Caccuri A.M., Federici G.,
RA   Parker M.W.;
RT   "The three-dimensional structure of the human Pi class glutathione
RT   transferase P1-1 in complex with the inhibitor ethacrynic acid and its
RT   glutathione conjugate.";
RL   Biochemistry 36:576-585(1997).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS).
RX   MEDLINE=97392635; PubMed=9245401; DOI=10.1021/bi970805s;
RA   Ji X., Tordova M., O'Donnell R., Parsons J.F., Hayden J.B.,
RA   Gilliland G.L., Zimniak P.;
RT   "Structure and function of the xenobiotic substrate-binding site and
RT   location of a potential non-substrate-binding site in a class pi
RT   glutathione S-transferase.";
RL   Biochemistry 36:9690-9702(1997).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS).
RX   MEDLINE=98062356; PubMed=9398518; DOI=10.1006/jmbi.1997.1364;
RA   Oakley A.J., Lo Bello M., Battistoni A., Ricci G., Rossjohn J.,
RA   Villar H.O., Parker M.W.;
RT   "The structures of human glutathione transferase P1-1 in complex with
RT   glutathione and various inhibitors at high resolution.";
RL   J. Mol. Biol. 274:84-100(1997).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS).
RX   MEDLINE=98035452; PubMed=9351803; DOI=10.1016/S0969-2126(97)00281-5;
RA   Prade L., Huber R., Manoharan T.H., Fahl W.E., Reuter W.;
CC   -!- FUNCTION: Conjugation of reduced glutathione to a wide number of
CC       exogenous and endogenous hydrophobic electrophiles.
CC   -!- CATALYTIC ACTIVITY: RX + glutathione = HX + R-S-glutathione.
CC   -!- SUBUNIT: Homodimer.
CC   -!- SIMILARITY: Belongs to the GST superfamily. Pi family.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; M24485; AAA56823.1; -; Genomic_DNA.
DR   EMBL; X06547; CAA29794.1; -; mRNA.
DR   EMBL; X08094; CAA30894.1; -; Genomic_DNA.
DR   EMBL; X08095; CAA30894.1; JOINED; Genomic_DNA.
DR   EMBL; X08096; CAA30894.1; JOINED; Genomic_DNA.
DR   EMBL; X08058; CAA30847.1; -; Genomic_DNA.
DR   EMBL; X15480; CAA33508.1; -; mRNA.
DR   EMBL; U12472; AAA64919.1; -; Genomic_DNA.
DR   EMBL; U30897; AAC51280.1; -; mRNA.
DR   EMBL; U21689; AAC13869.1; -; Genomic_DNA.
DR   EMBL; U62589; AAC51237.1; -; mRNA.
DR   EMBL; AY324387; AAP72967.1; -; Genomic_DNA.
DR   EMBL; BC010915; AAH10915.1; -; mRNA.
DR   PIR; JS0153; A37378.
DR   PDB; 10GS; X-ray; A/B=1-209.
DR   PDB; 11GS; X-ray; A/B=1-209.
DR   PDB; 12GS; X-ray; A/B=1-209.
DR   PDB; 13GS; X-ray; A/B=1-209.
DR   PDB; 14GS; X-ray; A/B=1-209.
DR   PDB; 16GS; X-ray; A/B=1-209.
DR   PDB; 17GS; X-ray; A/B=1-209.
DR   PDB; 18GS; X-ray; A/B=1-209.
DR   PDB; 19GS; X-ray; A/B=1-209.
DR   PDB; 1AQV; X-ray; A/B=1-209.
DR   PDB; 1AQW; X-ray; A/B/C/D=1-209.
DR   PDB; 1AQX; X-ray; A/B/C/D=1-209.
DR   PDB; 1EOG; X-ray; A/B=2-209.
DR   PDB; 1EOH; X-ray; A/B/C/D/E/F/G/H=1-209.
DR   PDB; 1GSS; X-ray; A/B=1-209.
DR   PDB; 1KBN; X-ray; A/B=1-209.
DR   PDB; 1LBK; X-ray; A/B=-.
DR   PDB; 1MD3; X-ray; A/B=1-209.
DR   PDB; 1MD4; X-ray; A/B=1-209.
DR   PDB; 1PGT; X-ray; A/B=1-209.
DR   PDB; 1PX6; X-ray; A/B=1-209.
DR   PDB; 1PX7; X-ray; A/B=1-209.
DR   PDB; 20GS; X-ray; A/B=1-209.
DR   PDB; 21GS; X-ray; A/B=1-209.
DR   PDB; 22GS; X-ray; A/B=1-209.
DR   PDB; 2GSS; X-ray; A/B=1-209.
DR   PDB; 2PGT; X-ray; A/B=1-209.
DR   PDB; 3GSS; X-ray; A/B=1-209.
DR   PDB; 3PGT; X-ray; A/B=1-209.
DR   PDB; 4GSS; X-ray; A/B=1-209.
DR   PDB; 4PGT; X-ray; A/B=1-209.
DR   PDB; 5GSS; X-ray; A/B=1-209.
DR   PDB; 6GSS; X-ray; A/B=1-209.
DR   PDB; 7GSS; X-ray; A/B=1-209.
DR   PDB; 8GSS; X-ray; A/B/C=1-209.
DR   PDB; 9GSS; X-ray; A/B=1-209.
DR   IntAct; P09211; -.
DR   SWISS-2DPAGE; P09211; HUMAN.
DR   Aarhus/Ghent-2DPAGE; 5101; IEF.
DR   HSC-2DPAGE; P09211; HUMAN.
DR   OGP; P09211; -.
DR   PHCI-2DPAGE; P09211; -.
DR   Siena-2DPAGE; P09211; -.
DR   Ensembl; ENSG00000084207; Homo sapiens.
DR   Genew; HGNC:4638; GSTP1.
DR   H-InvDB; HIX0009866; -.
DR   MIM; 134660; -.
DR   GO; GO:0007417; P:central nervous system development; TAS.
DR   InterPro; IPR010987; GST_C_like.
DR   InterPro; IPR004046; GST_Cterm.
DR   InterPro; IPR004045; GST_Nterm.
DR   InterPro; IPR003082; GST_pi.
DR   Pfam; PF00043; GST_C; 1.
DR   Pfam; PF02798; GST_N; 1.
DR   PRINTS; PR01268; GSTRNSFRASEP.
KW   3D-structure; Direct protein sequencing; Multigene family;
KW   Polymorphism; Transferase.
FT   INIT_MET      0      0
FT   VARIANT     104    104       I -> V (in allele GSTP1*B and allele
FT                                GSTP1*C; dbSNP:1695).
FT                                /FTId=VAR_014499.
FT   VARIANT     113    113       A -> V (in allele GSTP1*C;
FT                                dbSNP:1799811).
FT                                /FTId=VAR_014500.
FT   CONFLICT    185    185       A -> P (in Ref. 2).
FT   STRAND        3      7
FT   HELIX        12     14
FT   HELIX        15     23
FT   TURN         24     25
FT   STRAND       28     32
FT   HELIX        35     40
FT   HELIX        42     46
FT   TURN         48     49
FT   STRAND       54     57
FT   TURN         58     59
FT   STRAND       60     63
FT   HELIX        65     76
FT   TURN         77     77
FT   HELIX        83    109
FT   HELIX       111    134
FT   TURN        135    136
FT   HELIX       137    139
FT   TURN        140    140
FT   TURN        145    146
FT   HELIX       150    165
FT   TURN        167    172
FT   HELIX       174    184
FT   TURN        185    185
FT   HELIX       187    194
FT   HELIX       196    199
FT   TURN        200    200
FT   TURN        205    206
SQ   SEQUENCE   209 AA;  23225 MW;  247DB5D4B67D058A CRC64;
     PPYTVVYFPV RGRCAALRML LADQGQSWKE EVVTVETWQE GSLKASCLYG QLPKFQDGDL
     TLYQSNTILR HLGRTLGLYG KDQQEAALVD MVNDGVEDLR CKYISLIYTN YEAGKDDYVK
     ALPGQLKPFE TLLSQNQGGK TFIVGDQISF ADYNLLDLLL IHEVLAPGCL DAFPLLSAYV
     GRLSARPKLK AFLASPEYVN LPINGNGKQ
//
ID   Q6Q757_BOVIN PRELIMINARY;      PRT;   307 AA.
AC   Q6Q757;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Myocyte enhancer factor 2A (Fragment).
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC   Pecora; Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Skeletal muscle;
RA   Yu S.L., Chung H.J., Jung K.C., Lee J.H., Yoon D.H., Lee S.H.,
RA   Sang B.C.;
RL   Submitted (FEB-2004) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AY555276; AAS50178.1; -; mRNA.
FT   NON_TER       1      1
FT   NON_TER     307    307
SQ   SEQUENCE   307 AA;  31709 MW;  9DC18B5260309E63 CRC64;
     KEHRGCDSPD PDTSYVLTPH TEEKYKKINE EFDNMMRNHK IAPGLPPQNF SMSVTVPVTS
     PSALSYTNPG SSLVSPSLAA SSALADTSML SPPQATLHRN VSPGAPQRPP STGSAGGMLS
     TSDLTVPNGA GSSPVGNGFV NSRASPNLIG TTGANSLGKV MPTKSPPPPG GGSLGMNSRK
     PDLRVVIPPS SKGMMPPLSE EEELELNTQR ISSSQATQPL ATPVVSVTTP SLPPQGLVYS
     AMPTAYNTDY SLTSADLSAL QGFNSPGMLS LGQVSAWQQH HLGQAALNSL VAGGQLSQGS
     NLSINTN
//
ID   MEF2A_HUMAN    STANDARD;      PRT;   507 AA.
AC   Q02078; O43814; Q14223; Q14224; Q96D14;
DT   01-NOV-1995 (Rel. 32, Created)
DT   01-NOV-1995 (Rel. 32, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Myocyte-specific enhancer factor 2A (Serum response factor-like
DE   protein 1).
GN   Name=MEF2A; Synonyms=MEF2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Heart, and Skeletal muscle;
RX   MEDLINE=92387551; PubMed=1516833;
RA   Yu Y.-T., Breitbart R.E., Smoot L.B., Lee Y., Mahdavi V.,
RA   Nadal-Ginard B.;
RT   "Human myocyte-specific enhancer factor 2 comprises a group of tissue-
RT   restricted MADS box transcription factors.";
RL   Genes Dev. 6:1783-1798(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Placenta;
RX   MEDLINE=92084105; PubMed=1748287;
RA   Pollock R., Treisman R.;
RT   "Human SRF-related proteins: DNA-binding properties and potential
RT   regulatory targets.";
RL   Genes Dev. 5:2327-2341(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE (ISOFORM RSFRC9), AND SEQUENCE REVISION.
RA   Treisman R.;
RL   Submitted (NOV-1993) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE (RSRFC4 AND RSFRC9).
RA   Suzuki E., Lowry J., Sonoda G., Testa J.R., Walsh K.;
RL   Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE (ISOFORM RSFRC9).
RC   TISSUE=Placenta;
RA   Pollock R.M.;
RL   Submitted (NOV-1991) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Pancreas;
RX   MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA   Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA   Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA   Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA   Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA   Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA   Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA   Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA   Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA   Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA   Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA   Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA   Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA   Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA   Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA   Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA   Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA   Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT   "Generation and initial analysis of more than 15,000 full-length human
RT   and mouse cDNA sequences.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN   [7]
RP   INTERACTION WITH HDAC4.
RX   MEDLINE=99417590; PubMed=10487761; DOI=10.1093/emboj/18.18.5099;
RA   Miska E.A., Karlsson C., Langley E., Nielsen S.J., Pines J.,
RA   Kouzarides T.;
RT   "HDAC4 deacetylase associates with and represses the MEF2
RT   transcription factor.";
RL   EMBO J. 18:5099-5107(1999).
RN   [8]
RP   VARIANT ADCAD1 440-GLN--PRO-446 DEL.
RX   PubMed=14645853; DOI=10.1126/science.1088477;
RA   Wang L., Fan C., Topol S.E., Topol E.J., Wang Q.;
RT   "Mutation of MEF2A in an inherited disorder with features of coronary
RT   artery disease.";
RL   Science 302:1578-1581(2003).
CC   -!- FUNCTION: Transcription factor which binds specifically to the
CC       MEF2 element present in the regulatory regions of many muscle-
CC       specific genes. Activates transcription via this element. May be
CC       involved in muscle-specific and/or growth factor-related
CC       transcription.
CC   -!- SUBUNIT: Interacts with HDAC7 (By similarity). Heterodimer.
CC       Interacts with HDAC4.
CC   -!- SUBCELLULAR LOCATION: Nuclear.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=MEF2;
CC         IsoId=Q02078-1; Sequence=Displayed;
CC       Name=MEFA;
CC         IsoId=Q02078-2; Sequence=VSP_006240;
CC       Name=RSRFC4;
CC         IsoId=Q02078-3; Sequence=VSP_006241, VSP_006242;
CC       Name=RSRFC9;
CC         IsoId=Q02078-4; Sequence=VSP_006240, VSP_006241, VSP_006242;
CC       Name=5;
CC         IsoId=Q02078-5; Sequence=VSP_006241;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Isoform MEF2 and isoform MEFA are expressed
CC       only in skeletal and cardiac muscle and in the brain while isoform
CC       RSRFC4 and isoform RSRFC9 are expressed in all tissues examined.
CC   -!- DISEASE: Defects in MEF2A are a cause of autosomal dominant
CC       coronary artery disease 1 with myocardial infarction (ADCAD1)
CC       [MIM:608320].
CC   -!- SIMILARITY: Belongs to the MEF2 family.
CC   -!- SIMILARITY: Contains 1 MADS-box domain.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; X68505; CAA48517.1; -; mRNA.
DR   EMBL; X63381; CAA44979.1; -; mRNA.
DR   EMBL; X68503; CAA48516.1; -; mRNA.
DR   EMBL; U49020; AAB17195.1; -; Genomic_DNA.
DR   EMBL; U44889; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49012; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49013; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49015; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49016; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49017; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49018; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49019; AAB17195.1; JOINED; Genomic_DNA.
DR   EMBL; U49020; AAB17196.1; -; Genomic_DNA.
DR   EMBL; U44889; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; U49012; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; U49013; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; U49015; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; U49016; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; U49017; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; U49018; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; U49019; AAB17196.1; JOINED; Genomic_DNA.
DR   EMBL; Y16312; CAA76175.1; -; mRNA.
DR   EMBL; BC013437; AAH13437.1; -; mRNA.
DR   PIR; S25831; S25831.
DR   PDB; 1C7U; NMR; A/B=2-86.
DR   PDB; 1EGW; X-ray; A/B/C/D=2-78.
DR   TRANSFAC; T01005; -.
DR   TRANSFAC; T01010; -.
DR   Ensembl; ENSG00000068305; Homo sapiens.
DR   Genew; HGNC:6993; MEF2A.
DR   H-InvDB; HIX0012611; -.
DR   MIM; 600660; -.
DR   MIM; 608320; -.
DR   GO; GO:0005634; C:nucleus; TAS.
DR   GO; GO:0003700; F:transcription factor activity; NAS.
DR   GO; GO:0007517; P:muscle development; TAS.
DR   InterPro; IPR002100; TF_MADSbox.
DR   Pfam; PF00319; SRF-TF; 1.
DR   PRINTS; PR00404; MADSDOMAIN.
DR   PROSITE; PS00350; MADS_BOX_1; 1.
DR   PROSITE; PS50066; MADS_BOX_2; 1.
KW   3D-structure; Activator; Alternative splicing; Disease mutation;
KW   DNA-binding; Multigene family; Nuclear protein; Phosphorylation;
KW   Transcription; Transcription regulation.
FT   DOMAIN        3     57       MADS-box.
FT   DNA_BIND     58     86       Mef2-type (Potential).
FT   COMPBIAS      4     31       Lys-rich (basic).
FT   COMPBIAS    141    186       Ser/Thr-rich.
FT   COMPBIAS    420    446       Gln/Pro-rich.
FT   MOD_RES     289    289       Phosphoserine (by CK2) (Potential).
FT   VARSPLIC     87    132       ALNKKEHRGCDSPDPDTSYVLTPHTEEKYKKINEEFDNMMR
FT                                NHKIA -> TLRKKGLNGCESPDADDYFEHSPLSEDRFSKL
FT                                NEDSDFIFKRGP (in isoform MEFA and isoform
FT                                RSRFC9).
FT                                /FTId=VSP_006240.
FT   VARSPLIC    288    295       Missing (in isoform RSRFC4, isoform
FT                                RSRFC9 and isoform 5).
FT                                /FTId=VSP_006241.
FT   VARSPLIC    420    421       Missing (in isoform RSRFC4 and isoform
FT                                RSRFC9).
FT                                /FTId=VSP_006242.
FT   VARIANT     440    446       Missing (in ADCAD1; loss of nuclear
FT                                localization; 66% decrease in
FT                                transcription activation; loss of
FT                                synergistic activation by MEF2A and GATA1
FT                                through a dominant-negative mechanism).
FT                                /FTId=VAR_017743.
FT   CONFLICT    430    430       Missing (in Ref. 4).
FT   HELIX        14     38
FT   TURN         39     40
FT   STRAND       42     48
FT   TURN         50     51
FT   STRAND       54     58
FT   HELIX        62     72
SQ   SEQUENCE   507 AA;  54811 MW;  362BA4FBCC792CE2 CRC64;
     MGRKKIQITR IMDERNRQVT FTKRKFGLMK KAYELSVLCD CEIALIIFNS SNKLFQYAST
     DMDKVLLKYT EYNEPHESRT NSDIVEALNK KEHRGCDSPD PDTSYVLTPH TEEKYKKINE
     EFDNMMRNHK IAPGLPPQNF SMSVTVPVTS PNALSYTNPG SSLVSPSLAA SSTLTDSSML
     SPPQTTLHRN VSPGAPQRPP STGNAGGMLS TTDLTVPNGA GSSPVGNGFV NSRASPNLIG
     ATGANSLGKV MPTKSPPPPG GGNLGMNSRK PDLRVVIPPS SKGMMPPLSE EEELELNTQR
     ISSSQATQPL ATPVVSVTTP SLPPQGLVYS AMPTAYNTDY SLTSADLSAL QGFNSPGMLS
     LGQVSAWQQH HLGQAALSSL VAGGQLSQGS NLSINTNQNI SIKSEPISPP RDRMTPSGFQ
     QQQQQQQQQQ PPPPPQPQPQ PPQPQPRQEM GRSPVDSLSS SSSSYDGSDR EDPRGDFHSP
     IVLGRPPNTE DRESPSVKRM RMDAWVT
//
ID   MK14_MOUSE     STANDARD;      PRT;   359 AA.
AC   P47811; O08666; Q8C289; Q9JLV8; Q9QZ80;
DT   01-FEB-1996 (Rel. 33, Created)
DT   05-JUL-2004 (Rel. 44, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Mitogen-activated protein kinase 14 (EC 2.7.1.37) (Mitogen-activated
DE   protein kinase p38 alpha) (MAP kinase p38 alpha) (CRK1).
GN   Name=Mapk14; Synonyms=Crk1, Csbp1, Csbp2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 1), AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Liver;
RX   MEDLINE=94323764; PubMed=7914033;
RA   Han J., Lee J.-D., Bibbs L., Ulevitch R.J.;
RT   "A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian
RT   cells.";
RL   Science 265:808-811(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 3).
RC   STRAIN=C57BL/6; TISSUE=Brain;
RA   Higashitsuji H., Fujita J.;
RL   Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 2).
RC   STRAIN=C57BL/6; TISSUE=Kidney;
RA   Faccio L., Fusco C., Zervos S.A.;
RT   "Piccolo, a new alternative spliced form of p38/CSBP1/Mxi2 that is
RT   specifically expressed in kidney and liver.";
RL   Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Thymus;
RX   MEDLINE=22354683; PubMed=12466851; DOI=10.1038/nature01266;
RA   Okazaki Y., Furuno M., Kasukawa T., Adachi J., Bono H., Kondo S.,
RA   Nikaido I., Osato N., Saito R., Suzuki H., Yamanaka I., Kiyosawa H.,
RA   Yagi K., Tomaru Y., Hasegawa Y., Nogami A., Schonbach C., Gojobori T.,
RA   Baldarelli R., Hill D.P., Bult C., Hume D.A., Quackenbush J.,
RA   Schriml L.M., Kanapin A., Matsuda H., Batalov S., Beisel K.W.,
RA   Blake J.A., Bradt D., Brusic V., Chothia C., Corbani L.E., Cousins S.,
RA   Dalla E., Dragani T.A., Fletcher C.F., Forrest A., Frazer K.S.,
RA   Gaasterland T., Gariboldi M., Gissi C., Godzik A., Gough J.,
RA   Grimmond S., Gustincich S., Hirokawa N., Jackson I.J., Jarvis E.D.,
RA   Kanai A., Kawaji H., Kawasawa Y., Kedzierski R.M., King B.L.,
RA   Konagaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,
RA   Maglott D.R., Maltais L., Marchionni L., McKenzie L., Miki H.,
RA   Nagashima T., Numata K., Okido T., Pavan W.J., Pertea G., Pesole G.,
RA   Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramachandran S.,
RA   Ravasi T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,
RA   Sandelin A., Schneider C., Semple C.A., Setou M., Shimada K.,
RA   Sultana R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita M.,
RA   Verardo R., Wagner L., Wahlestedt C., Wang Y., Watanabe Y., Wells C.,
RA   Wilming L.G., Wynshaw-Boris A., Yanagisawa M., Yang I., Yang L.,
RA   Yuan Z., Zavolan M., Zhu Y., Zimmer A., Carninci P., Hayatsu N.,
RA   Hirozane-Kishikawa T., Konno H., Nakamura M., Sakazume N., Sato K.,
RA   Shiraki T., Waki K., Kawai J., Aizawa K., Arakawa T., Fukuda S.,
RA   Hara A., Hashizume W., Imotani K., Ishii Y., Itoh M., Kagawa I.,
RA   Miyazaki A., Sakai K., Sasaki D., Shibata K., Shinagawa A.,
RA   Yasunishi A., Yoshino M., Waterston R., Lander E.S., Rogers J.,
RA   Birney E., Hayashizaki Y.;
RT   "Analysis of the mouse transcriptome based on functional annotation of
RT   60,770 full-length cDNAs.";
RL   Nature 420:563-573(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA   Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA   Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA   Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA   Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA   Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA   Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA   Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA   Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA   Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA   Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA   Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA   Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA   Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA   Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA   Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA   Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA   Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT   "Generation and initial analysis of more than 15,000 full-length human
RT   and mouse cDNA sequences.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE OF 93-317 (ISOFORM 3).
RC   TISSUE=Testis;
RA   Yin Z., Li J., Sha J., Zhou Z., Lin M., Wang L.;
RL   Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE OF 153-185.
RC   STRAIN=CBA; TISSUE=Bone marrow;
RX   MEDLINE=93185941; PubMed=8444355; DOI=10.1016/0378-1119(93)90411-U;
RA   Ershler M.A., Nagorskaya T.V., Visser J.W.M., Belyavsky A.V.;
RT   "Novel CDC2-related protein kinases produced in murine hematopoietic
RT   stem cells.";
RL   Gene 124:305-306(1993).
RN   [8]
RP   MUTAGENESIS.
RX   MEDLINE=95141073; PubMed=7839144;
RA   Derijard B., Raingeaud J., Barrett T., Wu I.-H., Han J.,
RA   Ulevitch R.J., Davis R.J.;
RT   "Independent human MAP-kinase signal transduction pathways defined by
RT   MEK and MKK isoforms.";
RL   Science 267:682-685(1995).
RN   [9]
RP   INTERACTION WITH PTPRR, AND SUBCELLULAR LOCATION.
RX   MEDLINE=20069779; PubMed=10601328; DOI=10.1083/jcb.147.6.1129;
RA   Blanco-Aparicio C., Torres J., Pulido R.;
RT   "A novel regulatory mechanism of MAP kinases activation and nuclear
RT   translocation mediated by PKA and the PTP-SL tyrosine phosphatase.";
RL   J. Cell Biol. 147:1129-1136(1999).
RN   [10]
RP   FUNCTION, AND ENZYME REGULATION.
RC   TISSUE=Embryonic stem cells;
RX   MEDLINE=20171471; PubMed=10704466;
RA   Allen M., Svensson L., Roach M., Hambor J., McNeish J., Gabel C.A.;
RT   "Deficiency of the stress kinase p38alpha results in embryonic
RT   lethality: characterization of the kinase dependence of stress
RT   responses of enzyme-deficient embryonic stem cells.";
RL   J. Exp. Med. 191:859-870(2000).
RN   [11]
RP   FUNCTION, AND SUBUNIT.
RC   STRAIN=C57BL/6J;
RX   MEDLINE=20397758; PubMed=10943842; DOI=10.1016/S0092-8674(00)00027-1;
RA   Tamura K., Sudo T., Senftleben U., Dadak A.M., Johnson R., Karin M.;
RT   "Requirement for p38alpha in erythropoietin expression: a role for
RT   stress kinases in erythropoiesis.";
RL   Cell 102:221-231(2000).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS).
RX   MEDLINE=97225952; PubMed=9122194; DOI=10.1073/pnas.94.6.2327;
RA   Wang Z., Harkins P.C., Ulevitch R.J., Han J., Cobb M.H.,
RA   Goldsmith E.J.;
RT   "The structure of mitogen-activated protein kinase p38 at 2.1-A
RT   resolution.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:2327-2332(1997).
CC   -!- FUNCTION: Responds to activation by environmental stress, pro-
CC       inflammatory cytokines and lipopolysaccharide (LPS) by
CC       phosphorylating a number of transcription factors, such as ELK1
CC       and ATF2 and several downstream kinases, such as MAPKAPK2 and
CC       MAPKAPK5. Plays a critical role in the production of some
CC       cytokines, for example IL-6. Required in mid-fetal development for
CC       the growth of embryo-derived blood vessels in the labyrinth layer
CC       of the placenta. Also plays an essential role in developmental and
CC       stress-induced erythropoiesis, through regulation of EPO gene
CC       expression.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Magnesium.
CC   -!- ENZYME REGULATION: Activated by threonine and tyrosine
CC       phosphorylation by either of two dual
DR   EMBL; U10871; AAA20888.1; -; mRNA.
DR   EMBL; D83073; BAA19741.1; -; mRNA.
DR   EMBL; AF128892; AAF34818.1; -; mRNA.
DR   EMBL; AK089059; BAC40726.1; -; mRNA.
DR   EMBL; BC012235; AAH12235.1; -; mRNA.
DR   EMBL; AF195850; AAF06348.1; -; mRNA.
DR   EMBL; X65067; CAA46200.1; -; mRNA.
DR   PIR; I49066; I49066.
DR   PDB; 1LEW; X-ray; A=-.
DR   PDB; 1LEZ; X-ray; A=1-359.
DR   PDB; 1P38; X-ray; @=1-359.
DR   IntAct; P47811; -.
DR   Ensembl; ENSMUSG00000053436; Mus musculus.
DR   MGI; MGI:1346865; Mapk14.
DR   GO; GO:0005623; C:cell; IDA.
DR   GO; GO:0005737; C:cytoplasm; IDA.
DR   GO; GO:0005634; C:nucleus; IDA.
DR   GO; GO:0000922; C:spindle pole; IDA.
DR   GO; GO:0016301; F:kinase activity; IDA.
DR   GO; GO:0004708; F:MAP kinase kinase activity; ISS.
DR   GO; GO:0008339; F:MP kinase activity; IDA.
DR   GO; GO:0001525; P:angiogenesis; IMP.
DR   GO; GO:0019735; P:antimicrobial humoral response (sensu Verte...; ISS.
DR   GO; GO:0006928; P:cell motility; ISS.
DR   GO; GO:0007166; P:cell surface receptor linked signal transdu...; ISS.
DR   GO; GO:0006935; P:chemotaxis; ISS.
DR   GO; GO:0000077; P:DNA damage checkpoint; IMP.
DR   GO; GO:0019395; P:fatty acid oxidation; IMP.
DR   GO; GO:0006006; P:glucose metabolism; IMP.
DR   GO; GO:0007243; P:protein kinase cascade; IDA.
DR   GO; GO:0006950; P:response to stress; IDA.
DR   InterPro; IPR003527; MAP_kin.
DR   InterPro; IPR008352; p38_MAPK.
DR   InterPro; IPR000719; Prot_kinase.
DR   InterPro; IPR008271; Ser_thr_pkin_AS.
DR   InterPro; IPR002290; Ser_thr_pkinase.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01773; P38MAPKINASE.
DR   ProDom; PD000001; Prot_kinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; FALSE_NEG.
KW   3D-structure; Alternative splicing; ATP-binding;
KW   Direct protein sequencing; Kinase; Nuclear protein; Phosphorylation;
KW   Serine/threonine-protein kinase; Transferase.
FT   INIT_MET      0      0       By similarity.
FT   DOMAIN       23    307       Protein kinase.
FT   NP_BIND      29     37       ATP (By similarity).
FT   ACT_SITE    167    167       Proton acceptor (By similarity).
FT   BINDING      52     52       ATP (By similarity).
FT   MOD_RES     179    179       Phosphothreonine.
FT   MOD_RES     181    181       Phosphotyrosine.
FT   VARSPLIC    229    253       DQLKLILRLVGTPGAELLKKISSES -> NQLQQIMRMTGT
FT                                PPAYLINRMPSHE (in isoform 3).
FT                                /FTId=VSP_007544.
FT   VARSPLIC    254    277       ARNYIQSLAQMPKMNFANVFIGAN -> DAK (in
FT                                isoform 2).
FT                                /FTId=VSP_004846.
FT   VARSPLIC    278    359       Missing (in isoform 2).
FT                                /FTId=VSP_007545.
FT   MUTAGEN     179    179       T->A: Phosphorylation blocked.
FT   MUTAGEN     181    181       Y->F: Phosphorylation blocked.
FT   CONFLICT     97     97       E -> G (in Ref. 6).
FT   CONFLICT    106    107       HL -> LS (in Ref. 6).
FT   CONFLICT    114    114       N -> R (in Ref. 6).
FT   CONFLICT    123    123       D -> G (in Ref. 6).
FT   CONFLICT    158    161       NEDC -> TQVI (in Ref. 6).
FT   CONFLICT    165    165       I -> L (in Ref. 6).
FT   CONFLICT    201    201       Q -> R (in Ref. 6).
FT   CONFLICT    210    211       CI -> GF (in Ref. 6).
FT   CONFLICT    223    223       P -> L (in Ref. 6).
FT   CONFLICT    270    270       A -> P (in Ref. 6).
FT   CONFLICT    298    298       A -> V (in Ref. 6).
FT   CONFLICT    314    314       D -> Y (in Ref. 6).
FT   STRAND        7     12
FT   TURN         13     14
FT   STRAND       15     20
FT   TURN         21     22
FT   STRAND       23     30
FT   STRAND       35     42
FT   TURN         43     45
FT   STRAND       48     54
FT   TURN         57     58
FT   HELIX        61     76
FT   TURN         80     81
FT   STRAND       82     82
FT   STRAND       87     89
FT   TURN         96     97
FT   STRAND      102    106
FT   STRAND      111    111
FT   HELIX       112    118
FT   HELIX       123    142
FT   TURN        143    144
FT   HELIX       152    154
FT   STRAND      155    157
FT   TURN        159    160
FT   STRAND      163    165
FT   HELIX       183    186
FT   TURN        187    187
FT   HELIX       190    193
FT   TURN        194    195
FT   TURN        201    202
FT   HELIX       203    217
FT   HELIX       227    238
FT   HELIX       243    246
FT   TURN        247    248
FT   HELIX       252    260
FT   HELIX       269    271
FT   TURN        272    272
FT   TURN        274    275
FT   HELIX       278    287
FT   HELIX       292    294
FT   HELIX       298    302
FT   TURN        303    303
FT   HELIX       305    307
FT   TURN        308    310
FT   HELIX       313    315
FT   HELIX       325    328
FT   HELIX       333    345
FT   TURN        346    346
SQ   SEQUENCE   359 AA;  41156 MW;  415763DEABBBBEC4 CRC64;
     SQERPTFYRQ ELNKTIWEVP ERYQNLSPVG SGAYGSVCAA FDTKTGHRVA VKKLSRPFQS
     IIHAKRTYRE LRLLKHMKHE NVIGLLDVFT PARSLEEFND VYLVTHLMGA DLNNIVKCQK
     LTDDHVQFLI YQILRGLKYI HSADIIHRDL KPSNLAVNED CELKILDFGL ARHTDDEMTG
     YVATRWYRAP EIMLNWMHYN QTVDIWSVGC IMAELLTGRT LFPGTDHIDQ LKLILRLVGT
     PGAELLKKIS SESARNYIQS LAQMPKMNFA NVFIGANPLA VDLLEKMLVL DSDKRITAAQ
     ALAHAYFAQY HDPDDEPVAD PYDQSFESRD LLIDEWKSLT YDEVISFVPP PLDQEEMES
//
ID   TGFA_HUMAN     STANDARD;      PRT;   160 AA.
AC   P01135; Q15577;
DT   21-JUL-1986 (Rel. 01, Created)
DT   21-JUL-1986 (Rel. 01, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Transforming growth factor alpha precursor (TGF-alpha) (EGF-like TGF)
DE   (ETGF) (TGF type 1).
GN   Name=TGFA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=84282712; PubMed=6088071; DOI=10.1016/0092-8674(84)90550-6;
RA   Derynck R., Roberts A.B., Winkler M.E., Chen E.Y., Goeddel D.V.;
RT   "Human transforming growth factor-alpha: precursor structure and
RT   expression in E. coli.";
RL   Cell 38:287-297(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=89127251; PubMed=2464748;
RA   Jakowlew S.B., Kondaiah P., Dillard P.J., Sporn M.B., Roberts A.B.;
RT   "A novel low molecular weight ribonucleic acid (RNA) related to
RT   transforming growth factor alpha messenger RNA.";
RL   Mol. Endocrinol. 2:1056-1063(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Colon;
RX   MEDLINE=94040776; PubMed=8224876; DOI=10.1016/0378-1119(93)90210-T;
RA   Qian J.F., Lazar-Wesley E., Breugnot C., May E.;
RT   "Human transforming growth factor alpha: sequence analysis of the 4.5-
RT   kb and 1.6-kb mRNA species.";
RL   Gene 132:291-296(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=93304410; PubMed=8100397;
RA   Qian J.F., Feingold J., Stoll C., May E.;
RT   "Transforming growth factor-alpha: characterization of the BamHI,
RT   RsaI, and TaqI polymorphic regions.";
RL   Am. J. Hum. Genet. 53:168-175(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=20021761; PubMed=10552925; DOI=10.1006/geno.1999.5962;
RA   Machida J., Yoshiura K.-I., Funkhauser C.D., Natsume N., Kawai T.,
RA   Murray J.C.;
RT   "Transforming growth factor-alpha (TGFA): genomic structure, boundary
RT   sequences, and mutation analysis in nonsyndromic cleft lip/palate and
RT   cleft palate only.";
RL   Genomics 61:237-242(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE OF 1-58.
RX   MEDLINE=89219018; PubMed=2907605;
RA   Jakobovits E.B., Schlokat U., Vannice J.L., Derynck R., Levinson A.D.;
RT   "The human transforming growth factor alpha promoter directs
RT   transcription initiation from a single site in the absence of a TATA
RT   sequence.";
RL   Mol. Cell. Biol. 8:5549-5554(1988).
RN   [7]
RP   DISULFIDE BONDS.
RX   MEDLINE=92337137; PubMed=1632509;
RA   Bean M.F., Carr S.A.;
RT   "Characterization of disulfide bond position in proteins and sequence
RT   analysis of cystine-bridged peptides by tandem mass spectrometry.";
RL   Anal. Biochem. 201:216-226(1992).
RN   [8]
RP   PALMITOYLATION OF CYS-153 AND CYS-154.
RX   MEDLINE=97067076; PubMed=8910478; DOI=10.1074/jbc.271.45.28502;
RA   Shum L., Turck C.W., Derynck R.;
RT   "Cysteines 153 and 154 of transmembrane transforming growth factor-
RT   alpha are palmitoylated and mediate cytoplasmic protein association.";
RL   J. Biol. Chem. 271:28502-28508(1996).
RN   [9]
RP   INTERACTIONS WITH SNTA1 AND SDCBP.
RX   MEDLINE=99247010; PubMed=10230395; DOI=10.1016/S1097-2765(00)80470-0;
RA   Fernandez-Larrea J., Merlos-Suarez A., Urena J.M., Baselga J.,
RA   Arribas J.;
RT   "A role for a PDZ protein in the early secretory pathway for the
RT   targeting of proTGF-alpha to the cell surface.";
RL   Mol. Cell 3:423-433(1999).
RN   [10]
RP   STRUCTURE BY NMR OF TGF-ALPHA.
RX   MEDLINE=91084439; PubMed=2261437;
RA   Kline T.P., Brown F.K., Brown S.C., Jeffs P.W., Kopple K.D.,
RA   Mueller L.;
RT   "Solution structures of human transforming growth factor alpha derived
RT   from 1H NMR data.";
RL   Biochemistry 29:7805-7813(1990).
RN   [11]
RP   STRUCTURE BY NMR OF TGF-ALPHA.
RX   MEDLINE=91266935; PubMed=2050136;
RA   Harvey T.S., Wilkinson A.J., Tappin M.J., Cooke R.M., Campbell I.D.;
RT   "The solution structure of human transforming growth factor alpha.";
RL   Eur. J. Biochem. 198:555-562(1991).
RN   [12]
RP   STRUCTURE BY NMR OF TGF-ALPHA.
RX   MEDLINE=93332939; PubMed=8338831;
RA   Moy F.J., Li Y.C., Rauenbuehler P., Winkler M.E., Scheraga H.A.,
RA   Montelione G.T.;
RT   "Solution structure of human type-alpha transforming growth factor
RT   determined by heteronuclear NMR spectroscopy and refined by energy
RT   minimization with restraints.";
RL   Biochemistry 32:7334-7353(1993).
CC   -!- FUNCTION: TGF alpha is a mitogenic polypeptide that is able to
CC       bind to the EGF receptor and to act synergistically with TGF beta
CC       to promote anchorage-independent cell proliferation in soft agar.
CC   -!- SUBUNIT: Interacts with the PDZ domains of SDCBP and SNTA1. The
CC       interaction with SDCBP, is required for the targeting to the cell
CC       surface.
CC   -!- SUBCELLULAR LOCATION: Type I membrane protein (precursor form);
CC       extracellular (mature form).
CC   -!- SIMILARITY: Contains 1 EGF-like domain.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; K03222; AAA61159.1; -; mRNA.
DR   EMBL; M31172; AAA61157.1; -; mRNA.
DR   EMBL; X70340; CAA49806.1; -; mRNA.
DR   EMBL; AF123243; AAF13491.1; -; Genomic_DNA.
DR   EMBL; AF123238; AAF13491.1; JOINED; Genomic_DNA.
DR   EMBL; AF123239; AAF13491.1; JOINED; Genomic_DNA.
DR   EMBL; AF123240; AAF13491.1; JOINED; Genomic_DNA.
DR   EMBL; AF123241; AAF13491.1; JOINED; Genomic_DNA.
DR   EMBL; AF123242; AAF13491.1; JOINED; Genomic_DNA.
DR   EMBL; M22440; AAA52530.1; -; Genomic_DNA.
DR   PIR; JN0876; WFHU1.
DR   PDB; 1GK5; NMR; A=-.
DR   PDB; 1MOX; X-ray; C/D=40-89.
DR   PDB; 1YUF; NMR; @=40-89.
DR   PDB; 1YUG; NMR; @=40-89.
DR   PDB; 2TGF; NMR; @=40-89.
DR   PDB; 3TGF; NMR; @=40-89.
DR   PDB; 4TGF; NMR; @=40-89.
DR   Ensembl; ENSG00000163235; Homo sapiens.
DR   Genew; HGNC:11765; TGFA.
DR   H-InvDB; HIX0002140; -.
DR   MIM; 190170; -.
DR   GO; GO:0005886; C:plasma membrane; NAS.
DR   GO; GO:0005515; F:protein binding; TAS.
DR   GO; GO:0004713; F:protein-tyrosine kinase activity; TAS.
DR   GO; GO:0004871; F:signal transducer activity; TAS.
DR   GO; GO:0008283; P:cell proliferation; TAS.
DR   InterPro; IPR001336; EGF_1.
DR   InterPro; IPR000742; EGF_2.
DR   InterPro; IPR006209; EGF_like.
DR   InterPro; IPR006210; IEGF.
DR   PRINTS; PR00009; EGFTGF.
DR   SMART; SM00181; EGF; 1.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 1.
KW   3D-structure; EGF-like domain; Glycoprotein; Growth factor;
KW   Lipoprotein; Mitogen; Palmitate; Signal; Transmembrane.
FT   SIGNAL        1     23       Potential.
FT   PROPEP       24     39       Removed in mature form.
FT   CHAIN        40     89       Transforming growth factor alpha.
FT   PROPEP       90    160       Removed in mature form.
FT   TOPO_DOM     24     98       Extracellular (Potential).
FT   TRANSMEM     99    124       Potential.
FT   TOPO_DOM    125    160       Cytoplasmic (Potential).
FT   DOMAIN       43     83       EGF-like.
FT   LIPID       153    153       S-palmitoyl cysteine.
FT   LIPID       154    154       S-palmitoyl cysteine.
FT   CARBOHYD     25     25       N-linked (GlcNAc...) (Potential).
FT   DISULFID     47     60
FT   DISULFID     55     71
FT   DISULFID     73     82
FT   CONFLICT     58     58       G -> A (in Ref. 2).
FT   CONFLICT     65     65       Q -> H (in Ref. 2).
FT   CONFLICT    159    159       V -> L (in Ref. 2).
FT   TURN         41     44
FT   STRAND       50     50
FT   TURN         51     51
FT   TURN         56     56
FT   STRAND       57     63
FT   HELIX        64     66
FT   TURN         67     67
FT   STRAND       68     73
FT   TURN         75     76
FT   STRAND       77     78
FT   TURN         79     82
FT   STRAND       84     85
SQ   SEQUENCE   160 AA;  17006 MW;  D692184F9353DE47 CRC64;
     MVPSAGQLAL FALGIVLAAC QALENSTSPL SADPPVAAAV VSHFNDCPDS HTQFCFHGTC
     RFLVQEDKPA CVCHSGYVGA RCEHADLLAV VAASQKKQAI TALVVVSIVA LAVLIITCVL
     IHCCQVRKHC EWCRALICRH EKPSALLKGR TACCHSETVV
//
ID   EGF_MOUSE      STANDARD;      PRT;  1217 AA.
AC   P01132; Q6P9J2;
DT   21-JUL-1986 (Rel. 01, Created)
DT   21-JUL-1986 (Rel. 01, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Pro-epidermal growth factor precursor (EGF) [Contains: Epidermal
DE   growth factor].
GN   Name=Egf;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=83223630; PubMed=6602382;
RA   Scott J., Urdea M., Quiroga M., Sanchez-Pescador R., Fong N.M.,
RA   Selby M., Rutter W.J., Bell G.I.;
RT   "Structure of a mouse submaxillary messenger RNA encoding epidermal
RT   growth factor and seven related proteins.";
RL   Science 221:236-240(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=83219309; PubMed=6304537;
RA   Gray A., Dull T.J., Ullrich A.;
RT   "Nucleotide sequence of epidermal growth factor cDNA predicts a
RT   128,000-molecular weight protein precursor.";
RL   Nature 303:722-725(1983).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Salivary gland;
RX   MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA   Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA   Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA   Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA   Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA   Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA   Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA   Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA   Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA   Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA   Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA   Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA   Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA   Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA   Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA   Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA   Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA   Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT   "Generation and initial analysis of more than 15,000 full-length human
RT   and mouse cDNA sequences.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN   [4]
RP   PROTEIN SEQUENCE OF 977-1029.
RX   MEDLINE=73048516; PubMed=4636327;
RA   Savage C.R. Jr., Inagami T., Cohen S.;
RT   "The primary structure of epidermal growth factor.";
RL   J. Biol. Chem. 247:7612-7621(1972).
RN   [5]
RP   DISULFIDE BONDS.
RX   MEDLINE=74025498; PubMed=4750422;
RA   Savage C.R. Jr., Hash J.H., Cohen S.;
RT   "Epidermal growth factor. Location of disulfide bonds.";
RL   J. Biol. Chem. 248:7669-7672(1973).
RN   [6]
RP   STRUCTURE BY NMR OF 977-1029.
RX   MEDLINE=92118798; PubMed=1731873;
RA   Montelione G.T., Wuethrich K., Burgess A.W., Nice E.C., Wagner G.,
RA   Gibson K.D., Scheraga H.A.;
RT   "Solution structure of murine epidermal growth factor determined by
RT   NMR spectroscopy and refined by energy minimization with restraints.";
RL   Biochemistry 31:236-249(1992).
RN   [7]
RP   STRUCTURE BY NMR OF 977-1029.
RX   MEDLINE=93075811; PubMed=1445923;
RA   Kohda D., Inagaki F.;
RT   "Three-dimensional nuclear magnetic resonance structures of mouse
RT   epidermal growth factor in acidic and physiological pH solutions.";
RL   Biochemistry 31:11928-11939(1992).
RN   [8]
RP   STRUCTURE BY NMR OF 980-1024.
RX   MEDLINE=99180407; PubMed=10082370;
RA   Barnham K.J., Torres A.M., Alewood D., Alewood P.F., Domagala T.,
RA   Nice E.C., Norton R.S.;
RT   "Role of the 6-20 disulfide bridge in the structure and activity of
RT   epidermal growth factor.";
RL   Protein Sci. 7:1738-1749(1998).
CC   -!- FUNCTION: EGF stimulates the growth of various epidermal and
CC       epithelial tissues in vivo and in vitro and of some fibroblasts in
CC       cell culture.
CC   -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC   -!- SIMILARITY: Contains 9 EGF-like domains.
CC   -!- CAUTION: Ref.2 sequence differs from that shown in positions 1134
CC       to 1168 due to a frameshift.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; J00380; AAA37539.1; -; mRNA.
DR   EMBL; V00741; CAA24115.1; ALT_FRAME; mRNA.
DR   EMBL; V00741; CAA24116.1; -; mRNA.
DR   EMBL; BC060741; AAH60741.1; -; mRNA.
DR   PIR; A94272; EGMSMG.
DR   PDB; 1A3P; NMR; @=981-1024.
DR   PDB; 1EGF; NMR; @=977-1029.
DR   PDB; 1EPG; NMR; @=977-1029.
DR   PDB; 1EPH; NMR; @=977-1029.
DR   PDB; 1EPI; NMR; @=977-1029.
DR   PDB; 1EPJ; NMR; @=977-1029.
DR   PDB; 1GK5; NMR; A=-.
DR   PDB; 3EGF; NMR; @=977-1029.
DR   Ensembl; ENSMUSG00000028017; Mus musculus.
DR   MGI; MGI:95290; Egf.
DR   GO; GO:0005615; C:extracellular space; TAS.
DR   GO; GO:0016021; C:integral to membrane; TAS.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphoryla...; IDA.
DR   InterPro; IPR000152; Asx_hydroxyl_S.
DR   InterPro; IPR001336; EGF_1.
DR   InterPro; IPR000742; EGF_2.
DR   InterPro; IPR001881; EGF_Ca.
DR   InterPro; IPR006209; EGF_like.
DR   InterPro; IPR009030; Grow_fac_recept.
DR   InterPro; IPR000033; Ldl_receptor_rep.
DR   Pfam; PF00008; EGF; 8.
DR   Pfam; PF00058; Ldl_recept_b; 7.
DR   PRINTS; PR00009; EGFTGF.
DR   SMART; SM00179; EGF_CA; 2.
DR   SMART; SM00135; LY; 9.
DR   PROSITE; PS00010; ASX_HYDROXYL; 3.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 6.
DR   PROSITE; PS50026; EGF_3; 5.
DR   PROSITE; PS01187; EGF_CA; 3.
KW   3D-structure; Direct protein sequencing; EGF-like domain;
KW   Glycoprotein; Growth factor; Repeat; Signal; Transmembrane.
FT   SIGNAL        1     28       Potential.
FT   CHAIN        29   1217       Pro-epidermal growth factor.
FT   CHAIN       977   1029       Epidermal growth factor.
FT   TOPO_DOM     29   1038       Extracellular (Potential).
FT   TRANSMEM   1039   1058       Potential.
FT   TOPO_DOM   1059   1217       Cytoplasmic (Potential).
FT   DOMAIN      327    361       EGF-like 1 (incomplete).
FT   DOMAIN      362    402       EGF-like 2, calcium-binding (Potential).
FT   DOMAIN      403    443       EGF-like 3.
FT   DOMAIN      441    483       EGF-like 4.
FT   DOMAIN      747    787       EGF-like 5.
FT   DOMAIN      838    876       EGF-like 6.
FT   DOMAIN      877    918       EGF-like 7, calcium-binding (Potential).
FT   DOMAIN      919    959       EGF-like 8, calcium-binding (Potential).
FT   DOMAIN      978   1019       EGF-like 9.
FT   REGION     1024   1029       Not required for full biological
FT                                activity.
FT   CARBOHYD    111    111       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    410    410       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    810    810       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    944    944       N-linked (GlcNAc...) (Potential).
FT   DISULFID    366    377       By similarity.
FT   DISULFID    373    386       By similarity.
FT   DISULFID    388    401       By similarity.
FT   DISULFID    407    418       By similarity.
FT   DISULFID    414    427       By similarity.
FT   DISULFID    429    442       By similarity.
FT   DISULFID    445    457       By similarity.
FT   DISULFID    453    467       By similarity.
FT   DISULFID    469    482       By similarity.
FT   DISULFID    751    762       By similarity.
FT   DISULFID    758    771       By similarity.
FT   DISULFID    773    786       By similarity.
FT   DISULFID    930    945       By similarity.
FT   DISULFID    947    958       By similarity.
FT   DISULFID    982    996
FT   DISULFID    990   1007
FT   DISULFID   1009   1018
FT   CONFLICT    790    790       D -> Y (in Ref. 2).
FT   CONFLICT   1048   1048       A -> S (in Ref. 2).
FT   CONFLICT   1217   1217       K -> Q (in Ref. 3).
FT   TURN        983    984
FT   STRAND      995    998
FT   TURN       1000   1002
FT   STRAND     1005   1008
FT   TURN       1011   1012
FT   STRAND     1013   1014
FT   TURN       1015   1018
FT   STRAND     1020   1021
SQ   SEQUENCE   1217 AA;  133144 MW;  A9C7F3D512F82873 CRC64;
     MPWGRRPTWL LLAFLLVFLK ISILSVTAWQ TGNCQPGPLE RSERSGTCAG PAPFLVFSQG
     KSISRIDPDG TNHQQLVVDA GISADMDIHY KKERLYWVDV ERQVLLRVFL NGTGLEKVCN
     VERKVSGLAI DWIDDEVLWV DQQNGVITVT DMTGKNSRVL LSSLKHPSNI AVDPIERLMF
     WSSEVTGSLH RAHLKGVDVK TLLETGGISV LTLDVLDKRL FWVQDSGEGS HAYIHSCDYE
     GGSVRLIRHQ ARHSLSSMAF FGDRIFYSVL KSKAIWIANK HTGKDTVRIN LHPSFVTPGK
     LMVVHPRAQP RTEDAAKDPD PELLKQRGRP CRFGLCERDP KSHSSACAEG YTLSRDRKYC
     EDVNECATQN HGCTLGCENT PGSYHCTCPT GFVLLPDGKQ CHELVSCPGN VSKCSHGCVL
     TSDGPRCICP AGSVLGRDGK TCTGCSSPDN GGCSQICLPL RPGSWECDCF PGYDLQSDRK
     SCAASGPQPL LLFANSQDIR HMHFDGTDYK VLLSRQMGMV FALDYDPVES KIYFAQTALK
     WIERANMDGS QRERLITEGV DTLEGLALDW IGRRIYWTDS GKSVVGGSDL SGKHHRIIIQ
     ERISRPRGIA VHPRARRLFW TDVGMSPRIE SASLQGSDRV LIASSNLLEP SGITIDYLTD
     TLYWCDTKRS VIEMANLDGS KRRRLIQNDV GHPFSLAVFE DHLWVSDWAI PSVIRVNKRT
     GQNRVRLQGS MLKPSSLVVV HPLAKPGADP CLYRNGGCEH ICQESLGTAR CLCREGFVKA
     WDGKMCLPQD YPILSGENAD LSKEVTSLSN STQAEVPDDD GTESSTLVAE IMVSGMNYED
     DCGPGGCGSH ARCVSDGETA ECQCLKGFAR DGNLCSDIDE CVLARSDCPS TSSRCINTEG
     GYVCRCSEGY EGDGISCFDI DECQRGAHNC AENAACTNTE GGYNCTCAGR PSSPGRSCPD
     STAPSLLGED GHHLDRNSYP GCPSSYDGYC LNGGVCMHIE SLDSYTCNCV IGYSGDRCQT
     RDLRWWELRH AGYGQKHDIM VVAVCMVALV LLLLLGMWGT YYYRTRKQLS NPPKNPCDEP
     SGSVSSSGPD SSSGAAVASC PQPWFVVLEK HQDPKNGSLP ADGTNGAVVD AGLSPSLQLG
     SVHLTSWRQK PHIDGMGTGQ SCWIPPSSDR GPQEIEGNSH LPSYRPVGPE KLHSLQSANG
     SCHERAPDLP RQTEPVK
//
ID   LYS_BPT4       STANDARD;      PRT;   164 AA.
AC   P00720; Q38170; Q94N07;
DT   21-JUL-1986 (Rel. 01, Created)
DT   21-JUL-1986 (Rel. 01, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Lysozyme (EC 3.2.1.17) (Lysis protein) (Muramidase) (Endolysin).
GN   Name=E;
OS   Bacteriophage T4.
OC   Viruses; dsDNA viruses, no RNA stage; Caudovirales; Myoviridae;
OC   T4-like viruses.
OX   NCBI_TaxID=10665;
RN   [1]
RP   PROTEIN SEQUENCE.
RX   MEDLINE=71007898; PubMed=5470817;
RA   Inouye M., Imada M., Tsugita A.;
RT   "The amino acid sequence of T4 phage lysozyme. IV. Dilute acid
RT   hydrolysis and the order of tryptic peptides.";
RL   J. Biol. Chem. 245:3479-3484(1970).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=83189145; PubMed=6302287;
RA   Owen J.E., Schultz D.W., Taylor A., Smith G.R.;
RT   "Nucleotide sequence of the lysozyme gene of bacteriophage T4.
RT   Analysis of mutations involving repeated sequences.";
RL   J. Mol. Biol. 165:229-248(1983).
RN   [3]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=87066735; PubMed=3024113;
RA   Valerie K., Stevens J., Lynch M., Henderson E.E., de Riel J.K.;
RT   "Nucleotide sequence and analysis of the 58.3 to 65.5-kb early region
RT   of bacteriophage T4.";
RL   Nucleic Acids Res. 14:8637-8654(1986).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=22514363; PubMed=12626685; DOI=10.1128/MMBR.67.1.86-156.2003;
RA   Miller E.S., Kutter E., Mosig G., Arisaka F., Kunisawa T., Ruger W.;
RT   "Bacteriophage T4 genome.";
RL   Microbiol. Mol. Biol. Rev. 67:86-156(2003).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS).
RX   PubMed=4530293;
RA   Matthews B.W., Remington S.J.;
RT   "The three dimensional structure of the lysozyme from bacteriophage
RT   T4.";
RL   Proc. Natl. Acad. Sci. U.S.A. 71:4178-4182(1974).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS).
RX   MEDLINE=87226186; PubMed=3586019;
RA   Weaver L.H., Matthews B.W.;
RT   "Structure of bacteriophage T4 lysozyme refined at 1.7-A resolution.";
RL   J. Mol. Biol. 193:189-200(1987).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).
RX   MEDLINE=77157239; PubMed=322662;
RA   Remington S.J., ten Eyck L.F., Matthews B.W.;
RT   "Atomic coordinates for T4 phage lysozyme.";
RL   Biochem. Biophys. Res. Commun. 75:265-270(1977).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF MUTANT ILE-3.
RX   MEDLINE=88302415; PubMed=3405287; DOI=10.1038/334406a0;
RA   Matsumura M., Becktel W.J., Matthews B.W.;
RT   "Hydrophobic stabilization in T4 lysozyme determined directly by
RT   multiple substitutions of Ile 3.";
RL   Nature 334:406-410(1988).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF MUTANT.
RX   MEDLINE=91043097; PubMed=2234094; DOI=10.1038/348263a0;
RA   Faber H.R., Matthews B.W.;
RT   "A mutant T4 lysozyme displays five different crystal conformations.";
RL   Nature 348:263-266(1990).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF MUTANT.
RX   MEDLINE=92115004; PubMed=1731252; DOI=10.1038/355371a0;
RA   Eriksson A.E., Baase W.A., Wozniak J.A., Matthews B.W.;
RT   "A cavity-containing mutant of T4 lysozyme is stabilized by buried
RT   benzene.";
RL   Nature 355:371-373(1992).
RN   [11]
RP   STRUCTURE BY NMR.
RX   MEDLINE=91002526; PubMed=2207079;
RA   McIntosh L.P., Wand A.J., Lowry D.F., Redfield A.G., Dahlquist F.W.;
RT   "Assignment of the backbone 1H and 15N NMR resonances of bacteriophage
RT   T4 lysozyme.";
RL   Biochemistry 29:6341-6362(1990).
CC   -!- FUNCTION: Helps to release the mature phage particles from the
CC       cell wall by breaking down the peptidoglycan.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of 1,4-beta-linkages between N-
CC       acetylmuramic acid and N-acetyl-D-glucosamine residues in a
CC       peptidoglycan and between N-acetyl-D-glucosamine residues in
CC       chitodextrins.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 24 family.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; X04567; CAA28212.1; -; Genomic_DNA.
DR   EMBL; AF158101; AAD42568.1; -; Genomic_DNA.
DR   PIR; A92896; LZBPT4.
DR   PDB; 102L; X-ray; @=1-164.
DR   PDB; 103L; X-ray; @=1-164.
DR   PDB; 104L; X-ray; A/B=1-164.
DR   PDB; 107L; X-ray; @=1-164.
DR   PDB; 108L; X-ray; @=1-164.
DR   PDB; 109L; X-ray; @=1-164.
DR   PDB; 110L; X-ray; @=1-164.
DR   PDB; 111L; X-ray; @=1-164.
DR   PDB; 112L; X-ray; @=1-164.
DR   PDB; 113L; X-ray; @=1-164.
DR   PDB; 114L; X-ray; @=1-164.
DR   PDB; 115L; X-ray; @=1-164.
DR   PDB; 118L; X-ray; @=1-164.
DR   PDB; 119L; X-ray; @=1-164.
DR   PDB; 120L; X-ray; @=1-164.
DR   PDB; 122L; X-ray; @=1-164.
DR   PDB; 123L; X-ray; @=1-164.
DR   PDB; 125L; X-ray; @=1-164.
DR   PDB; 126L; X-ray; @=1-164.
DR   PDB; 127L; X-ray; @=1-164.
DR   PDB; 128L; X-ray; @=1-164.
DR   PDB; 129L; X-ray; @=1-164.
DR   PDB; 130L; X-ray; @=1-164.
DR   PDB; 131L; X-ray; @=1-164.
DR   PDB; 137L; X-ray; A/B=1-164.
DR   PDB; 138L; X-ray; @=1-164.
DR   PDB; 139L; X-ray; @=1-164.
DR   PDB; 140L; X-ray; @=1-164.
DR   PDB; 141L; X-ray; @=1-164.
DR   PDB; 142L; X-ray; @=1-164.
DR   PDB; 143L; X-ray; @=1-164.
DR   PDB; 144L; X-ray; @=1-164.
DR   PDB; 145L; X-ray; @=1-164.
DR   PDB; 146L; X-ray; @=1-164.
DR   PDB; 147L; X-ray; @=1-164.
DR   PDB; 148L; X-ray; E=1-164.
DR   PDB; 149L; X-ray; @=2-164.
DR   PDB; 150L; X-ray; A/B/C/D=1-164.
DR   PDB; 151L; X-ray; @=1-164.
DR   PDB; 152L; X-ray; @=2-163.
DR   PDB; 155L; X-ray; @=1-164.
DR   PDB; 156L; X-ray; @=1-164.
DR   PDB; 157L; X-ray; @=1-164.
DR   PDB; 158L; X-ray; @=1-164.
DR   PDB; 159L; X-ray; @=1-164.
DR   PDB; 160L; X-ray; @=1-164.
DR   PDB; 161L; X-ray; @=1-164.
DR   PDB; 162L; X-ray; @=1-164.
DR   PDB; 163L; X-ray; @=1-164.
DR   PDB; 164L; X-ray; @=1-164.
DR   PDB; 165L; X-ray; @=1-164.
DR   PDB; 166L; X-ray; @=1-164.
DR   PDB; 167L; X-ray; A/B=2-163.
DR   PDB; 168L; X-ray; A/B/C/D/E=1-164.
DR   PDB; 169L; X-ray; A/B/C/D/E=1-164.
DR   PDB; 170L; X-ray; @=1-164.
DR   PDB; 171L; X-ray; @=1-164.
DR   PDB; 172L; X-ray; @=2-164.
DR   PDB; 173L; X-ray; @=1-164.
DR   PDB; 174L; X-ray; A/B=1-164.
DR   PDB; 175L; X-ray; A/B=1-164.
DR   PDB; 176L; X-ray; A/B=1-164.
DR   PDB; 177L; X-ray; @=1-164.
DR   PDB; 178L; X-ray; @=1-164.
DR   PDB; 179L; X-ray; @=1-164.
DR   PDB; 180L; X-ray; A/B=1-164.
DR   PDB; 181L; X-ray; @=1-164.
DR   PDB; 182L; X-ray; @=1-164.
DR   PDB; 183L; X-ray; @=1-164.
DR   PDB; 184L; X-ray; @=1-164.
DR   PDB; 185L; X-ray; @=1-164.
DR   PDB; 186L; X-ray; @=1-164.
DR   PDB; 187L; X-ray; @=1-164.
DR   PDB; 188L; X-ray; @=1-164.
DR   PDB; 189L; X-ray; @=2-164.
DR   PDB; 190L; X-ray; @=1-164.
DR   PDB; 191L; X-ray; @=1-164.
DR   PDB; 192L; X-ray; @=1-164.
DR   PDB; 195L; X-ray; @=1-164.
DR   PDB; 196L; X-ray; @=1-164.
DR   PDB; 197L; X-ray; @=1-164.
DR   PDB; 198L; X-ray; @=1-164.
DR   PDB; 199L; X-ray; @=1-164.
DR   PDB; 1B6I; X-ray; A=1-164.
DR   PDB; 1C60; X-ray; A=1-164.
DR   PDB; 1C61; X-ray; A=1-164.
DR   PDB; 1C62; X-ray; A=1-164.
DR   PDB; 1C63; X-ray; A=1-164.
DR   PDB; 1C64; X-ray; A=1-164.
DR   PDB; 1C65; X-ray; A=1-164.
DR   PDB; 1C66; X-ray; A=1-164.
DR   PDB; 1C67; X-ray; A=1-164.
DR   PDB; 1C68; X-ray; A=1-164.
DR   PDB; 1C69; X-ray; A=1-164.
DR   PDB; 1C6A; X-ray; A=1-164.
DR   PDB; 1C6B; X-ray; A=1-164.
DR   PDB; 1C6C; X-ray; A=1-164.
DR   PDB; 1C6D; X-ray; A=1-164.
DR   PDB; 1C6E; X-ray; A=1-164.
DR   PDB; 1C6F; X-ray; A=1-164.
DR   PDB; 1C6G; X-ray; A=1-164.
DR   PDB; 1C6H; X-ray; A=1-164.
DR   PDB; 1C6I; X-ray; A=1-164.
DR   PDB; 1C6J; X-ray; A=1-164.
DR   PDB; 1C6K; X-ray; A=1-164.
DR   PDB; 1C6L; X-ray; A=1-164.
DR   PDB; 1C6M; X-ray; A=1-164.
DR   PDB; 1C6N; X-ray; A=1-164.
DR   PDB; 1C6P; X-ray; A=1-164.
DR   PDB; 1C6Q; X-ray; A=1-164.
DR   PDB; 1C6T; X-ray; A=1-164.
DR   PDB; 1CTW; X-ray; A=1-164.
DR   PDB; 1CU0; X-ray; A=1-164.
DR   PDB; 1CU2; X-ray; A=1-164.
DR   PDB; 1CU3; X-ray; A=1-164.
DR   PDB; 1CU5; X-ray; A=1-164.
DR   PDB; 1CU6; X-ray; A=1-164.
DR   PDB; 1CUP; X-ray; A=1-164.
DR   PDB; 1CUQ; X-ray; A=1-164.
DR   PDB; 1CV0; X-ray; A=1-164.
DR   PDB; 1CV1; X-ray; A=1-164.
DR   PDB; 1CV3; X-ray; A=1-164.
DR   PDB; 1CV4; X-ray; A=1-164.
DR   PDB; 1CV5; X-ray; A=1-164.
DR   PDB; 1CV6; X-ray; A=1-164.
DR   PDB; 1CVK; X-ray; A=1-164.
DR   PDB; 1CX6; X-ray; A=2-164.
DR   PDB; 1CX7; X-ray; A=1-164.
DR   PDB; 1D2W; X-ray; A=1-164.
DR   PDB; 1D2Y; X-ray; A=1-164.
DR   PDB; 1D3F; X-ray; A=1-164.
DR   PDB; 1D3J; X-ray; A=1-164.
DR   PDB; 1D3M; X-ray; A=1-164.
DR   PDB; 1D3N; X-ray; A=2-164.
DR   PDB; 1D9W; X-ray; A=1-164.
DR   PDB; 1DYA; X-ray; @=1-164.
DR   PDB; 1DYB; X-ray; @=1-164.
DR   PDB; 1DYC; X-ray; @=1-164.
DR   PDB; 1DYD; X-ray; @=1-164.
DR   PDB; 1DYE; X-ray; @=1-164.
DR   PDB; 1DYF; X-ray; @=1-164.
DR   PDB; 1DYG; X-ray; @=1-164.
DR   PDB; 1EPY; X-ray; A=1-164.
DR   PDB; 1G06; X-ray; A=1-164.
DR   PDB; 1G07; X-ray; A=1-164.
DR   PDB; 1G0G; X-ray; A=1-164.
DR   PDB; 1G0J; X-ray; A=1-164.
DR   PDB; 1G0K; X-ray; A=1-164.
DR   PDB; 1G0L; X-ray; A=1-164.
DR   PDB; 1G0M; X-ray; A=1-164.
DR   PDB; 1G0P; X-ray; A=1-164.
DR   PDB; 1G0Q; X-ray; A=1-164.
DR   PDB; 1G1V; X-ray; A=1-164.
DR   PDB; 1G1W; X-ray; A=1-164.
DR   PDB; 1I6S; X-ray; A=1-164.
DR   PDB; 1JQU; X-ray; A/B/C/D=1-164.
DR   PDB; 1JTM; X-ray; A=1-164.
DR   PDB; 1KNI; X-ray; A=1-164.
DR   PDB; 1KS3; X-ray; A=1-162.
DR   PDB; 1KW5; X-ray; A=1-162.
DR   PDB; 1KW7; X-ray; A=1-162.
DR   PDB; 1KY0; X-ray; A=1-162.
DR   PDB; 1KY1; X-ray; A=1-162.
DR   PDB; 1L00; X-ray; @=1-164.
DR   PDB; 1L01; X-ray; @=1-164.
DR   PDB; 1L02; X-ray; @=1-164.
DR   PDB; 1L03; X-ray; @=1-164.
DR   PDB; 1L04; X-ray; @=1-164.
DR   PDB; 1L05; X-ray; @=1-164.
DR   PDB; 1L06; X-ray; @=1-164.
DR   PDB; 1L07; X-ray; @=1-164.
DR   PDB; 1L08; X-ray; @=1-164.
DR   PDB; 1L09; X-ray; @=1-164.
DR   PDB; 1L0J; X-ray; A=1-162.
DR   PDB; 1L0K; X-ray; A=1-162.
DR   PDB; 1L10; X-ray; @=1-164.
DR   PDB; 1L11; X-ray; @=1-164.
DR   PDB; 1L12; X-ray; @=1-164.
DR   PDB; 1L13; X-ray; @=1-164.
DR   PDB; 1L14; X-ray; @=1-164.
DR   PDB; 1L15; X-ray; @=1-164.
DR   PDB; 1L16; X-ray; @=1-164.
DR   PDB; 1L17; X-ray; @=2-164.
DR   PDB; 1L18; X-ray; @=2-164.
DR   PDB; 1L19; X-ray; @=1-164.
DR   PDB; 1L20; X-ray; @=1-164.
DR   PDB; 1L21; X-ray; @=1-164.
DR   PDB; 1L22; X-ray; @=1-164.
DR   PDB; 1L23; X-ray; @=1-164.
DR   PDB; 1L24; X-ray; @=1-164.
DR   PDB; 1L25; X-ray; @=1-164.
DR   PDB; 1L26; X-ray; @=-.
DR   PDB; 1L27; X-ray; @=1-164.
DR   PDB; 1L28; X-ray; @=1-164.
DR   PDB; 1L29; X-ray; @=1-164.
DR   PDB; 1L30; X-ray; @=1-164.
DR   PDB; 1L31; X-ray; @=1-164.
DR   PDB; 1L32; X-ray; @=1-164.
DR   PDB; 1L33; X-ray; @=1-164.
DR   PDB; 1L34; X-ray; @=1-164.
DR   PDB; 1L35; X-ray; @=1-163.
DR   PDB; 1L36; X-ray; @=1-164.
DR   PDB; 1L37; X-ray; @=1-164.
DR   PDB; 1L38; X-ray; @=1-164.
DR   PDB; 1L39; X-ray; @=1-164.
DR   PDB; 1L40; X-ray; @=1-164.
DR   PDB; 1L41; X-ray; @=1-164.
DR   PDB; 1L42; X-ray; @=1-164.
DR   PDB; 1L43; X-ray; @=1-164.
DR   PDB; 1L44; X-ray; @=1-164.
DR   PDB; 1L45; X-ray; @=1-164.
DR   PDB; 1L46; X-ray; @=1-164.
DR   PDB; 1L47; X-ray; @=1-164.
DR   PDB; 1L48; X-ray; @=1-164.
DR   PDB; 1L49; X-ray; @=1-164.
DR   PDB; 1L50; X-ray; @=1-164.
DR   PDB; 1L51; X-ray; @=1-164.
DR   PDB; 1L52; X-ray; @=1-164.
DR   PDB; 1L53; X-ray; @=1-164.
DR   PDB; 1L54; X-ray; @=1-164.
DR   PDB; 1L55; X-ray; @=1-164.
DR   PDB; 1L56; X-ray; @=1-164.
DR   PDB; 1L57; X-ray; @=1-164.
DR   PDB; 1L58; X-ray; @=1-164.
DR   PDB; 1L59; X-ray; @=1-164.
DR   PDB; 1L60; X-ray; @=1-164.
DR   PDB; 1L61; X-ray; @=1-164.
DR   PDB; 1L62; X-ray; @=1-164.
DR   PDB; 1L63; X-ray; @=1-164.
DR   PDB; 1L64; X-ray; @=1-164.
DR   PDB; 1L65; X-ray; @=1-164.
DR   PDB; 1L66; X-ray; @=1-164.
DR   PDB; 1L67; X-ray; @=1-164.
DR   PDB; 1L68; X-ray; @=1-164.
DR   PDB; 1L69; X-ray; @=1-164.
DR   PDB; 1L70; X-ray; @=1-164.
DR   PDB; 1L71; X-ray; @=1-164.
DR   PDB; 1L72; X-ray; @=1-164.
DR   PDB; 1L73; X-ray; @=1-164.
DR   PDB; 1L74; X-ray; @=1-164.
DR   PDB; 1L75; X-ray; @=1-164.
DR   PDB; 1L76; X-ray; @=1-164.
DR   PDB; 1L77; X-ray; @=1-164.
DR   PDB; 1L79; X-ray; @=1-164.
DR   PDB; 1L80; X-ray; @=1-164.
DR   PDB; 1L81; X-ray; @=1-164.
DR   PDB; 1L82; X-ray; @=1-164.
DR   PDB; 1L83; X-ray; @=1-164.
DR   PDB; 1L84; X-ray; @=1-164.
DR   PDB; 1L85; X-ray; @=1-164.
DR   PDB; 1L86; X-ray; @=1-164.
DR   PDB; 1L87; X-ray; @=1-164.
DR   PDB; 1L88; X-ray; @=1-164.
DR   PDB; 1L89; X-ray; @=1-164.
DR   PDB; 1L90; X-ray; @=1-164.
DR   PDB; 1L91; X-ray; @=1-164.
DR   PDB; 1L92; X-ray; @=1-164.
DR   PDB; 1L93; X-ray; @=1-164.
DR   PDB; 1L94; X-ray; @=1-164.
DR   PDB; 1L95; X-ray; @=1-164.
DR   PDB; 1L96; X-ray; @=2-164.
DR   PDB; 1L97; X-ray; A/B=2-164.
DR   PDB; 1L98; X-ray; @=1-164.
DR   PDB; 1L99; X-ray; @=1-164.
DR   PDB; 1LGU; X-ray; A=1-164.
DR   PDB; 1LGW; X-ray; A=1-164.
DR   PDB; 1LGX; X-ray; A=1-164.
DR   PDB; 1LI2; X-ray; A=1-164.
DR   PDB; 1LI3; X-ray; A=1-164.
DR   PDB; 1LI6; X-ray; A=1-164.
DR   PDB; 1LLH; X-ray; A=1-164.
DR   PDB; 1LPY; X-ray; A=2-164.
DR   PDB; 1LW9; X-ray; A=1-164.
DR   PDB; 1LWG; X-ray; A=1-164.
DR   PDB; 1LWK; X-ray; A=2-164.
DR   PDB; 1LYD; X-ray; @=1-164.
DR   PDB; 1LYE; X-ray; @=1-164.
DR   PDB; 1LYF; X-ray; @=1-164.
DR   PDB; 1LYG; X-ray; @=1-164.
DR   PDB; 1LYH; X-ray; @=1-164.
DR   PDB; 1LYI; X-ray; @=1-164.
DR   PDB; 1LYJ; X-ray; @=1-164.
DR   PDB; 1NHB; X-ray; @=1-164.
DR   PDB; 1OV5; X-ray; A=1-164.
DR   PDB; 1OV7; X-ray; A=1-164.
DR   PDB; 1OVH; X-ray; A=1-164.
DR   PDB; 1OVJ; X-ray; A=1-164.
DR   PDB; 1OVK; X-ray; A=1-164.
DR   PDB; 1OWY; X-ray; A=1-164.
DR   PDB; 1OWZ; X-ray; A=1-164.
DR   PDB; 1OYU; X-ray; A/B=1-164.
DR   PDB; 1P2L; X-ray; A=1-164.
DR   PDB; 1P2R; X-ray; A=1-164.
DR   PDB; 1P36; X-ray; A=1-164.
DR   PDB; 1P37; X-ray; A=1-164.
DR   PDB; 1P3N; X-ray; A=1-164.
DR   PDB; 1P46; X-ray; A=1-164.
DR   PDB; 1P5C; X-ray; A/B/C/D=13-163.
DR   PDB; 1P64; X-ray; A=1-164.
DR   PDB; 1P6Y; X-ray; A=1-164.
DR   PDB; 1P7S; X-ray; A=1-164.
DR   PDB; 1PQD; X-ray; A=1-164.
DR   PDB; 1PQI; X-ray; A=1-164.
DR   PDB; 1PQJ; X-ray; A=1-164.
DR   PDB; 1PQK; X-ray; A/B/C=1-164.
DR   PDB; 1PQM; X-ray; A=1-164.
DR   PDB; 1PQO; X-ray; A=1-164.
DR   PDB; 1QS5; X-ray; A=1-162.
DR   PDB; 1QS9; X-ray; A=1-162.
DR   PDB; 1QSB; X-ray; A=1-162.
DR   PDB; 1QSQ; X-ray; A=1-164.
DR   PDB; 1QT3; X-ray; A=1-164.
DR   PDB; 1QT4; X-ray; A=1-164.
DR   PDB; 1QT5; X-ray; A=1-164.
DR   PDB; 1QT6; X-ray; A=1-164.
DR   PDB; 1QT7; X-ray; A=1-164.
DR   PDB; 1QT8; X-ray; A=1-164.
DR   PDB; 1QTB; X-ray; A=1-162.
DR   PDB; 1QTC; X-ray; A=1-162.
DR   PDB; 1QTD; X-ray; A=1-162.
DR   PDB; 1QTH; X-ray; A/B=1-164.
DR   PDB; 1QTV; X-ray; A=1-164.
DR   PDB; 1QTZ; X-ray; A=1-164.
DR   PDB; 1QUD; X-ray; A=1-162.
DR   PDB; 1QUG; X-ray; A=1-162.
DR   PDB; 1QUH; X-ray; A=1-162.
DR   PDB; 1QUO; X-ray; A=1-162.
DR   PDB; 1SSW; X-ray; A=1-164.
DR   PDB; 1SSY; X-ray; A/B=1-164.
DR   PDB; 1SWY; X-ray; A=1-164.
DR   PDB; 1SWZ; X-ray; A=1-164.
DR   PDB; 1SX2; X-ray; A=1-164.
DR   PDB; 1SX7; X-ray; A=1-164.
DR   PDB; 1T6H; X-ray; A=1-164.
DR   PDB; 1T8A; X-ray; A=1-164.
DR   PDB; 1T8F; X-ray; A=1-164.
DR   PDB; 1T8G; X-ray; A=1-164.
DR   PDB; 1T97; X-ray; A/B=1-164.
DR   PDB; 1TLA; X-ray; @=1-164.
DR   PDB; 200L; X-ray; @=1-164.
DR   PDB; 201L; X-ray; A/B=1-164.
DR   PDB; 205L; X-ray; @=1-164.
DR   PDB; 216L; X-ray; A/B=1-164.
DR   PDB; 217L; X-ray; @=1-164.
DR   PDB; 221L; X-ray; @=1-164.
DR   PDB; 224L; X-ray; @=1-164.
DR   PDB; 255L; X-ray; @=1-164.
DR   PDB; 2L78; X-ray; @=1-164.
DR   PDB; 2LZM; X-ray; @=1-164.
DR   PDB; 3LZM; X-ray; @=1-164.
DR   PDB; 4LZM; X-ray; @=1-164.
DR   PDB; 5LZM; X-ray; @=1-164.
DR   PDB; 6LZM; X-ray; @=1-164.
DR   PDB; 7LZM; X-ray; @=1-164.
DR   InterPro; IPR002196; Glyco_hydro_24.
DR   InterPro; IPR001165; Glyco_hydro_30T4.
DR   Pfam; PF00959; Phage_lysozyme; 1.
DR   PRINTS; PR00684; T4LYSOZYME.
KW   3D-structure; Bacteriolytic enzyme; Direct protein sequencing;
KW   Glycosidase; Hydrolase.
FT   ACT_SITE     11     11       Proton donor.
FT   ACT_SITE     20     20       Nucleophile.
FT   CONFLICT     12     12       G -> R (in Ref. 3 and 4).
FT   CONFLICT    137    137       R -> I (in Ref. 3 and 4).
FT   HELIX         3     11
FT   STRAND       14     19
FT   TURN         21     22
FT   STRAND       25     28
FT   TURN         29     30
FT   STRAND       31     34
FT   HELIX        39     50
FT   TURN         51     51
FT   TURN         55     56
FT   STRAND       57     57
FT   HELIX        60     80
FT   TURN         82     83
FT   HELIX        84     90
FT   HELIX        93    112
FT   TURN        113    113
FT   HELIX       115    122
FT   TURN        123    124
FT   HELIX       126    134
FT   HELIX       137    141
FT   HELIX       143    155
FT   HELIX       159    161
SQ   SEQUENCE   164 AA;  18635 MW;  6042E2F77B6308A0 CRC64;
     MNIFEMLRID EGLRLKIYKD TEGYYTIGIG HLLTKSPSLN AAKSELDKAI GRNCNGVITK
     DEAEKLFNQD VDAAVRGILR NAKLKPVYDS LDAVRRCALI NMVFQMGETG VAGFTNSLRM
     LQQKRWDEAA VNLAKSRWYN QTPNRAKRVI TTFRTGTWDA YKNL
//
ID   CDN2A_HUMAN    STANDARD;      PRT;   156 AA.
AC   P42771; Q15191;
DT   01-NOV-1995 (Rel. 32, Created)
DT   15-JUL-1998 (Rel. 36, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Cyclin-dependent kinase 4 inhibitor A (CDK4I) (p16-INK4) (p16-INK4a)
DE   (Multiple tumor suppressor 1) (MTS1).
GN   Name=CDKN2A; Synonyms=CDKN2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=94081956; PubMed=8259215; DOI=10.1038/366704a0;
RA   Serrano M., Hannon G.J., Beach D.;
RT   "A new regulatory motif in cell-cycle control causing specific
RT   inhibition of cyclin D/CDK4.";
RL   Nature 366:704-707(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RA   Kohno T., Inoue K., Kitagawa Y., Hayashi Y., Matsuo Y., Mizoguchi H.,
RA   Yokota J.;
RT   "Prevalent involvement of illegitimate V(D)J recombination in
RT   chromosome 9p21 deletions in lymphoid Leukemia.";
RL   Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Rieder M.J., Livingston R.J., Daniels M.R., Montoya M.A., Chung M.-W.,
RA   Miyamoto K.E., Nguyen C.P., Nguyen D.A., Poel C.L., Robertson P.D.,
RA   Schackwitz W.S., Sherwood J.K., Witrak L.A., Nickerson D.A.;
RT   "NIEHS-SNPs, environmental genome project, NIEHS ES15478, Department
RT   of Genome Sciences, Seattle, WA (URL: http://egp.gs.washington.edu).";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE OF 51-152.
RX   MEDLINE=94204645; PubMed=8153634;
RA   Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K.,
RA   Tavtigian S.V., Stockert E., Day R.S. III, Johnson B.E.,
RA   Skolnick M.H.;
RT   "A cell cycle regulator potentially involved in genesis of many tumor
RT   types.";
RL   Science 264:436-440(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE OF 1-20.
RX   MEDLINE=96182088; PubMed=8622687;
RA   Hara E., Smith R., Parry D., Tahara H., Stone S., Peters G.;
RT   "Regulation of p16CDKN2 expression and its implications for cell
RT   immortalization and senescence.";
RL   Mol. Cell. Biol. 16:859-867(1996).
RN   [6]
RP   FUNCTION.
RX   PubMed=7972006;
RA   Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P.,
RA   Bennett W.P., Forrester K., Gerwin B., Serrano M., Beach D.H.,
RA   Harris C.C.;
RT   "Mutations and altered expression of p16INK4 in human cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF COMPLEX WITH CDK6.
RX   MEDLINE=98421670; PubMed=9751050; DOI=10.1038/26155;
RA   Russo A.A., Tong L., Lee J.O., Jeffrey P.D., Pavletich N.P.;
RT   "Structural basis for inhibition of the cyclin-dependent kinase Cdk6
RT   by the tumour suppressor p16INK4a.";
RL   Nature 395:237-243(1998).
RN   [8]
RP   STRUCTURE BY NMR.
RX   MEDLINE=20026852; PubMed=10559205; DOI=10.1074/jbc.274.47.33296;
RA   Yuan C., Li J., Selby T.L., Byeon I.J., Tsai M.D.;
RT   "Tumor suppressor INK4: comparisons of conformational properties
RT   between p16(INK4A) and p18(INK4C).";
RL   J. Mol. Biol. 294:201-211(1999).
RN   [9]
RP   REVIEW ON MELANOMA VARIANTS.
RX   MEDLINE=96377761; PubMed=8783570;
RA   Dracopoli N.C., Fountain J.W.;
RT   "CDKN2 mutations in melanoma.";
RL   Cancer Surv. 26:115-132(1996).
RN   [10]
RP   REVIEW ON VARIANTS.
RX   MEDLINE=96303699; PubMed=8723678;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.3.CO;2-I;
RA   Smith-Soerensen B., Hovig E.;
RT   "CDKN2A (p16INK4A) somatic and germline mutations.";
RL   Hum. Mutat. 7:294-303(1996).
RN   [11]
RP   VARIANTS NON-SMALL CELL LUNG CARCINOMA TYR-66; HIS-84; ALA-93; ALA-95;
RP   GLN-99; LEU-114; ALA-120; LYS-120; PRO-132; VAL-134; TYR-142 AND
RP   VAL-150.
RX   MEDLINE=94338359; PubMed=8060323;
RA   Hayashi N., Sugimoto Y., Tsuchiya E., Ogawa M., Nakamura Y.;
RT   "Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l
RT   (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small
RT   cell lung carcinomas.";
RL   Biochem. Biophys. Res. Commun. 202:1426-1430(1994).
RN   [12]
CC   -!- FUNCTION: Interacts strongly with CDK4 and CDK6. Inhibits their
CC       ability to interact with cyclins D. Could act as a negative
CC       regulator of the proliferation of normal cells.
CC   -!- SUBUNIT: Heterodimer with CDK4 or CDK6.
CC   -!- INTERACTION:
CC       O75419:CDC45L; NbExp=1; IntAct=EBI-375053, EBI-374969;
CC       Q99741:CDC6; NbExp=1; IntAct=EBI-375053, EBI-374862;
CC       O00311:CDC7; NbExp=1; IntAct=EBI-375053, EBI-374980;
CC       P11802:CDK4; NbExp=1; IntAct=EBI-375053, EBI-295644;
CC       Q00534:CDK6; NbExp=1; IntAct=EBI-375053, EBI-295663;
CC       O75496:GMNN; NbExp=1; IntAct=EBI-375053, EBI-371669;
CC       Q7L590:MCM10; NbExp=1; IntAct=EBI-375053, EBI-374912;
CC       P49736:MCM2; NbExp=1; IntAct=EBI-375053, EBI-374819;
CC       P33992:MCM5; NbExp=1; IntAct=EBI-375053, EBI-359410;
CC       O43929:ORC4L; NbExp=1; IntAct=EBI-375053, EBI-374889;
CC       O43913:ORC5L; NbExp=1; IntAct=EBI-375053, EBI-374928;
CC   -!- DISEASE: Defects in CDKN2A are involved in tumor formation in a
CC       wide range of tissues.
CC   -!- DISEASE: Defects in CDKN2A are the cause of cutaneous malignant
CC       melanoma 2 (CMM2) [MIM:155601]. Inheritance is autosomal dominant.
CC       Malignant melanoma is a malignant neoplasm of melanocytes, arising
CC       de novo or from a preexisting benign nevus, which occurs most
CC       often in the skin but also may involve other sites.
CC   -!- DISEASE: Defects in CDKN2A are the cause of familial atypical
CC       multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC)
CC       [MIM:606719].
CC   -!- DISEASE: Defects in CDKN2A are a cause of Li-Fraumeni syndrome
CC       (LFS) [MIM:151623]. LFS is a highly penetrant familial cancer
CC       phenotype usually associated with inherited mutations in TP53.
CC   -!- SIMILARITY: Belongs to the CDKN2 cyclin-dependent kinase inhibitor
CC       family.
CC   -!- SIMILARITY: Contains 4 ANK repeats.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; L27211; AAA92554.1; -; mRNA.
DR   EMBL; AB060808; BAB91133.1; -; Genomic_DNA.
DR   EMBL; AF527803; AAR05391.1; -; Genomic_DNA.
DR   EMBL; U12820; AAB60645.1; ALT_INIT; Genomic_DNA.
DR   EMBL; U12818; AAB60645.1; JOINED; Genomic_DNA.
DR   EMBL; U12819; AAB60645.1; JOINED; Genomic_DNA.
DR   EMBL; S69804; AAD14048.1; -; Genomic_DNA.
DR   EMBL; X94154; CAA63870.1; -; Genomic_DNA.
DR   PIR; JE0141; JE0141.
DR   PDB; 1A5E; NMR; @=1-156.
DR   PDB; 1BI7; X-ray; B=1-156.
DR   PDB; 1DC2; NMR; A=1-156.
DR   PDB; 2A5E; NMR; @=1-156.
DR   IntAct; P42771; -.
DR   Ensembl; ENSG00000147889; Homo sapiens.
DR   Genew; HGNC:1787; CDKN2A.
DR   MIM; 600160; -.
DR   MIM; 155601; -.
DR   MIM; 606719; -.
DR   MIM; 151623; -.
DR   GO; GO:0004861; F:cyclin-dependent protein kinase inhibitor a...; TAS.
DR   GO; GO:0007050; P:cell cycle arrest; TAS.
DR   GO; GO:0000075; P:cell cycle checkpoint; TAS.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; TAS.
DR   GO; GO:0000079; P:regulation of cyclin dependent protein kina...; TAS.
DR   InterPro; IPR002110; ANK.
DR   Pfam; PF00023; Ank; 3.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; FALSE_NEG.
KW   3D-structure; ANK repeat; Anti-oncogene; Cell cycle; Disease mutation;
KW   Li-Fraumeni syndrome; Polymorphism; Repeat.
FT   REPEAT       11     40       ANK 1.
FT   REPEAT       44     72       ANK 2.
FT   REPEAT       77    106       ANK 3.
FT   REPEAT      110    139       ANK 4.
FT   VARIANT      14     14       D -> E (in a biliary tract tumor).
FT                                /FTId=VAR_001408.
FT   VARIANT      16     16       L -> P (in a biliary tract tumor and a
FT                                familial melanoma).
FT                                /FTId=VAR_001409.
FT   VARIANT      20     20       A -> P (in a lung tumor and melanoma).
FT                                /FTId=VAR_001410.
FT   VARIANT      20     20       A -> S (in a biliary tract tumor).
FT                                /FTId=VAR_001411.
FT   VARIANT      23     23       G -> D (in a pancreas tumor).
FT                                /FTId=VAR_001412.
FT   VARIANT      24     24       R -> C (in melanoma).
FT                                /FTId=VAR_001413.
FT   VARIANT      24     24       R -> P (in CMM2 and melanoma).
FT                                /FTId=VAR_001414.
FT   VARIANT      26     26       E -> D (in a biliary tract tumor).
FT                                /FTId=VAR_001415.
FT   VARIANT      32     32       L -> P (in CMM2).
FT                                /FTId=VAR_001416.
FT   VARIANT      33     33       E -> D (in a biliary tract tumor).
FT                                /FTId=VAR_001417.
FT   VARIANT      35     35       G -> A (in CMM2 and a biliary tract
FT                                tumor).
FT                                /FTId=VAR_001418.
FT   VARIANT      35     35       G -> E (in melanoma).
FT                                /FTId=VAR_001419.
FT   VARIANT      48     48       P -> L (in melanoma and a head and neck
FT                                tumor; somatic mutation).
FT                                /FTId=VAR_001420.
FT   VARIANT      49     49       I -> S (in a biliary tract tumor).
FT                                /FTId=VAR_001421.
FT   VARIANT      49     49       I -> T.
FT                                /FTId=VAR_001422.
FT   VARIANT      50     50       Q -> R (in CMM2).
FT                                /FTId=VAR_001423.
FT   VARIANT      53     53       M -> I (in CMM2).
FT                                /FTId=VAR_001424.
FT   VARIANT      56     56       S -> I (possible polymorphism).
FT                                /FTId=VAR_001425.
FT   VARIANT      57     57       A -> V (in pancreas carcinoma; somatic
FT                                mutation).
FT                                /FTId=VAR_001426.
FT   VARIANT      59     59       V -> G (in CMM2).
FT                                /FTId=VAR_001427.
FT   VARIANT      60     60       A -> T.
FT                                /FTId=VAR_001428.
FT   VARIANT      61     62       EL -> DV.
FT                                /FTId=VAR_001429.
FT   VARIANT      62     62       L -> P (in familial melanoma).
FT                                /FTId=VAR_001430.
FT   VARIANT      66     66       H -> Y (in non-small cell lung
FT                                carcinoma).
FT                                /FTId=VAR_001431.
FT   VARIANT      68     68       A -> L (in familial melanoma; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_001432.
FT   VARIANT      68     68       A -> T (in an esophagus tumor).
FT                                /FTId=VAR_001433.
FT   VARIANT      68     68       A -> V.
FT                                /FTId=VAR_001434.
FT   VARIANT      69     69       E -> K (in a bladder tumor).
FT                                /FTId=VAR_001435.
FT   VARIANT      69     69       E -> V (in a lung tumor).
FT                                /FTId=VAR_001436.
FT   VARIANT      71     71       N -> K (in familial melanoma).
FT                                /FTId=VAR_001437.
FT   VARIANT      71     71       N -> S.
FT                                /FTId=VAR_001438.
FT   VARIANT      72     72       C -> G (in an esophagus tumor).
FT                                /FTId=VAR_001439.
FT   VARIANT      74     74       D -> N (in a bladder tumor).
FT                                /FTId=VAR_001440.
FT   VARIANT      74     74       D -> V (in a biliary tract tumor).
FT                                /FTId=VAR_001441.
FT   VARIANT      80     80       R -> L (in a head and neck tumor).
FT                                /FTId=VAR_001442.
FT   VARIANT      81     81       P -> L (in melanoma; impairs the
FT                                function; dbSNP:11552823).
FT                                /FTId=VAR_001443.
FT   VARIANT      83     83       H -> N (in a lung tumor).
FT                                /FTId=VAR_001445.
FT   VARIANT      83     83       H -> Y (in a pancreas and a head and neck
FT                                tumor).
FT                                /FTId=VAR_001444.
FT   VARIANT      84     84       D -> E (in a bladder tumor).
FT                                /FTId=VAR_001446.
FT   VARIANT      84     84       D -> H (in non-small cell lung
FT                                carcinoma).
FT                                /FTId=VAR_001447.
FT   VARIANT      84     84       D -> N (in an esophagus, a head and neck
FT                                and a lung tumor).
FT                                /FTId=VAR_001448.
FT   VARIANT      84     84       D -> Y (in CMM2; also found in a lung and
FT                                a prostate tumor; dbSNP:11552822).
FT                                /FTId=VAR_001449.
FT   VARIANT      85     85       A -> T.
FT                                /FTId=VAR_001450.
FT   VARIANT      87     87       R -> P (in CMM2; impairs the function).
FT                                /FTId=VAR_001451.
FT   VARIANT      87     87       R -> W (in CMM2).
FT                                /FTId=VAR_012317.
FT   VARIANT      88     88       E -> D (in a biliary tract tumor).
FT                                /FTId=VAR_001452.
FT   VARIANT      89     89       G -> D (in melanoma; somatic mutation).
FT                                /FTId=VAR_001453.
FT   VARIANT      89     89       G -> S (in melanoma).
FT                                /FTId=VAR_001454.
FT   VARIANT      93     93       T -> A (in non-small cell lung
FT                                carcinoma).
FT                                /FTId=VAR_001455.
FT   VARIANT      95     95       V -> A (in non-small cell lung
FT                                carcinoma).
FT                                /FTId=VAR_001456.
FT   VARIANT      97     97       L -> R (possible polymorphism).
FT                                /FTId=VAR_001457.
FT   VARIANT      98     98       H -> P (in melanoma).
FT                                /FTId=VAR_001458.
FT   VARIANT      98     98       H -> Q (in melanoma).
FT                                /FTId=VAR_001459.
FT   VARIANT      99     99       R -> P (in familial melanoma).
FT                                /FTId=VAR_001460.
FT   VARIANT      99     99       R -> Q (in non-small cell lung
FT                                carcinoma).
FT                                /FTId=VAR_001461.
FT   VARIANT     100    100       A -> L (in melanoma; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_001462.
FT   VARIANT     100    100       A -> P.
FT                                /FTId=VAR_001463.
FT   VARIANT     101    101       G -> W (in CMM2 and FAMMMPC; impairs the
FT                                function).
FT                                /FTId=VAR_001464.
FT   VARIANT     102    102       A -> E (in LFS; somatic mutation).
FT                                /FTId=VAR_015818.
FT   VARIANT     104    105       Missing.
FT                                /FTId=VAR_001465.
FT   VARIANT     107    107       R -> C (in CMM2).
FT                                /FTId=VAR_001466.
FT   VARIANT     107    107       R -> H.
FT                                /FTId=VAR_001467.
FT   VARIANT     108    108       D -> H (in a bladder tumor).
FT                                /FTId=VAR_001469.
FT   VARIANT     108    108       D -> Y (in a head and neck tumor).
FT                                /FTId=VAR_001468.
FT   VARIANT     114    114       P -> L (in non-small cell lung
FT                                carcinoma).
FT                                /FTId=VAR_001470.
FT   VARIANT     117    117       L -> M (in melanoma; somatic mutation).
FT                                /FTId=VAR_001471.
FT   VARIANT     118    118       A -> T (in CMM2).
FT                                /FTId=VAR_001472.
FT   VARIANT     119    119       E -> Q (in a biliary tract tumor).
FT                                /FTId=VAR_001473.
FT   VARIANT     120    120       E -> A (in non-small cell lung
FT                                carcinoma).
FT                                /FTId=VAR_001474.
FT   VARIANT     120    120       E -> K (in non-small cell lung
FT                                carcinoma).
FT                                /FTId=VAR_001475.
FT   VARIANT     122    122       G -> S (in a biliary tract tumor).
FT                                /FTId=VAR_001476.
FT   VARIANT     123    123       H -> Q (in leukemia; dbSNP:6413463).
FT                                /FTId=VAR_001477.
FT   VARIANT     124    124       R -> H (in an esophagus tumor).
FT                                /FTId=VAR_001478.
FT   VARIANT     126    126       V -> D (in CMM2; impairs the function).
FT                                /FTId=VAR_001479.
FT   VARIANT     127    127       A -> S (in squamous cell carcinoma;
FT                                dbSNP:6413464).
FT                                /FTId=VAR_001480.
FT   VARIANT     132    132       A -> P (in non-small cell lung
FT                                carcinoma).
FT                                /FTId=VAR_001481.
FT   VARIANT     134    134       A -> V (in non-small cell lung
FT                                carcinoma).
FT                                /FTId=VAR_001482.
FT   VARIANT     142    142       H -> Y (in non-small cell lung
FT                                carcinoma).
FT                                /FTId=VAR_001483.
FT   VARIANT     144    144       R -> C (in squamous cell carcinoma).
FT                                /FTId=VAR_001484.
FT   VARIANT     148    148       A -> T (in dbSNP:3731249).
FT                                /FTId=VAR_001486.
FT   VARIANT     150    150       G -> V (in non-small cell lung
FT                                carcinoma).
FT                                /FTId=VAR_001487.
FT   TURN         13     14
FT   HELIX        15     22
FT   TURN         23     23
FT   HELIX        25     32
FT   TURN         33     35
FT   TURN         38     39
FT   TURN         48     50
FT   TURN         54     55
FT   HELIX        57     64
FT   TURN         65     67
FT   TURN         75     77
FT   HELIX        81     88
FT   TURN         89     89
FT   HELIX        91    100
FT   TURN        101    101
FT   TURN        109    110
FT   HELIX       114    121
FT   TURN        122    122
FT   HELIX       124    130
SQ   SEQUENCE   156 AA;  16533 MW;  E59C0E6174B48255 CRC64;
     MEPAAGSSME PSADWLATAA ARGRVEEVRA LLEAGALPNA PNSYGRRPIQ VMMMGSARVA
     ELLLLHGAEP NCADPATLTR PVHDAAREGF LDTLVVLHRA GARLDVRDAW GRLPVDLAEE
     LGHRDVARYL RAAAGGTRGS NHARIDAAEG PSDIPD
//
ID   ITHA_HIRME     STANDARD;      PRT;    65 AA.
AC   P28501;
DT   01-DEC-1992 (Rel. 24, Created)
DT   01-DEC-1992 (Rel. 24, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Hirudin I (Fragments).
OS   Hirudo medicinalis (Medicinal leech).
OC   Eukaryota; Metazoa; Annelida; Clitellata; Hirudinida; Hirudinea;
OC   Arhynchobdellida; Hirudiniformes; Hirudinidae; Hirudo.
OX   NCBI_TaxID=6421;
RN   [1]
RP   PROTEIN SEQUENCE.
RX   MEDLINE=90005945; PubMed=2792365; DOI=10.1016/0014-5793(89)81070-1;
RA   Scharf M., Engels J., Tripier D.;
RT   "Primary structures of new 'iso-hirudins'.";
RL   FEBS Lett. 255:105-110(1989).
CC   -!- FUNCTION: Hirudin is a potent thrombin-specific protease
CC       inhibitor. It forms a stable non-covalent complex with alpha-
CC       thrombin, thereby abolishing its ability to cleave fibrinogen.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- SIMILARITY: Belongs to the hirudin family.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   PIR; S05672; S05672.
DR   PDB; 1A2C; X-ray; I=54-62.
DR   PDB; 1A46; X-ray; I=54-62.
DR   PDB; 1AE8; X-ray; I=55-62.
DR   PDB; 1AFE; X-ray; I=55-62.
DR   PDB; 1AI8; X-ray; I=55-62.
DR   PDB; 1AWF; X-ray; I=55-62.
DR   PDB; 1D3D; X-ray; H=54-64.
DR   PDB; 1D3P; X-ray; H=54-64.
DR   PDB; 1D3Q; X-ray; H=54-64.
DR   PDB; 1D3T; X-ray; H=54-64.
DR   PDB; 1D4P; X-ray; H=54-64.
DR   PDB; 1QHR; X-ray; I=55-62.
DR   PDB; 1QJ1; X-ray; I=55-62.
DR   PDB; 1QJ6; X-ray; I=55-62.
DR   PDB; 1QJ7; X-ray; I=55-62.
DR   PDB; 1UMA; X-ray; I=55-64.
DR   PDB; 1WBG; X-ray; I=-.
DR   SMR; P28501; 1-65.
DR   InterPro; IPR011061; Antihaemostatic.
DR   InterPro; IPR000429; Prot_inh_hirudin.
DR   PIRSF; PIRSF001640; Hirudin; 1.
DR   PRINTS; PR00777; HIRUDIN.
DR   ProDom; PD004216; Prot_inh_hirudin; 1.
KW   3D-structure; Direct protein sequencing; Multigene family;
KW   Protease inhibitor; Serine protease inhibitor; Sulfation.
FT   MOD_RES      63     63       Sulfotyrosine.
FT   DISULFID      6     14       By similarity.
FT   DISULFID     16     28       By similarity.
FT   DISULFID     22     39       By similarity.
SQ   SEQUENCE   65 AA;  7138 MW;  B79C5A9D11677AD5 CRC64;
     VVYTDCTESG QNLCLCEXXX XXXXXXXCIL GSDGEKNQCV TGEGTPKPQS HNDGDFEEIP
     EEYLQ
//
ID   THRB_HUMAN     STANDARD;      PRT;   622 AA.
AC   P00734;
DT   21-JUL-1986 (Rel. 01, Created)
DT   01-JAN-1990 (Rel. 13, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Prothrombin precursor (EC 3.4.21.5) (Coagulation factor II).
GN   Name=F2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=88077877; PubMed=2825773;
RA   Degen S.J.F., Davie E.W.;
RT   "Nucleotide sequence of the gene for human prothrombin.";
RL   Biochemistry 26:6165-6177(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT MET-165.
RA   Rieder M.J., Armel T.Z., Carrington D.P., Chung M.-W., Lee K.L.,
RA   Ozuna M., Poel C.L., Toth E.J., Yi Q., Nickerson D.A.;
RT   "SeattleSNPs. NHLBI HL66682 program for genomic applications, UW-
RT   FHCRC, Seattle, WA (URL: http://pga.gs.washington.edu).";
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE OF 8-622.
RX   MEDLINE=83231469; PubMed=6305407;
RA   Degen S.J.F., McGillivray R.T.A., Davie E.W.;
RT   "Characterization of the complementary deoxyribonucleic acid and gene
RT   coding for human prothrombin.";
RL   Biochemistry 22:2087-2097(1983).
RN   [4]
RP   PROTEIN SEQUENCE OF 44-314.
RX   MEDLINE=77193964; PubMed=266717;
RA   Walz D.A., Hewett-Emmett D., Seegers W.H.;
RT   "Amino acid sequence of human prothrombin fragments 1 and 2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 74:1969-1972(1977).
RN   [5]
RP   PROTEIN SEQUENCE OF 315-622.
RX   MEDLINE=77207112; PubMed=873923;
RA   Butkowski R.J., Elion J., Downing M.R., Mann K.G.;
RT   "Primary structure of human prethrombin 2 and alpha-thrombin.";
RL   J. Biol. Chem. 252:4942-4957(1977).
RN   [6]
RP   PROCESSING.
RX   MEDLINE=87008532; PubMed=3759958;
RA   Rabiet M.J., Blashill A., Furie B., Furie B.C.;
RT   "Prothrombin fragment 1 X 2 X 3, a major product of prothrombin
RT   activation in human plasma.";
RL   J. Biol. Chem. 261:13210-13215(1986).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS).
RX   MEDLINE=90059942; PubMed=2583108;
RA   Bode W., Mayr I., Baumann U., Huber R., Stone S.R., Hofsteenge J.;
RT   "The refined 1.9 A crystal structure of human alpha-thrombin:
RT   interaction with D-Phe-Pro-Arg chloromethylketone and significance of
RT   the Tyr-Pro-Pro-Trp insertion segment.";
RL   EMBO J. 8:3467-3475(1989).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
RX   MEDLINE=90327074; PubMed=2374926;
RA   Rydel T.J., Ravichandran K.G., Tulinsky A., Bode W., Huber R.,
RA   Roitsch C., Fenton J.W. II;
RT   "The structure of a complex of recombinant hirudin and human alpha-
RT   thrombin.";
RL   Science 249:277-280(1990).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS).
RX   MEDLINE=94350942; PubMed=8071320;
RA   Rydel T.J., Yin M., Padmanabhan K.P., Blankenship D.T., Cardin A.D.,
RA   Correa P.E., Fenton J.W. II, Tulinsky A.;
RT   "Crystallographic structure of human gamma-thrombin.";
RL   J. Biol. Chem. 269:22000-22006(1994).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
RX   MEDLINE=97357286; PubMed=9214615; DOI=10.1093/emboj/16.11.2977;
RA   van de Locht A., Bode W., Huber R., le Bonniec B.F., Stone S.R.,
RA   Esmon C.T., Stubbs M.T.;
RT   "The thrombin E192Q-BPTI complex reveals gross structural
RT   rearrangements: implications for the interaction with antithrombin and
RT   thrombomodulin.";
RL   EMBO J. 16:2977-2984(1997).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 328-601.
RX   MEDLINE=99162521; PubMed=10051558; DOI=10.1073/pnas.96.5.1852;
RA   Guinto E.R., Caccia S., Rose T., Fuetterer K., Waksman G., di Cera E.;
RT   "Unexpected crucial role of residue 225 in serine proteases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:1852-1857(1999).
RN   [12]
RP   VARIANT DYSPROTHROMBINEMIA CYS-314.
RX   MEDLINE=87033739; PubMed=3771562;
RA   Rabiet M.-J., Furie B.C., Furie B.;
RT   "Molecular defect of prothrombin Barcelona. Substitution of cysteine
RT   for arginine at residue 273.";
RL   J. Biol. Chem. 261:15045-15048(1986).
RN   [13]
RP   VARIANT DYSPROTHROMBINEMIA ALA-509.
RX   MEDLINE=95313001; PubMed=7792730;
RA   Degen S.J.F., McDowell S.A., Sparks L.M., Scharrer I.;
RT   "Prothrombin Frankfurt: a dysfunctional prothrombin characterized by
RT   substitution of Glu-466 by Ala.";
RL   Thromb. Haemost. 73:203-209(1995).
RN   [14]
RP   VARIANTS DYSPROTHROMBINEMIA THR-380 AND HIS-431.
RX   MEDLINE=93043342; PubMed=1421398;
RA   Morishita E., Saito M., Kumabashiri I., Asakura H., Matsuda T.,
RA   Yamaguchi K.;
RT   "Prothrombin Himi: a compound heterozygote for two dysfunctional
RT   prothrombin molecules (Met-337-->Thr and Arg-388-->His).";
RL   Blood 80:2275-2280(1992).
RN   [15]
RP   VARIANT DYSPROTHROMBINEMIA HIS-314.
RX   MEDLINE=95169898; PubMed=7865694;
RA   James H.L., Kim D.J., Zheng D.-Q., Girolami A.;
RT   "Prothrombin Padua I: incomplete activation due to an amino acid
RT   substitution at a factor Xa cleavage site.";
RL   Blood Coagul. Fibrinolysis 5:841-844(1994).
RN   [16]
RP   VARIANT DYSPROTHROMBINEMIA CYS-425.
RX   MEDLINE=89207504; PubMed=3242619;
RA   Henriksen R.A., Mann K.G.;
RT   "Identification of the primary structural defect in the dysthrombin
RT   thrombin Quick I: substitution of cysteine for arginine-382.";
RL   Biochemistry 27:9160-9165(1988).
RN   [17]
RP   VARIANT DYSPROTHROMBINEMIA VAL-601.
RX   MEDLINE=89247398; PubMed=2719946;
RA   Henriksen R.A., Mann K.G.;
RT   "Substitution of valine for glycine-558 in the congenital dysthrombin
RT   thrombin Quick II alters primary substrate specificity.";
RL   Biochemistry 28:2078-2082(1989).
RN   [18]
RP   VARIANT DYSPROTHROMBINEMIA ALA-509.
RX   MEDLINE=92378975; PubMed=1354985;
RA   Miyata T., Aruga R., Umeyama H., Bezeaud A., Guillin M.-C.,
RA   Iwanaga S.;
RT   "Prothrombin Salakta: substitution of glutamic acid-466 by alanine
RT   reduces the fibrinogen clotting activity and the esterase activity.";
RL   Biochemistry 31:7457-7462(1992).
RN   [19]
RP   VARIANT DYSPROTHROMBINEMIA TRP-461.
RX   MEDLINE=87185407; PubMed=3567158;
RA   Miyata T., Morita T., Inomoto T., Kawauchi S., Shirakami A.,
RA   Iwanaga S.;
RT   "Prothrombin Tokushima, a replacement of arginine-418 by tryptophan
RT   that impairs the fibrinogen clotting activity of derived thrombin
RT   Tokushima.";
RL   Biochemistry 26:1117-1122(1987).
RN   [20]
RP   VARIANT DYSPROTHROMBINEMIA TRP-461.
RX   MEDLINE=87101511; PubMed=3801671;
RA   Inomoto T., Shirakami A., Kawauchi S., Shigekiyo T., Saito S.,
RA   Miyoshi K., Morita T., Iwanaga S.;
RT   "Prothrombin Tokushima: characterization of dysfunctional thrombin
RT   derived from a variant of human prothrombin.";
RL   Blood 69:565-569(1987).
RN   [21]
RP   VARIANT DYSPROTHROMBINEMIA TRP-461.
RX   MEDLINE=92256895; PubMed=1349838;
RA   Iwahana H., Yoshimoto K., Shigekiyo T., Shirakami A., Saito S.,
RA   Itakura M.;
RT   "Detection of a single base substitution of the gene for prothrombin
RT   Tokushima. The application of PCR-SSCP for the genetic and molecular
RT   analysis of dysprothrombinemia.";
RL   Int. J. Hematol. 55:93-100(1992).
RN   [22]
RP   VARIANT DYSPROTHROMBINEMIA LYS-200.
RX   MEDLINE=83204687; PubMed=6405779;
RA   Board P.G., Shaw D.C.;
RT   "Determination of the amino acid substitution in human prothrombin
RT   type 3 (157 Glu leads to Lys) and the localization of a third thrombin
RT   cleavage site.";
RL   Br. J. Haematol. 54:245-254(1983).
RN   [23]
RP   VARIANTS MET-165 AND THR-386.
RX   MEDLINE=99318093; PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [24]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
CC   -!- FUNCTION: Thrombin, which cleaves bonds after Arg and Lys,
CC       converts fibrinogen to fibrin and activates factors V, VII, VIII,
CC       XIII, and, in complex with thrombomodulin, protein C.
CC   -!- CATALYTIC ACTIVITY: Selective cleavage of Arg-|-Gly bonds in
CC       fibrinogen to form fibrin and release fibrinopeptides A and B.
CC   -!- SUBCELLULAR LOCATION: Extracellular.
CC   -!- TISSUE SPECIFICITY: Expressed by the liver and secreted in plasma.
CC   -!- PTM: The gamma-carboxyglutamyl residues, which bind calcium ions,
CC       result from the carboxylation of glutamyl residues by a microsomal
CC       enzyme, the vitamin K-dependent carboxylase. The modified residues
CC       are necessary for the calcium-dependent interaction with a
CC       negatively charged phospholipid surface, which is essential for
CC       the conversion of prothrombin to thrombin.
CC   -!- DISEASE: Defects in F2 are the cause of various forms of
CC       dysprothrombinemia [MIM:176930].
CC   -!- MISCELLANEOUS: Prothrombin is activated on the surface of a
CC       phospholipid membrane that binds the amino end of prothrombin and
CC       factors Va and Xa in Ca-dependent interactions; factor Xa removes
CC       the activation peptide and cleaves the remaining part into light
CC       and heavy chains. The activation process starts slowly because
CC       factor V itself has to be activated by the initial, small amounts
CC       of thrombin.
CC   -!- MISCELLANEOUS: It is not known whether 1 or 2 smaller activation
CC       peptides, with additional cleavage after Arg-314, are released in
CC       natural blood clotting.
CC   -!- MISCELLANEOUS: Thrombin can itself cleave the N-terminal fragment
CC       (fragment 1) of the prothrombin, prior to its activation by factor
CC       Xa.
CC   -!- MISCELLANEOUS: The cleavage after Arg-198, observed in vitro, does
CC       not occur in plasma.
CC   -!- SIMILARITY: Belongs to the peptidase S1 family.
CC   -!- SIMILARITY: Contains 1 Gla (gamma-carboxy-glutamate) domain.
CC   -!- SIMILARITY: Contains 2 kringle domains.
CC   -!- SIMILARITY: Contains 1 peptidase S1 domain.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; M17262; AAC63054.1; -; Genomic_DNA.
DR   EMBL; AF478696; AAL77436.1; -; Genomic_DNA.
DR   EMBL; V00595; CAA23842.1; -; mRNA.
DR   PIR; A29351; TBHU.
DR   PDB; 1A2C; X-ray; H=364-622, L=328-363.
DR   PDB; 1A3B; X-ray; H=364-622, L=328-363.
DR   PDB; 1A3E; X-ray; H=364-622, L=328-363.
DR   PDB; 1A46; X-ray; H=364-622, L=328-363.
DR   PDB; 1A4W; X-ray; H=364-622, L=328-363.
DR   PDB; 1A5G; X-ray; H=364-622, L=328-363.
DR   PDB; 1A61; X-ray; H=364-622, L=328-363.
DR   PDB; 1ABI; X-ray; H=364-622, L=328-363.
DR   PDB; 1ABJ; X-ray; H=364-622, L=328-363.
DR   PDB; 1AD8; X-ray; H=364-622, L=328-363.
DR   PDB; 1AE8; X-ray; H=364-622, L=328-363.
DR   PDB; 1AFE; X-ray; H=364-622, L=328-363.
DR   PDB; 1AHT; X-ray; H=364-622, L=328-363.
DR   PDB; 1AI8; X-ray; H=364-622, L=328-363.
DR   PDB; 1AIX; X-ray; H=364-622, L=328-363.
DR   PDB; 1AWF; X-ray; H=364-622, L=328-363.
DR   PDB; 1AWH; X-ray; A/C=328-363, B/D=364-622.
DR   PDB; 1AY6; X-ray; H=364-622, L=328-363.
DR   PDB; 1B5G; X-ray; H=364-622, L=328-363.
DR   PDB; 1B7X; X-ray; A=328-363, B=364-622.
DR   PDB; 1BA8; X-ray; A=328-363, B=364-622.
DR   PDB; 1BB0; X-ray; A=328-363, B=364-622.
DR   PDB; 1BCU; X-ray; H=364-622, L=328-363.
DR   PDB; 1BHX; X-ray; A=331-360, B=364-510, F=518-622.
DR   PDB; 1BMM; X-ray; H=364-622, L=328-363.
DR   PDB; 1BMN; X-ray; H=364-622, L=328-363.
DR   PDB; 1BTH; X-ray; H/K=364-622, J/L=328-363.
DR   PDB; 1C1U; X-ray; H=364-622, L=328-363.
DR   PDB; 1C1V; X-ray; H=364-622, L=328-363.
DR   PDB; 1C1W; X-ray; H=364-622, L=328-363.
DR   PDB; 1C4U; X-ray; 1=328-363, 2=364-622.
DR   PDB; 1C4V; X-ray; 1=328-363, 2=364-622.
DR   PDB; 1C4Y; X-ray; 1=328-363, 2=364-622.
DR   PDB; 1C5L; X-ray; H=364-622, L=328-363.
DR   PDB; 1C5N; X-ray; H=364-622, L=328-363.
DR   PDB; 1C5O; X-ray; H=364-622, L=328-363.
DR   PDB; 1CA8; X-ray; A=328-363, B=364-622.
DR   PDB; 1D3D; X-ray; A=333-360, B=364-620.
DR   PDB; 1D3P; X-ray; A=328-363, B=364-622.
DR   PDB; 1D3Q; X-ray; A=328-363, B=364-622.
DR   PDB; 1D3T; X-ray; A=328-363, B=364-622.
DR   PDB; 1D4P; X-ray; A=328-363, B=364-622.
DR   PDB; 1D6W; X-ray; A=334-620.
DR   PDB; 1D9I; X-ray; A=334-621.
DR   PDB; 1DE7; X-ray; H/K=364-622, J/L=328-363.
DR   PDB; 1DIT; X-ray; H=364-622, L=328-363.
DR   PDB; 1DM4; X-ray; A=328-362, B=363-622.
DR   PDB; 1DOJ; X-ray; A=328-622.
DR   PDB; 1DWB; X-ray; H=364-622, L=328-363.
DR   PDB; 1DWC; X-ray; H=364-622, L=328-363.
DR   PDB; 1DWD; X-ray; H=364-622, L=328-363.
DR   PDB; 1DWE; X-ray; H=364-622, L=328-363.
DR   PDB; 1DX5; X-ray; A/B/C=328-363, D/M=-, N/O/P=364-622.
DR   PDB; 1E0F; X-ray; A/B/C=328-363, D/E/F=364-622.
DR   PDB; 1EB1; X-ray; H=364-620, L=337-360.
DR   PDB; 1EOJ; X-ray; A=334-620.
DR   PDB; 1EOL; X-ray; A=334-620.
DR   PDB; 1FPC; X-ray; H=364-622, L=328-363.
DR   PDB; 1FPH; X-ray; H=364-622, L=328-363.
DR   PDB; 1G30; X-ray; A=328-363, B=364-622.
DR   PDB; 1G32; X-ray; A=328-363, B=364-622.
DR   PDB; 1G37; X-ray; A=334-620.
DR   PDB; 1GHV; X-ray; H=364-620, L=328-363.
DR   PDB; 1GHW; X-ray; H=364-620, L=328-363.
DR   PDB; 1GHX; X-ray; H=364-620, L=328-363.
DR   PDB; 1GHY; X-ray; H=364-620, L=328-363.
DR   PDB; 1GJ4; X-ray; H=364-621, L=328-363.
DR   PDB; 1GJ5; X-ray; H=364-621, L=328-363.
DR   PDB; 1H8D; X-ray; H=364-621, L=333-360.
DR   PDB; 1H8I; X-ray; H=364-622, L=334-360.
DR   PDB; 1HAG; X-ray; E=328-622.
DR   PDB; 1HAH; X-ray; H=364-622, L=328-363.
DR   PDB; 1HAI; X-ray; H=364-622, L=328-363.
DR   PDB; 1HAO; X-ray; H=364-622, L=328-363.
DR   PDB; 1HAP; X-ray; H=364-622, L=328-363.
DR   PDB; 1HBT; X-ray; H=364-622, L=328-363.
DR   PDB; 1HDT; X-ray; H/L=-.
DR   PDB; 1HGT; X-ray; H=364-622, L=328-363.
DR   PDB; 1HLT; X-ray; H/K=364-622, J/L=334-360.
DR   PDB; 1HUT; X-ray; H=364-622, L=328-363.
DR   PDB; 1HXE; X-ray; H=364-622, L=328-363.
DR   PDB; 1HXF; X-ray; H=364-622, L=328-363.
DR   PDB; 1IHS; X-ray; H=364-622, L=328-363.
DR   PDB; 1IHT; X-ray; H=364-622, L=328-363.
DR   PDB; 1JMO; X-ray; H=363-622, L=-.
DR   PDB; 1JOU; X-ray; A/C/E=315-363, B/D/F=364-622.
DR   PDB; 1JWT; X-ray; A=328-622.
DR   PDB; 1K21; X-ray; H=364-622, L=328-363.
DR   PDB; 1K22; X-ray; H=364-622, L=328-363.
DR   PDB; 1KTS; X-ray; A=328-363, B=364-622.
DR   PDB; 1KTT; X-ray; A=328-363, B=364-622.
DR   PDB; 1LHC; X-ray; H=364-622, L=328-363.
DR   PDB; 1LHD; X-ray; H=364-622, L=328-363.
DR   PDB; 1LHE; X-ray; H=364-622, L=328-363.
DR   PDB; 1LHF; X-ray; H=364-622, L=328-363.
DR   PDB; 1LHG; X-ray; H=364-622, L=328-363.
DR   PDB; 1MH0; X-ray; A/B=334-620.
DR   PDB; 1MU6; X-ray; A=328-363, B=364-622.
DR   PDB; 1MU8; X-ray; A=328-363, B=364-622.
DR   PDB; 1MUE; X-ray; A=328-363, B=364-622.
DR   PDB; 1NM6; X-ray; A=335-621.
DR   PDB; 1NO9; X-ray; H=364-622, L=-.
DR   PDB; 1NRN; X-ray; H=364-622, L=328-363.
DR   PDB; 1NRO; X-ray; H=364-622, L=328-363.
DR   PDB; 1NRP; X-ray; H=364-622, L=328-363.
DR   PDB; 1NRQ; X-ray; H=364-622, L=328-363.
DR   PDB; 1NRR; X-ray; H=364-622, L=-.
DR   PDB; 1NRS; X-ray; H=364-622, L=328-363.
DR   PDB; 1NT1; X-ray; A=335-621.
DR   PDB; 1NU7; X-ray; A/E=332-359, B/F=364-622.
DR   PDB; 1NU9; X-ray; A/D=332-622.
DR   PDB; 1NY2; X-ray; 1=328-363, 2=364-622.
DR   PDB; 1NZQ; X-ray; H=364-622, L=328-363.
DR   PDB; 1O0D; X-ray; H=364-622, L=328-363.
DR   PDB; 1O2G; X-ray; H=364-622, L=328-363.
DR   PDB; 1O5G; X-ray; H=364-622, L=-.
DR   PDB; 1OOK; X-ray; A=328-363, B=364-622.
DR   PDB; 1OYT; X-ray; H=364-622, L=-.
DR   PDB; 1P8V; X-ray; B=333-361, C=364-622.
DR   PDB; 1PPB; X-ray; H=364-622, L=328-363.
DR   PDB; 1QBV; X-ray; H=364-622, L=328-363.
DR   PDB; 1QHR; X-ray; A=328-363, B=364-622.
DR   PDB; 1QJ1; X-ray; A=328-363, B=364-622.
DR   PDB; 1QJ6; X-ray; A=328-363, B=364-622.
DR   PDB; 1QJ7; X-ray; A=328-363, B=364-622.
DR   PDB; 1QUR; X-ray; H=364-620, L=334-360.
DR   PDB; 1QVH; X-ray; A/D=328-363, B/E=364-622.
DR   PDB; 1RD3; X-ray; A/C=328-363, B/D=364-622.
DR   PDB; 1RIW; X-ray; A=328-363, B=364-510, C=518-622.
DR   PDB; 1SB1; X-ray; H=364-621, L=333-361.
DR   PDB; 1SFQ; X-ray; A/D=328-363, B/E=364-622.
DR   PDB; 1SG8; X-ray; A/D=328-363, B/E=364-622.
DR   PDB; 1SGI; X-ray; A/D=328-363, B/E=364-622.
DR   PDB; 1SHH; X-ray; A/D=328-363, B/E=364-622.
DR   PDB; 1SL3; X-ray; A=335-621.
DR   PDB; 1SR5; X-ray; B=328-363, C=364-622.
DR   PDB; 1TA2; X-ray; A=335-621.
DR   PDB; 1TA6; X-ray; A=335-621.
DR   PDB; 1TB6; X-ray; H=364-622, L=315-363.
DR   PDB; 1TBZ; X-ray; H=364-622, L=328-363.
DR   PDB; 1THP; X-ray; A=328-363, B=364-622.
DR   PDB; 1THR; X-ray; H=364-622, L=328-363.
DR   PDB; 1THS; X-ray; H=364-622, L=328-363.
DR   PDB; 1TMB; X-ray; H=364-622, L=328-363.
DR   PDB; 1TMT; X-ray; H=364-622, L=328-363.
DR   PDB; 1TMU; X-ray; H=364-622, L=333-360.
DR   PDB; 1TOM; X-ray; H=364-622, L=328-363.
DR   PDB; 1TQ0; X-ray; A/C=333-363, B/D=364-620.
DR   PDB; 1TQ7; X-ray; A=320-363, B=364-620.
DR   PDB; 1UMA; X-ray; H=364-622, L=328-363.
DR   PDB; 1UVS; X-ray; H=364-622, L=328-363.
DR   PDB; 1VR1; X-ray; H=364-620.
DR   PDB; 1WAY; X-ray; A=328-363, B=364-622.
DR   PDB; 1WBG; X-ray; A/B=-.
DR   PDB; 1XMN; X-ray; A/C/E/G=328-363, B/D/F/H=364-622.
DR   PDB; 2HGT; X-ray; H=364-622, L=328-363.
DR   PDB; 2HNT; X-ray; C=364-433, E=437-517, F=518-622, L=328-363.
DR   PDB; 2HPP; X-ray; H=364-622, L=328-363.
DR   PDB; 2HPQ; X-ray; H=364-622, L=328-363, P=213-291.
DR   PDB; 2THF; X-ray; A=328-363, B=364-622.
DR   PDB; 3HAT; X-ray; H=364-622, L=-.
DR   PDB; 3HTC; X-ray; H=364-622, L=328-363.
DR   PDB; 4HTC; X-ray; H=364-622, L=328-363.
DR   PDB; 4THN; X-ray; H=364-622.
DR   PDB; 5GDS; X-ray; H=364-622, L=328-363.
DR   PDB; 7KME; X-ray; H=364-622, L=328-363.
DR   PDB; 8KME; X-ray; 1=328-363, 2=364-622.
DR   SMR; P00734; 207-363.
DR   IntAct; P00734; -.
DR   MEROPS; S01.217; -.
DR   GlycoSuiteDB; P00734; -.
DR   SWISS-2DPAGE; P00734; HUMAN.
DR   Ensembl; ENSG00000180210; Homo sapiens.
DR   Genew; HGNC:3535; F2.
DR   MIM; 176930; -.
DR   GO; GO:0005615; C:extracellular space; TAS.
DR   GO; GO:0005625; C:soluble fraction; TAS.
DR   GO; GO:0005102; F:receptor binding; IPI.
DR   GO; GO:0008236; F:serine-type peptidase activity; TAS.
DR   GO; GO:0003809; F:thrombin activity; IDA.
DR   GO; GO:0006915; P:apoptosis; TAS.
DR   GO; GO:0006919; P:caspase activation; TAS.
DR   GO; GO:0007275; P:development; TAS.
DR   GO; GO:0042730; P:fibrinolysis; IDA.
DR   GO; GO:0030168; P:platelet activation; TAS.
DR   GO; GO:0006508; P:proteolysis and peptidolysis; TAS.
DR   GO; GO:0030193; P:regulation of blood coagulation; TAS.
DR   GO; GO:0000074; P:regulation of cell cycle; TAS.
DR   GO; GO:0009611; P:response to wounding; TAS.
DR   GO; GO:0007262; P:STAT protein nuclear translocation; TAS.
DR   GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; TAS.
DR   InterPro; IPR002383; GLA_blood.
DR   InterPro; IPR000001; Kringle.
DR   InterPro; IPR001254; Peptidase_S1_S6.
DR   InterPro; IPR001314; Peptidase_S1A.
DR   InterPro; IPR003966; Peptidase_S1A_pr.
DR   InterPro; IPR012051; Thrombin.
DR   InterPro; IPR000294; VitK_dep_GLA.
DR   Pfam; PF00594; Gla; 1.
DR   Pfam; PF00051; Kringle; 2.
DR   Pfam; PF00089; Trypsin; 1.
DR   PIRSF; PIRSF001149; Thrombin; 1.
DR   PRINTS; PR00722; CHYMOTRYPSIN.
DR   PRINTS; PR00001; GLABLOOD.
DR   PRINTS; PR00018; KRINGLE.
DR   PRINTS; PR01505; PROTHROMBIN.
DR   ProDom; PD000395; Kringle; 2.
DR   PROSITE; PS00011; GLA_1; 1.
DR   PROSITE; PS50998; GLA_2; 1.
DR   PROSITE; PS00021; KRINGLE_1; 2.
DR   PROSITE; PS50070; KRINGLE_2; 2.
DR   PROSITE; PS50240; TRYPSIN_DOM; 1.
DR   PROSITE; PS00134; TRYPSIN_HIS; 1.
DR   PROSITE; PS00135; TRYPSIN_SER; 1.
KW   3D-structure; Acute phase; Blood coagulation; Calcium;
KW   Calcium-binding; Direct protein sequencing; Disease mutation;
KW   Gamma-carboxyglutamic acid; Glycoprotein; Hydrolase; Kringle; Plasma;
KW   Polymorphism; Protease; Repeat; Serine protease; Signal; Zymogen.
FT   SIGNAL        1     24       Potential.
FT   PROPEP       25     43
FT   CHAIN        44    622       Prothrombin.
FT   PEPTIDE      44    198       Activation peptide (fragment 1).
FT   PEPTIDE     199    327       Activation peptide (fragment 2).
FT   CHAIN       328    363       Thrombin light chain.
FT   CHAIN       364    622       Thrombin heavy chain.
FT   DOMAIN       44     89       Gla.
FT   DOMAIN      108    186       Kringle 1.
FT   DOMAIN      213    291       Kringle 2.
FT   DOMAIN      364    618       Peptidase S1.
FT   ACT_SITE    406    406       Charge relay system.
FT   ACT_SITE    462    462       Charge relay system.
FT   ACT_SITE    568    568       Charge relay system.
FT   SITE        198    199       Cleavage (by thrombin).
FT   SITE        327    328       Cleavage (by factor Xa).
FT   SITE        363    364       Cleavage (by factor Xa).
FT   MOD_RES      49     49       4-carboxyglutamate.
FT   MOD_RES      50     50       4-carboxyglutamate.
FT   MOD_RES      57     57       4-carboxyglutamate.
FT   MOD_RES      59     59       4-carboxyglutamate.
FT   MOD_RES      62     62       4-carboxyglutamate.
FT   MOD_RES      63     63       4-carboxyglutamate.
FT   MOD_RES      68     68       4-carboxyglutamate.
FT   MOD_RES      69     69       4-carboxyglutamate.
FT   MOD_RES      72     72       4-carboxyglutamate.
FT   MOD_RES      75     75       4-carboxyglutamate.
FT   CARBOHYD    121    121       N-linked (GlcNAc...).
FT   CARBOHYD    143    143       N-linked (GlcNAc...).
FT   CARBOHYD    416    416       N-linked (GlcNAc...).
FT   DISULFID     60     65
FT   DISULFID     90    103
FT   DISULFID    108    186
FT   DISULFID    129    169
FT   DISULFID    157    181
FT   DISULFID    213    291
FT   DISULFID    234    274
FT   DISULFID    262    286
FT   DISULFID    336    482       Interchain (between light and heavy
FT                                chains).
FT   DISULFID    391    407
FT   DISULFID    536    550       By similarity.
FT   DISULFID    564    594       By similarity.
FT   VARIANT     165    165       T -> M (in dbSNP:5896).
FT                                /FTId=VAR_011781.
FT   VARIANT     200    200       E -> K (in dysprothrombinemia;
FT                                prothrombin type 3).
FT                                /FTId=VAR_006711.
FT   VARIANT     314    314       R -> C (in dysprothrombinemia; Barcelona/
FT                                Madrid).
FT                                /FTId=VAR_006712.
FT   VARIANT     314    314       R -> H (in dysprothrombinemia; Padua-1).
FT                                /FTId=VAR_006713.
FT   VARIANT     380    380       M -> T (in dysprothrombinemia; Himi-1).
FT                                /FTId=VAR_006714.
FT   VARIANT     386    386       P -> T (in dbSNP:5897).
FT                                /FTId=VAR_011782.
FT   VARIANT     425    425       R -> C (in dysprothrombinemia; Quick-1).
FT                                /FTId=VAR_006715.
FT   VARIANT     431    431       R -> H (in dysprothrombinemia; Himi-2).
FT                                /FTId=VAR_006716.
FT   VARIANT     461    461       R -> W (in dysprothrombinemia;
FT                                Tokushima).
FT                                /FTId=VAR_006717.
FT   VARIANT     509    509       E -> A (in dysprothrombinemia; Salakta/
FT                                Frankfurt).
FT                                /FTId=VAR_006718.
FT   VARIANT     601    601       G -> V (in dysprothrombinemia; Quick-2).
FT                                /FTId=VAR_006719.
FT   CONFLICT    119    119       H -> N (in Ref. 4).
FT   CONFLICT    121    121       N -> S (in Ref. 4).
FT   CONFLICT    164    164       T -> I (in Ref. 4).
FT   CONFLICT    164    164       T -> N (in Ref. 3).
FT   CONFLICT    176    176       V -> A (in Ref. 4).
FT   CONFLICT    183    183       I -> T (in Ref. 4).
FT   CONFLICT    194    195       AM -> MV (in Ref. 4).
FT   CONFLICT    308    308       D -> DEE (in Ref. 4).
FT   CONFLICT    335    335       D -> N (in Ref. 5).
FT   CONFLICT    349    349       D -> N (in Ref. 5).
FT   CONFLICT    369    369       D -> N (in Ref. 5).
FT   CONFLICT    398    398       D -> N (in Ref. 5).
FT   CONFLICT    414    414       D -> N (in Ref. 5).
FT   CONFLICT    485    485       D -> N (in Ref. 5).
FT   CONFLICT    494    494       Q -> G (in Ref. 5).
FT   CONFLICT    504    504       W -> Y (in Ref. 5).
FT   CONFLICT    509    509       E -> S (in Ref. 5).
FT   CONFLICT    511    511       W -> V (in Ref. 5).
FT   CONFLICT    514    514       N -> D (in Ref. 5).
FT   CONFLICT    529    530       PI -> AL (in Ref. 5).
FT   CONFLICT    532    532       E -> Q (in Ref. 5).
FT   STRAND      214    214
FT   HELIX       216    218
FT   TURN        219    220
FT   STRAND      227    228
FT   TURN        229    230
FT   STRAND      233    233
FT   TURN        237    238
FT   HELIX       242    245
FT   HELIX       246    248
FT   TURN        253    254
FT   TURN        259    260
FT   STRAND      263    263
FT   STRAND      273    273
FT   STRAND      275    275
FT   TURN        280    281
FT   STRAND      283    283
FT   STRAND      286    286
FT   STRAND      290    290
FT   TURN        336    337
FT   TURN        340    346
FT   TURN        350    351
FT   HELIX       352    360
FT   STRAND      365    365
FT   STRAND      368    369
FT   TURN        372    373
FT   TURN        376    377
FT   STRAND      378    383
FT   TURN        384    387
FT   STRAND      388    395
FT   STRAND      400    403
FT   HELIX       405    407
FT   TURN        408    408
FT   STRAND      409    410
FT   HELIX       411    413
FT   TURN        414    414
FT   STRAND      415    416
FT   TURN        419    421
FT   STRAND      422    426
FT   STRAND      430    430
FT   TURN        436    438
FT   STRAND      440    442
FT   STRAND      444    449
FT   TURN        451    452
FT   STRAND      454    454
FT   TURN        455    458
FT   STRAND      460    460
FT   TURN        461    461
FT   STRAND      464    468
FT   STRAND      475    475
FT   TURN        476    477
FT   STRAND      478    478
FT   STRAND      482    482
FT   HELIX       486    492
FT   TURN        495    496
FT   STRAND      498    503
FT   STRAND      522    522
FT   STRAND      524    531
FT   HELIX       533    537
FT   TURN        538    539
FT   TURN        546    547
FT   STRAND      548    551
FT   HELIX       555    557
FT   STRAND      562    562
FT   TURN        565    566
FT   TURN        568    569
FT   STRAND      571    575
FT   TURN        577    579
FT   STRAND      582    591
FT   TURN        597    598
FT   STRAND      601    605
FT   HELIX       607    609
FT   HELIX       610    617
FT   TURN        618    619
SQ   SEQUENCE   622 AA;  70037 MW;  8A25E1DA88208FCF CRC64;
     MAHVRGLQLP GCLALAALCS LVHSQHVFLA PQQARSLLQR VRRANTFLEE VRKGNLEREC
     VEETCSYEEA FEALESSTAT DVFWAKYTAC ETARTPRDKL AACLEGNCAE GLGTNYRGHV
     NITRSGIECQ LWRSRYPHKP EINSTTHPGA DLQENFCRNP DSSTTGPWCY TTDPTVRRQE
     CSIPVCGQDQ VTVAMTPRSE GSSVNLSPPL EQCVPDRGQQ YQGRLAVTTH GLPCLAWASA
     QAKALSKHQD FNSAVQLVEN FCRNPDGDEE GVWCYVAGKP GDFGYCDLNY CEEAVEEETG
     DGLDEDSDRA IEGRTATSEY QTFFNPRTFG SGEADCGLRP LFEKKSLEDK TERELLESYI
     DGRIVEGSDA EIGMSPWQVM LFRKSPQELL CGASLISDRW VLTAAHCLLY PPWDKNFTEN
     DLLVRIGKHS RTRYERNIEK ISMLEKIYIH PRYNWRENLD RDIALMKLKK PVAFSDYIHP
     VCLPDRETAA SLLQAGYKGR VTGWGNLKET WTANVGKGQP SVLQVVNLPI VERPVCKDST
     RIRITDNMFC AGYKPDEGKR GDACEGDSGG PFVMKSPFNN RWYQMGIVSW GEGCDRDGKY
     GFYTHVFRLK KWIQKVIDQF GE
//
ID   O67198_AQUAE PRELIMINARY;      PRT;   439 AA.
AC   O67198;
DT   01-AUG-1998 (TrEMBLrel. 07, Created)
DT   01-AUG-1998 (TrEMBLrel. 07, Last sequence update)
DT   01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE   Transcriptional regulator (NtrC family).
GN   Name=ntrC1; OrderedLocusNames=AQ_1117;
OS   Aquifex aeolicus.
OC   Bacteria; Aquificae; Aquificales; Aquificaceae; Aquifex.
OX   NCBI_TaxID=63363;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=VF5;
RX   MEDLINE=98196666; PubMed=9537320; DOI=10.1038/32831;
RA   Deckert G., Warren P.V., Gaasterland T., Young W.G., Lenox A.L.,
RA   Graham D.E., Overbeek R., Snead M.A., Keller M., Aujay M., Huber R.,
RA   Feldman R.A., Short J.M., Olsen G.J., Swanson R.V.;
RT   "The complete genome of the hyperthermophilic bacterium Aquifex
RT   aeolicus.";
RL   Nature 392:353-358(1998).
DR   EMBL; AE000724; AAC07159.1; -; Genomic_DNA.
DR   PIR; C70396; C70396.
DR   PDB; 1NY5; X-ray; A/B=1-387.
DR   PDB; 1NY6; X-ray; A/B/C/D/E/F/G/H/I/J/K/L/M/N=122-387.
DR   GO; GO:0005524; F:ATP binding; IEA.
DR   GO; GO:0016831; F:carboxy-lyase activity; IEA.
DR   GO; GO:0016829; F:lyase activity; IEA.
DR   GO; GO:0017111; F:nucleoside-triphosphatase activity; IEA.
DR   GO; GO:0000166; F:nucleotide binding; IEA.
DR   GO; GO:0003700; F:transcription factor activity; IEA.
DR   GO; GO:0000156; F:two-component response regulator activity; IEA.
DR   GO; GO:0006811; P:ion transport; IEA.
DR   GO; GO:0007600; P:sensory perception; IEA.
DR   GO; GO:0000160; P:two-component signal transduction system (p...; IEA.
DR   InterPro; IPR003593; AAA_ATPase.
DR   InterPro; IPR012287; Homeodomain-rel.
DR   InterPro; IPR002197; HTH_Fis.
DR   InterPro; IPR001789; Response_reg.
DR   InterPro; IPR002078; Sig54_interact.
DR   Pfam; PF02954; HTH_8; 1.
DR   Pfam; PF00072; Response_reg; 1.
DR   Pfam; PF00158; Sigma54_activat; 1.
DR   PRINTS; PR01590; HTHFIS.
DR   ProDom; PD000039; Response_reg; 1.
DR   SMART; SM00382; AAA; 1.
DR   SMART; SM00448; REC; 1.
DR   TIGRFAMs; TIGR01199; HTH_fis; 1.
DR   PROSITE; PS50110; RESPONSE_REGULATORY; 1.
DR   PROSITE; PS00675; SIGMA54_INTERACT_1; 1.
DR   PROSITE; PS00676; SIGMA54_INTERACT_2; 1.
DR   PROSITE; PS50045; SIGMA54_INTERACT_4; 1.
KW   Complete proteome.
SQ   SEQUENCE   439 AA;  50366 MW;  AAE1E9780271DFC0 CRC64;
     MNVLVIEDDK VFRGLLEEYL SMKGIKVESA ERGKEAYKLL SEKHFNVVLL DLLLPDVNGL
     EILKWIKERS PETEVIVITG HGTIKTAVEA MKMGAYDFLT KPCMLEEIEL TINKAIEHRK
     LRKENELLRR EKDLKEEEYV FESPKMKEIL EKIKKISCAE CPVLITGESG VGKEVVARLI
     HKLSDRSKEP FVALNVASIP RDIFEAELFG YEKGAFTGAV SSKEGFFELA DGGTLFLDEI
     GELSLEAQAK LLRVIESGKF YRLGGRKEIE VNVRILAATN RNIKELVKEG KFREDLYYRL
     GVIEIEIPPL RERKEDIIPL ANHFLKKFSR KYAKEVEGFT KSAQELLLSY PWYGNVRELK
     NVIERAVLFS EGKFIDRGEL SCLVNSKGIK NKHKSIKEIE KEEIIKVLKE VNFNKKLASE
     ILGIPLRTLY RRLKEYGIE
//
ID   FCERA_HUMAN    STANDARD;      PRT;   257 AA.
AC   P12319;
DT   01-OCT-1989 (Rel. 12, Created)
DT   01-OCT-1989 (Rel. 12, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   High affinity immunoglobulin epsilon receptor alpha-subunit precursor
DE   (FcERI) (IgE Fc receptor, alpha-subunit) (Fc-epsilon RI-alpha).
GN   Name=FCER1A; Synonyms=FCE1A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=88233953; PubMed=2967464;
RA   Kochan J., Pettine L.F., Hakimi J., Kishi K., Kinet J.-P.;
RT   "Isolation of the gene coding for the alpha subunit of the human high
RT   affinity IgE receptor.";
RL   Nucleic Acids Res. 16:3584-3584(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE, AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Mast cells;
RX   MEDLINE=88158102; PubMed=2964640;
RA   Shimizu A., Tepler I., Benfey P.N., Berenstein E.H., Siraganian R.P.,
RA   Leder P.;
RT   "Human and rat mast cell high-affinity immunoglobulin E receptors:
RT   characterization of putative alpha-chain gene products.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:1907-1911(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Prostate;
RX   MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA   Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA   Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA   Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA   Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA   Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA   Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA   Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA   Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA   Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA   Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA   Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA   Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA   Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA   Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA   Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA   Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA   Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT   "Generation and initial analysis of more than 15,000 full-length human
RT   and mouse cDNA sequences.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN   [4]
RP   PROTEIN SEQUENCE OF 26-197.
RX   PubMed=8125119;
RA   Yagi S., Yanagida M., Tanida I., Hasegawa A., Okumura K., Ra C.;
RT   "High-level expression of the truncated alpha chain of human high-
RT   affinity receptor for IgE as a soluble form by baculovirus-infected
RT   insect cells. Biochemical characterization of the recombinant
RT   product.";
RL   Eur. J. Biochem. 220:593-598(1994).
RN   [5]
RP   3D-STRUCTURE MODELING OF 26-197.
RX   MEDLINE=93113350; PubMed=1472946;
RA   Padlan E.A., Helm B.A.;
RT   "A modeling study of the alpha-subunit of human high-affinity receptor
RT   for immunoglobulin-E.";
RL   Receptor 2:129-144(1992).
CC   -!- FUNCTION: Binds to the Fc region of immunoglobulins epsilon. High
CC       affinity receptor. Responsible for initiating the allergic
CC       response. Binding of allergen to receptor-bound IgE leads to cell
CC       activation and the release of mediators (such as histamine)
CC       responsible for the manifestations of allergy. The same receptor
CC       also induces the secretion of important lymphokines.
CC   -!- SUBUNIT: Tetramer of an alpha chain, a beta chain, and two
CC       disulfide linked gamma chains.
CC   -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC   -!- SIMILARITY: Contains 2 Ig-like (immunoglobulin-like) domains.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; X06948; CAA30025.1; -; mRNA.
DR   EMBL; J03605; AAA36204.1; -; mRNA.
DR   EMBL; BC005912; AAH05912.1; -; mRNA.
DR   EMBL; A21606; CAA01564.1; -; Unassigned_DNA.
DR   PIR; S00682; S00682.
DR   PDB; 1ALS; Model; @=26-197.
DR   PDB; 1ALT; Model; @=26-197.
DR   PDB; 1F2Q; X-ray; A=26-201.
DR   PDB; 1F6A; X-ray; A=26-201.
DR   PDB; 1J86; X-ray; A/B=26-201.
DR   PDB; 1J87; X-ray; A=26-196.
DR   PDB; 1J88; X-ray; A/B/C/D/E=26-197.
DR   PDB; 1J89; X-ray; A/B/C/D/E=26-197.
DR   PDB; 1RPQ; X-ray; A/B/C/D=26-201.
DR   Ensembl; ENSG00000179639; Homo sapiens.
DR   Genew; HGNC:3609; FCER1A.
DR   H-InvDB; HIX0001199; -.
DR   MIM; 147140; -.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS.
DR   GO; GO:0005886; C:plasma membrane; TAS.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003598; Ig_c2.
DR   Pfam; PF00047; ig; 2.
DR   SMART; SM00408; IGc2; 1.
DR   PROSITE; PS50835; IG_LIKE; 2.
KW   3D-structure; Direct protein sequencing; Glycoprotein;
KW   IgE-binding protein; Immunoglobulin domain; Polymorphism; Receptor;
KW   Repeat; Signal; Transmembrane.
FT   SIGNAL        1     25
FT   CHAIN        26    257       High affinity immunoglobulin epsilon
FT                                receptor alpha-subunit.
FT   TOPO_DOM     26    205       Extracellular (Potential).
FT   TRANSMEM    206    224       Potential.
FT   TOPO_DOM    225    257       Cytoplasmic (Potential).
FT   DOMAIN       30    110       Ig-like 1.
FT   DOMAIN      111    193       Ig-like 2.
FT   CARBOHYD     46     46       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     67     67       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     75     75       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     99     99       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    160    160       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    165    165       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    191    191       N-linked (GlcNAc...) (Potential).
FT   DISULFID     51     93       By similarity.
FT   DISULFID    132    176       By similarity.
FT   VARIANT      84     84       K -> R (in dbSNP:2298804).
FT                                /FTId=VAR_020091.
FT   VARIANT     101    101       S -> N (in dbSNP:2298805).
FT                                /FTId=VAR_020092.
FT   STRAND       33     35
FT   STRAND       40     42
FT   TURN         43     44
FT   STRAND       47     50
FT   TURN         53     54
FT   STRAND       63     66
FT   TURN         67     68
FT   STRAND       69     70
FT   STRAND       77     80
FT   HELIX        85     87
FT   STRAND       89     94
FT   TURN         96     97
FT   STRAND      104    109
FT   STRAND      113    117
FT   STRAND      121    123
FT   TURN        124    125
FT   STRAND      128    134
FT   HELIX       135    137
FT   STRAND      140    147
FT   TURN        148    149
FT   STRAND      150    151
FT   STRAND      160    163
FT   HELIX       168    170
FT   STRAND      172    180
FT   TURN        181    182
FT   STRAND      183    186
FT   STRAND      190    195
SQ   SEQUENCE   257 AA;  29596 MW;  F183BB2357DDAD58 CRC64;
     MAPAMESPTL LCVALLFFAP DGVLAVPQKP KVSLNPPWNR IFKGENVTLT CNGNNFFEVS
     STKWFHNGSL SEETNSSLNI VNAKFEDSGE YKCQHQQVNE SEPVYLEVFS DWLLLQASAE
     VVMEGQPLFL RCHGWRNWDV YKVIYYKDGE ALKYWYENHN ISITNATVED SGTYYCTGKV
     WQLDYESEPL NITVIKAPRE KYWLQFFIPL LVVILFAVDT GLFISTQQQV TFLLKIKRTR
     KGFRLLNPHP KPNPKNN
//
ID   B2MG_MOUSE     STANDARD;      PRT;   119 AA.
AC   P01887;
DT   21-JUL-1986 (Rel. 01, Created)
DT   21-JUL-1986 (Rel. 01, Last sequence update)
DT   10-MAY-2005 (Rel. 47, Last annotation update)
DE   Beta-2-microglobulin precursor.
GN   Name=B2m;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE (A).
RX   MEDLINE=84028577; PubMed=6354707;
RA   Daniel F., Morello D., le Bail O., Chambon P., Cayre Y., Kourilsky P.;
RT   "Structure and expression of the mouse beta 2-microglobulin gene
RT   isolated from somatic and non-expressing teratocarcinoma cells.";
RL   EMBO J. 2:1061-1065(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE (A).
RC   STRAIN=BALB/c;
RX   MEDLINE=83001942; PubMed=6180834; DOI=10.1016/0092-8674(82)90182-9;
RA   Parnes J.R., Seidman J.G.;
RT   "Structure of wild-type and mutant mouse beta 2-microglobulin genes.";
RL   Cell 29:661-669(1982).
RN   [3]
RP   NUCLEOTIDE SEQUENCE (W2/W3/W4/W5).
RC   TISSUE=Liver;
RX   MEDLINE=93246292; PubMed=8482575;
RA   Hermel E., Robinson P.J., She J.-X., Lindahl K.F.;
RT   "Sequence divergence of B2m alleles of wild Mus musculus and Mus
RT   spretus implies positive selection.";
RL   Immunogenetics 38:106-116(1993).
RN   [4]
RP   PROTEIN SEQUENCE OF 21-119 (A/B).
RC   STRAIN=BALB/c, and C57BL/6;
RX   MEDLINE=81223779; PubMed=6165997;
RA   Gates F.T. III, Coligan J.E., Kindt T.J.;
RT   "Complete amino acid sequence of murine beta 2-microglobulin:
RT   structural evidence for strain-related polymorphism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 78:554-558(1981).
RN   [5]
RP   NUCLEOTIDE SEQUENCE OF 31-57 AND 86-119 (A).
RX   MEDLINE=81223857; PubMed=6166005;
RA   Parnes J.R., Velan B., Felsenfeld A., Ramanathan L., Ferrini U.,
RA   Appella E., Seidman J.G.;
RT   "Mouse beta 2-microglobulin cDNA clones: a screening procedure for
RT   cDNA clones corresponding to rare mRNAs.";
RL   Proc. Natl. Acad. Sci. U.S.A. 78:2253-2257(1981).
RN   [6]
RP   NUCLEOTIDE SEQUENCE OF 1-3 (A).
RX   MEDLINE=86106202; PubMed=3510743; DOI=10.1016/0092-8674(86)90760-9;
RA   Kimura A., Israel A., le Bail O., Kourilsky P.;
RT   "Detailed analysis of the mouse H-2Kb promoter: enhancer-like
RT   sequences and their role in the regulation of class I gene
RT   expression.";
RL   Cell 44:261-272(1986).
RN   [7]
RP   PROTEIN SEQUENCE OF 21-60 (A).
RX   MEDLINE=76231543; PubMed=59595;
RA   Appella E., Tanigaki N., Natori T., Pressman D.;
RT   "Partial amino acid sequence of mouse beta2-microglobulin.";
RL   Biochem. Biophys. Res. Commun. 70:425-430(1976).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
RX   MEDLINE=92367003; PubMed=1323877;
RA   Fremont D.H., Matsumura M., Stura E.A., Peterson P.A., Wilson I.A.;
RT   "Crystal structures of two viral peptides in complex with murine MHC
RT   class I H-2Kb.";
RL   Science 257:919-927(1992).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).
RX   MEDLINE=94116065; PubMed=7506996; DOI=10.1016/0092-8674(94)90171-6;
RA   Young A.C.M., Zhang W., Sacchettini J.C., Nathenson S.G.;
RT   "The three-dimensional structure of H-2Db at 2.4-A resolution:
RT   implications for antigen-determinant selection.";
RL   Cell 76:39-50(1994).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).
RX   MEDLINE=97338113; PubMed=9192660; DOI=10.1073/pnas.94.13.6880;
RA   Balendiran G.K., Solheim J.C., Young A.C., Hansen T.H.,
RA   Nathenson S.G., Sacchettini J.C.;
RT   "The three-dimensional structure of an H-2Ld-peptide complex explains
RT   the unique interaction of Ld with beta-2 microglobulin and peptide.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:6880-6885(1997).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).
RX   MEDLINE=98397257; PubMed=9729040; DOI=10.1016/S1074-7613(00)80602-0;
RA   Achour A., Persson K., Harris R.A., Sundbaeck J., Sentman C.L.,
RA   Lindqvist Y., Schneider G., Kaerre K.;
RT   "The crystal structure of H-2Dd MHC class I complexed with the HIV-1-
RT   and NK cell recognition.";
RL   Immunity 9:199-208(1998).
CC   -!- FUNCTION: Beta-2-microglobulin is the beta-chain of major
CC       histocompatibility complex class I molecules.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- POLYMORPHISM: The following alleles of B2M are known: A, B, W2,
CC       W3, W4 and W5 (C). The sequence shown is that of allele A.
CC   -!- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC   --------------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
CC   the European Bioinformatics Institute.  There are no  restrictions on  its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   --------------------------------------------------------------------------
DR   EMBL; X01838; CAA25970.1; -; mRNA.
DR   EMBL; M12485; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M84363; AAA39667.1; -; Genomic_DNA.
DR   EMBL; M84364; AAA39668.1; -; Genomic_DNA.
DR   EMBL; M84365; AAA39669.1; -; Genomic_DNA.
DR   EMBL; M84366; AAA39670.1; -; Genomic_DNA.
DR   EMBL; M84367; AAA39671.1; -; Genomic_DNA.
DR   EMBL; M10389; AAA39536.1; -; mRNA.
DR   EMBL; M10416; AAA39537.1; -; mRNA.
DR   PIR; A90822; MGMSB2.
DR   PDB; 1BII; X-ray; B=1-119.
DR   PDB; 1BQH; X-ray; B/E=21-119.
DR   PDB; 1BZ9; X-ray; B=21-119.
DR   PDB; 1CD1; X-ray; B/D=21-119.
DR   PDB; 1DDH; X-ray; B=22-119.
DR   PDB; 1FFN; X-ray; B/E=21-119.
DR   PDB; 1FFO; X-ray; B/E=21-119.
DR   PDB; 1FFP; X-ray; B/E=21-119.
DR   PDB; 1FG2; X-ray; B/E/H/K=21-119.
DR   PDB; 1FO0; X-ray; L=21-119.
DR   PDB; 1FZJ; X-ray; B=21-119.
DR   PDB; 1FZK; X-ray; B=21-119.
DR   PDB; 1FZM; X-ray; B=21-119.
DR   PDB; 1FZO; X-ray; B=21-119.
DR   PDB; 1G6R; X-ray; L/M=21-119.
DR   PDB; 1G7P; X-ray; B=21-119.
DR   PDB; 1G7Q; X-ray; B=21-119.
DR   PDB; 1HOC; X-ray; B=21-119.
DR   PDB; 1INQ; X-ray; B=21-119.
DR   PDB; 1JPF; X-ray; B=21-119.
DR   PDB; 1JPG; X-ray; B=21-119.
DR   PDB; 1JUF; X-ray; B=21-119.
DR   PDB; 1K8D; X-ray; B=21-119.
DR   PDB; 1KBG; X-ray; L=-.
DR   PDB; 1KJ2; X-ray; L/M=21-119.
DR   PDB; 1KJ3; X-ray; L/M=21-119.
DR   PDB; 1LD9; X-ray; B/E=-.
DR   PDB; 1LDP; X-ray; L=21-119.
DR   PDB; 1LEG; X-ray; B=21-119.
DR   PDB; 1LEK; X-ray; B=21-119.
DR   PDB; 1LK2; X-ray; B=21-119.
DR   PDB; 1MHC; X-ray; B/E=21-119.
DR   PDB; 1MWA; X-ray; L/M=21-119.
DR   PDB; 1N3N; X-ray; B/D/F/H=21-119.
DR   PDB; 1N59; X-ray; B/D=21-119.
DR   PDB; 1N5A; X-ray; B/E/H/K=21-119.
DR   PDB; 1NAM; X-ray; L=21-119.
DR   PDB; 1NAN; X-ray; I/P=21-119.
DR   PDB; 1OSZ; X-ray; B=21-119.
DR   PDB; 1P4L; X-ray; B=21-119.
DR   PDB; 1PQZ; X-ray; B=21-119.
DR   PDB; 1QO3; X-ray; B=21-119.
DR   PDB; 1RJY; X-ray; B/E=21-119.
DR   PDB; 1RJZ; X-ray; B/E=21-119.
DR   PDB; 1RK0; X-ray; B=21-119.
DR   PDB; 1RK1; X-ray; B=21-119.
DR   PDB; 1S7Q; X-ray; B=21-119.
DR   PDB; 1S7R; X-ray; B/E=21-119.
DR   PDB; 1S7S; X-ray; B=21-119.
DR   PDB; 1S7T; X-ray; B/E=21-119.
DR   PDB; 1S7U; X-ray; B/E/H/K=21-119.
DR   PDB; 1S7V; X-ray; B/E=21-119.
DR   PDB; 1S7W; X-ray; B/E/H/K=21-119.
DR   PDB; 1S7X; X-ray; B/E/H/K=21-119.
DR   PDB; 1T0M; X-ray; B/E=21-119.
DR   PDB; 1T0N; X-ray; B/E=21-119.
DR   PDB; 1VAC; X-ray; B=21-119.
DR   PDB; 1VAD; X-ray; B=21-119.
DR   PDB; 1WBX; X-ray; B=21-119.
DR   PDB; 1WBY; X-ray; B=21-119.
DR   PDB; 1WBZ; X-ray; B/D=21-119.
DR   PDB; 2CKB; X-ray; L/M=21-119.
DR   PDB; 2MHA; X-ray; B/D=21-119.
DR   PDB; 2VAA; X-ray; B=21-119.
DR   PDB; 2VAB; X-ray; B=21-119.
DR   SWISS-2DPAGE; P01887; MOUSE.
DR   Ensembl; ENSMUSG00000060802; Mus musculus.
DR   MGI; MGI:88127; B2m.
DR   GO; GO:0005615; C:extracellular space; TAS.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS.
DR   GO; GO:0006968; P:cellular defense response; TAS.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003006; Ig_MHC.
DR   Pfam; PF00047; ig; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
KW   3D-structure; Direct protein sequencing; Immunoglobulin domain; MHC I;
KW   Polymorphism; Signal.
FT   SIGNAL        1     20
FT   CHAIN        21    119       Beta-2-microglobulin.
FT   DOMAIN       25    114       Ig-like.
FT   DISULFID     45    100
FT   VARIANT       8      8       V -> I (in W3).
FT   VARIANT      54     54       H -> Q (in W4).
FT   VARIANT      64     64       K -> E (in W3).
FT   VARIANT     101    101       R -> T (in W2).
FT   VARIANT     105    105       D -> A (in B, strain C57BL/6).
FT   VARIANT     105    105       D -> V (in W2, W4 and W5).
FT   STRAND       23     23
FT   STRAND       26     31
FT   STRAND       36     36
FT   TURN         37     38
FT   STRAND       39     39
FT   STRAND       41     51
FT   STRAND       55     61
FT   TURN         62     63
FT   STRAND       64     65
FT   STRAND       70     71
FT   STRAND       75     76
FT   TURN         78     79
FT   STRAND       82     90
FT   TURN         94     95
FT   STRAND       98    104
FT   TURN        105    106
FT   STRAND      111    114
FT   TURN        117    119
SQ   SEQUENCE   119 AA;  13823 MW;  94F649EBCF1D7E1F CRC64;
     MARSVTLVFL VLVSLTGLYA IQKTPQIQVY SRHPPENGKP NILNCYVTQF HPPHIEIQML
     KNGKKIPKVE MSDMSFSKDW SFYILAHTEF TPTETDTYAC RVKHDSMAEP KTVYWDRDM
//
